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Abstract
Long non-coding RNAs (lncRNA) are a relatively new and mysterious class of RNA molecules
that are transcribed in eukaryotic cells. They are differentiated from mRNA transcripts in that
they do not code for proteins and are much larger than small RNA species, such as microRNAs.
Long intergenic non-coding RNAs (lincRNAs) are a subclass of lncRNAs that appear outside
the boundaries of known genes. At the current state, little is definitively known about lincR-
NAs. LincRNAs have a diverse range of functions, such as providing molecular scaffolding for
chromatin remodeling, acting as molecular sponges for microRNAs, or directly interacting with
promoter and enhancer regions to promote or downregulate gene expression.
In humans, there are a huge number of lincRNA genes, more than the number of genes that are
protein coding; it has been estimated that 80% of the human genome is transcribed, yet only
2-3% is translated. There is active debate in the field as to what proportion of those transcripts
are biologically relevant, as the alternative is that some of those transcripts are meaningless
noise, due to leaky RNA polymerases.
There is an increasing number of lincRNAs that are known to be functionally relevant to cancer
such as XIST, MALAT1, HOTAIR and PCAT1. XIST generally acts to silence one copy of the
X-chromosome in women; in breast cancer, it is found to be downregulated. HOTAIR, within
the HOX locus, is deregulated in aggressive metastatic tumors. HOTAIR expression is increased
in metastatic cancer and is a biomarker for poor prognosis. MALAT1 is enriched in the nucleus,
regulates cell motility and is also implicated in metastasis. PCAT1 is implicated in disease
progression in prostate cancer. However, the functions and mechanisms of most lincRNAs are
not definitively known.
This dissertation focuses on elucidating the roles of lincRNAs in relation to cancer pathogenesis.
The focus is on identifying lincRNA biomarkers in cancer and to further elucidate clinically
relevant lincRNA mutations. Using bioinformatics and computational biology approaches to
analyze lincRNA expression and mutation profiles, I will attempt to determine which lincRNAs
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are relevant to tumorigenesis and progression and how mutation data correlates with expression
and clinical phenotypes.
Information generated from this investigation will provide knowledge on the role of non-coding
RNAs in the development and progression of cancer. It will also help to elucidate the application
of machine learning methods to cancer and non-coding gene research domains. Most impor-
tantly, it will push forward the translational and clinical applications of lincRNAs as potential
cancer biomarkers and therapeutic targets.
In chapter 1, I further explain the technical background relevant to the projects contained in this
dissertation. Chapter 2 is a lincRNA review paper published in BioData Mining, focusing on
the upcoming computational challenges related to lincRNA research. Chapter 3 is an analysis of
RNA-Seq differential expression methods published in RNA; computational approaches in order
to find upregulated or downregulated lincRNAs. Chapter 4 is an exploration of the expression
landscape of lincRNA across 12 cancer types, published in eBioMedicine. Chapter 5 and 6 are
applications of machine learning methods to high dimensional biological data. In Chapter 5,
I explore a neural network-cox regression machine learning hybrid model, in order to predict
patient survival, and to elucidate the biological pathways relevant to each patient. In chapter
6, I elucidate the somatic mutation landscape in lincRNAs across 12 cancer types. I quantify
which molecular features are correlated with lincRNA mutation probability, and I show that
these results could be used to provide more robust subtyping and clustering of tumor samples.
Finally, in Chapter 7, I discuss what these research projects have accomplished in the grand
scheme of the lincRNA research field, and explain what further work needs to be accomplished
to follow up.
Specific aims
The goal of this work is to discover novel cancer biomarkers and to elucidate cancer biology
through the application of machine learning methods using “omics” data, particularly on the
expression and mutations of lincRNAs. I will apply classification and regression algorithms
to elucidate novel biological insights in cancer biology. The roles of ncRNA in cancer will be
addressed through completion of the following aims:
Specific aim 1: Use machine learning and statistical methods using RNA-Seq data to dis-
cover novel lincRNA biomarkers for cancer diagnosis or prognosis with preliminary functional
evaluation through cell line experiments.
Specific aim 2: Find important relations between somatic mutations and expression in lincR-
NAs and how they relate to clinical features or subtypes.
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Chapter 1
Background
The application of machine learning methods for the meta-analysis of high-throughput genomics
data can provide biological insights and discovery into the role that long intergenic non-coding
RNA has with respect to cancer. In this chapter, I describe these terms and the aims and goals
of this dissertation.
1.1 Next generation sequencing
Next generation sequencing (NGS) is a method that analyzes millions of short nucleic acids
fragments (often 100 base pairs) by multiplexed parallel sequencing. In recent years NGS
methods have significantly increased sequencing efficiency, producing faster results and also an
exponential reduction in cost. In 2007, one human genome cost roughly $10 million to sequence,
but now this cost has been reduced to $1000.
The most common sequencing platform is produced by the Illumina-Solexa Corporation. Before
the two companies merged in 2007, Solexa had developed a new method of sequencing using
fluorescent nucleotides rather than the traditional Sanger sequencing method of terminating nu-
cleotides. The method relies on re-polymerization of short fragments using modified fluorescent
nucleotides.
In the first step of the process, library preparation is performed by cutting genomic DNA (or
cDNA) into 300-600 base pair fragments and ligated at both free ends using adapters. The
ligated fragments are hybridized and bound to the surface of a flow cell. The flow cell also
contain oligonucleotide primers used to initiate polymerization. Each fragment is amplified
while fixed to the flow cell surface. Thermocycling (typically a 100 cycles) is performed using
1
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tagged fluorescent nucleotides. Each flow cell can contain millions of hybridized fragments that
are sequenced in parallel, resulting in massive data generation in a short time.
There are many applications to next generation sequencing. Two of the most common applica-
tions are DNA sequencing and RNA sequencing.
1.1.1 DNA sequencing
In the context of a human genome, DNA sequencing is often used for the purpose of discov-
ering and individual’s genetic alleles. DNA is typically extracted from a tissue sample and
pre-amplified for library construction. Due to the size of the human genome, traditionally, only
the exonic regions are analyzed, e.g., through probe specific amplification primers, or other
similar mechanisms (termed Exome Sequencing or Exome-Seq). However, whole genome se-
quencing (synonymously called shotgun sequencing) has become more common allowing for the
determination and analysis of previously unstudied genetic elements.
If the genome sequence is unknown, small nucleotide fragments must be assembled into pro-
gressively larger contigs for construction and determination of the full genome (i.e., de novo
sequencing). When the reference genome is known short reads can be aligned against a genomic
reference allowing for individual variation to be studied, including somatic tumor mutation
determination.
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The best known population scale Whole Genome Sequence (WGS) study in cancer research is
The Cancer Genome Atlas (TCGA) project. TCGA began in 2005 with the goal of determining
genome relationships for three different tumor types (glioblastoma, lung cancer and ovarian can-
cer). In 2009, TCGA expanded to include the determination of genetic elements associated with
20-25 different tumor types. Ordinarily, genomes must have roughly 10x sequencing coverage
in order to retrieve genetic variants and alleles. In addition to the difficulties associated with
sequencing a large genome, cancer identification in humans require greater sequencing coverage,
especially for identification of rare somatic mutations and alleles, which may only occur in a
small fraction of cells.
1.1.2 RNA sequencing (RNA-Seq)
RNA sequencing or RNA-Seq is the RNA counterpart to exome sequencing and whole genome
sequencing, utilizing RNA as template material instead of DNA. Whereas Exome-Seq and WGS
aim to sequence the whole exome or whole genome respectively, RNA-Seq aims to sequence the
whole transcriptome.
It is quickly replacing microarrays as the platform of choice for gene expression profiling, owing
to greater sensitivity and lower noise levels. Ribosomal RNA is usually removed from the library
preparation, through poly-A selection. This RNA is then converted to cDNA through reverse
transcription.
In addition, RNA-Seq has also greatly augmented our understanding of mechanisms of alter-
native splicing and has led to the discovery of novel isoforms and novel genes. This includes
the discovery of thousands of novel, robustly expressed long intergenic non-coding RNAs (lin-
cRNAs).[1–4]. Machine learning methods in cancer genomics
1.2 Machine learning in cancer
Many machine learning algorithms, including Artificial Neural Networks, Support Vector Ma-
chines and Decision Trees have been used extensively for understanding cancer genomics by
allowing for the development of predictive diagnosis and prognosis models and for therapeutic
intervention. However, due to massive size of available digitized biological data, finding impor-
tant signals within the large amount of biological and methodological noise can be challenging.
There are a handful of clinically related factors for cancer biology that researchers are interested
in; 1) Prediction of disease risk, 2) diagnosis of disease, 3) prediction of survival or tumor
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recurrence and 4) prediction of drug response. Traditionally, each individual biomarker has
been tested for its relevance to a particular aspect of cancer biology (such as disease progression
or tumor subtype) without regard for potential synergistic interactions between markers.
For example, genome-wide association studies have found that only 5% of the heritable risk for
colorectal cancer. However, analysis of familial inheritance patterns have shown that heritability
has a much more significant association of 35% [5]. The difference between the two examinations
can be attributed to non-linear gene-gene interactions. Studies such as these suggest that cancer
biology is clearly more complicated than the simple linear combination of markers. Many
important indicators may be missed if a variety of possible interactions are not taken into
consideration. E.g., interactions between mutations on the same gene or between different
omics level (i.e., between mutations and the expression level of a gene). While many non-
linear machine learning methods can take into account interaction terms (such as radial support
vector machines), overfitting and multiple hypothesis testing are major problems. Furthermore,
finding interaction terms in a machine learning framework requires greater sample size and
interpretation is difficult and may often yield inconclusive results.
1.3 Non-coding RNAs
Non-coding RNAs (ncRNAs) are a large superclass of RNA molecules, defined as RNAs that
are non-ribosomal and are not translated into proteins. While there is some discrepancy with
how researchers classify non-coding RNAs, generally they are divided into two sub-groups based
on size: small RNAs and long non-coding RNAs.
1.3.1 Small RNAs
Small RNAs are less than 200 base pairs, and are generally better characterized compared with
long non-coding RNAs. In all mammals, small RNAs are divided into at least five classes: 1)
microRNAs - attenuate translation of mRNAs, 2) small nuclear RNAs - assist in splicing of
mRNAs, 3) small nucleolar RNAs - assist in post-transcriptional modification of RNA such
as methylation and pseudouridinylation, 4) piRNAs - suppression of retro-transposons, and
5) tRNAs - transfer amino acids for peptide synthesis. MicroRNAs, as an example, are 20-25
base pairs and when properly spliced, their function is to attenuate gene expression. MicroRNAs
form an imprecise complementary RNA-protein hybrid with the RNA induced silencing complex
(RISC). The RISC complex expresses an enzyme that silences gene expression by cleaving
mRNA.
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1.3.2 Long non-coding RNAs
Long non-coding RNAs (lncRNAs) are a much less understood class of RNA molecules having
diverse functions and origins. LncRNAs are usually categorized by their location on the genome,
relative to known genes [6]. lncRNAs may be located within intronic regions, transcriptionally
overlapping coding genes, anti-sense to coding genes or intergenic regions (lincRNAs) [6].
LncRNAs are sometimes also categorized by their compositional content and putative function.
LncRNA may have sequence content that is homologous to protein coding genes and are termed
pseudogenes. LncRNAs may contain repetitive elements, such as tandem repeats, endogenous
retroviruses or microsatellites. lncRNAs act as transcriptional co-activators (enhancer RNAs)
or repressors that can sequester microRNAs and therefore downregulate microRNA function
(competitive endogenous RNAs or ceRNAs). lncRNAs have even been discovered to act as
scaffolds during chromatin remodeling [Wang2001, Prensner2011a].
1.3.3 LincRNAs
Finally, lincRNAs are a subset of lncRNAs and are defined as non-coding RNAs that are greater
than 200 bp in length and arise from intergenic regions within the genome. lincRNAs are
the focus of this dissertation. The majority of lincRNAs have only recently been discovered,
through genome wide RNA-Seq studies. One of the first high throughput studies, termed the
“Human Body Map project” [7] identified 9000 lincRNAs in the human genome through RNA
sequencing of many different human tissues. Many more lincRNAs have since been discovered,
and various projects have undertaken the task of providing a more comprehensive transcriptional
annotation. For example, the Lncipedia database has annotated 63,000 long non-coding RNAs,
of which approximately 30,000 are robustly transcribed lincRNAs.
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It is understood that protein coding exons constitute only about 3% of the human genome [8].
There are large regions of the human genome that have no protein coding potential. Many
of these “gene deserts” actually encode for long, “intergenic” non-coding RNAs (lincRNAs).
Furthermore, the large majority of RNA transcripts have been recently determined to actually
be non-coding. According to the Encyclopedia of DNA Elements (ENCODE) project, about
62% of the entire genome is transcribed into long (>200 base pairs) RNA sequences [8]. Given
that 3% of the genome encodes protein coding exons, majority of transcripts longer than 200 bp
are non-coding. Of these long non-coding RNAs, roughly one third come from intronic regions
or overlap with protein-coding genes, whereas about two thirds comes from intergenic regions
[8]. While the function of intronic and overlapping ncRNA can often be attributed to regulation
or association with the host gene, lincRNAs have no proximal association with genes and are
somewhat more mysterious. In fact, the functions of almost all lincRNAs are not definitively
known.
Although lincRNAs are believed to not be translated into proteins, lincRNAs are transcribed
by polymerase II and often have poly-A tails and 5’ Methyl cap. There are several well-studied
lincRNAs associated with cancer, such as MALAT1, HOTAIR and PCAT1 [9, 10]. HOTAIR is
found within the HOX loci and is deregulated in aggressive metastatic tumors [10]. This results
in overexpression and is a biomarker having poor clinical prognosis. MALAT1 is enriched in
the nucleus, regulates cell motility and is also implicated in metastasis. PCAT1 is implicated
in disease progression in prostate cancer. PCAT1 binds to the Polycomb Repressive Complex 2
(PRC2) which is a histone methyltransferase that alters histone code selectively in a sequence
specific manner citePrensner2011.
There have been attempts to extrapolate the function of lincRNAs on a genome-wide scale based
on the function of well-understood lincRNAs. The accuracy of these extrapolations have not
been systematically assessed. Furthermore it is also debatable as to the percentage of lincRNAs
that are functional as opposed to transcriptional “noise” – spurious transcripts that don’t have
biological functionality [11].
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2.1 Preface
Long intergenic non-coding RNAs (lincRNAs) represent one of the most mysterious RNA species
encoded by the human genome. Thanks to next generation sequencing (NGS) technology and
its applications, we have recently witnessed a surge in non-coding RNA research, including
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lincRNA research. Here, we summarize the recent advancement in genomics studies of lincR-
NAs. We review the emerging characteristics of lincRNAs, the experimental and computational
approaches to identify lincRNAs, their known mechanisms of regulation, the computational
methods and resources for lincRNA functional predictions, and discuss the challenges to under-
standing lincRNA comprehensively.
2.2 Introduction
The mainstream focus of biomedical research has been in elucidating the functions and inter-
actions among proteins within the cell. In line with the central dogma of molecular biology,
RNAs were once perceived as the intermediary for protein production and the archaic precursor
molecule of DNA. However, although RNAs are transcribed from more than 85% of genomic
region [1], proteins are only encoded in less than 3% of human genome sequence [2]. This
leaves a mysterious knowledge gap in either the efficiency of cellular transcription to transla-
tion or a foundational misunderstanding in gene expression regulation and RNA function. It
was thought that RNAs had limited but essential and evolutionarily common roles of basic cell
machinery such as tRNA, rRNA, and mRNA. The few examples of functional RNA or RNA
with enzymatic-like activity, were considered as evolutionary remnant [3]. For a long period
of time, non-coding RNA (ncRNA) transcripts were believed to be by-products derived from
mRNA degradation or nonspecific polymerase activity, and therefore termed “transcriptional
noise” [4].
It is now becoming evident that ncRNAs are responsible for many aspects of gene regulation.
Some small non-coding RNAs, such as microRNAs, siRNAs, snRNAs, snoRNAs, exRNAs and
piRNAs, have been well categorized over the past decade. However, long noncoding RNAs
(lncRNAs) remained relatively unexplored due to the challenges of computational prediction
under poor sequence conservation and low homology within the set of lncRNAs. However, some
of these challenges have been addressed by the revolutionary inventions of next generation se-
quencing (NGS) and its applications, such as RNA-Seq, which capture whole transcriptome
data, including lncRNAs. Among the human lncRNAs, tens of thousands of long intergenetic
noncoding RNAs (lincRNAs) have been discovered in the genomic regions outside of the well-
studied coding genomic regions, and they show many intriguing properties, such as associations
with various human diseases, tissue-specific expression, and expression changes during develop-
ment. Consequently, attributing organism complexity to the hidden regulation of lincRNAs is
a fascinating new area of research. Here, we review the emerging characteristics of lincRNAs;
the experimental and computational approaches to identifying lincRNAs and their mechanisms
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of regulation; the challenges in computational predictions; and the resources still required to
advance our understanding of lincRNA-related genetic regulation.
2.3 Review
2.3.1 Emerging characteristics of lincRNAs
LincRNAs are a putatively heterogeneous group, conventionally defined as ncRNA transcripts
of more than 200 bp located in regions with no overlap to any known protein-coding genes.
According to Lncipedia, a comprehensive lncRNA database, high-throughput studies of tran-
scriptome data have catalogued over 111,000 lncRNA transcripts, with roughly 50% coming
from intergenic region [5]. The majority of lincRNAs are thought to be transcribed from RNA
polymerase II, and are therefore usually modified by post-transcriptional 5’ capping and 3’
polyadenylatio [6]. Surprisingly, lincRNAs show ribosome occupancy similar to the 5’UTRs of
protein coding gene [7]. What differentiates lincRNAs from protein coding genes seems to be
the lack of release upon encountering a stop codon in the lincRNA sequence [7]. Therefore,
polyadenlyation and 5’ capping are not necessarily markers of function. However, lincRNAs
show a markedly higher degree of tissue-specific [8] and disease specific expressio [9], suggesting
some biological function.
LincRNA expression is generally much lower than protein coding genes, with a few exceptions
such as the XIST lincRN [10]. For some lincRNAs, even just a few or a single transcript
exist in a cell, determined by RNA-Seq dat [10]. However, rather than being spurious by-
products of non-specific RNA transcription, the expression levels of lincRNAs in any given cell
are precisely coordinated throughout the tissue, and dynamic through the course of developmen
[11]. Researchers have detected differential expression of lincRNA in a range of tissues, diseases,
and specific cellular responses. Efforts have been made to take advantage of these properties of
lincRNAs for translational and clinical applications, such as disease biomarker [12].
Another unique feature of lincRNAs is the low sequence conservation. LincRNAs exhibit 22-
25% of conserved bases under purifying selection, compared to 77% in protein coding sequences.
However, they are considerably more conserved than introns, which have 7% conservatio [13].
Under the assumption that sequence conservation reflects biological significance, the high ge-
nomic sequence variability in lincRNAs was the initial basis to call them “junk RNAs”. Unlike
proteins, where evolutionary conservation correlates highly with functional importance, lincR-
NAs seem to be under different selective pressures. Many lincRNA are predicted to have sec-
ondary structure and may therefore act in a sequence independent manne [14]. Consequently,
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there may be a greater functional importance on molecular 3D conformation over the primary
sequence. This is supported by a recent global study of genetic variants in human lincRNAs
in association with diseases, where single nucleotide polymorphisms (SNPs) in evolutionarily
conserved regions of lincRNAs had significant effects on predicted secondary structur [15].
2.3.2 Genome-wide detection of lincRNAs
Chromatin immunoprecipitation sequencing (ChIP-Seq) is an NGS method that has allowed
the discovery of global genomic binding sites of DNA-interacting proteins, such as transcription
factors and histones. Using ChIP-Seq signatures of histone 3 lysine 4 tri-methylation (H3K4me3)
and histone 3 lysine 36 tri-methylation (HK36me3), or so called “K4-K36” clusters, Guttman
et al. detected approximately 1700 transcriptional units > 5kb among four mouse cell lines,
which were confirmed by tiling microarrays, PCR and northern blot [16]. This type of chromatin
signature was later applied to human cell lines to identify lincRNAs and was shown that along
with HOTAIR, 20% of lincRNAs were associated with the Polycomb repressive complexes 2
(PRC2 [4]. ChIP-Seq has also been applied to the detection of RNA pol II occupancy to identify
lincRNAs in mouse macrophages upon endotoxin stimulatio [17]. The authors found that 70% of
extragenic polymerase II peaks were associated with genomic regions with a canonical chromatin
signature of enhancers.
Clearly, decisions made during the library preparation phase of an RNA-seq experiment will
affect lincRNA measurements. Since many but not all lincRNA transcripts are poly-adenylate
[18], the decision to select poly-adenylated RNAs or to use ribodepletion methods should be
made with care. Yang et al. [19] state that approximately 20% of transcripts are non-poly
adenylated, suggesting that ribo-depletion methods are necessary to gain a more comprehensive
picture of the transcriptome. In addition, Yang et al. find that some transcripts, such as the
Malat1 lincRNA are bimorphic, meaning they exist in poly-A(+) and poly-A(-) configurations.
Thus, ribo-depletion and poly-A selection methods could provide complementary information
on the relative proportions of poly-adenylation of transcripts. Moreover, the adoption of strand-
specific sequencing protocols provides a means of making more detailed annotations of lncRNAs,
especially the antisense lncRNAs [20]. Nevertheless, even without strand information, RNA-
seq has proven useful for the identification of lincRNAs. For example, Cabili et al. analysed
lincRNAs in 24 tissues and mapped out nearly 9000 lincRNAs coupled to expression profile
information [8].
Not all NGS methods are ideal for identifying the precise boundaries of lincRNAs. ChIP-Seq
using antibodies against RNA polymerases can only provide a rough estimation of transcription
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location but not the precise boundaries of transcripts [17]. RNA-Seq may also have trouble
to detect isoforms and their exact start and end sites, as the cDNA is randomly fragmented,
and accumulated from all isoforms within a given genomic loci [21]. Moreover, if RNA-Seq is
conducted by a poly-A enriched approach, the internal bias against 5’ ends make it difficult
to map out the exact start sites of a transcript. However, some other NGS methods have
been adopted to overcome this problem. For example, cap analysis gene expression (CAGE)
tag sequencing has been used to aid the identification of transcription start sites in human
cell [18], and 3’-end sequencing (3SEQ) has also been used in a zebrafish model to aid the
determination of the 3’ bounds of lincRNA transcript [22]. Additionally, tiling arrays that
enable direct observation of lincRNAs transcript exons have been used to detect gene boundaries
and alternative splicing. For example, Tahira et al. sampled intergenic and intronic ESTs from
over one million ESTs from The Cancer Genome Project to develop a custom microarray,
and subsequently identified lincRNAs differentially expressed between primary and metastatic
pancreatic cancer [23].
2.3.3 Computational methods to predict lincRNAs
Most computational studies of lincRNAs rely on RNA-Seq results initially, with quality-control
filtering steps to remove reads arising from spurious background nois [24]. Additional steps
should be taken involving the removal of protein coding genes and small non-coding RNAs such
as microRNAs. Methods to do such removals include ORF detection, BLAST to identify ho-
mologs of protein coding genes, domain based searches such as Pfa [1, 8, 9, 16], and predictions
of coding potential based on nucleotide substitution frequencies given sequences from multiple
species. The Coding Potential Calculator (CPC) [25] and iSeeRNA [26] programs are popular
choices in determining coding potential. However, the extent to which some lincRNAs may be
hosts of smaller RNA species such as microRNAs requires further study [27]. Another selection
criterion is the number of exons in a transcript. Most of the exons (about 80% in human) are
less than 200b [28], the minimum length requirement of lincRNA by definition. Transcripts
with only one exon are less likely to be lincRNAs. Additionally, the number of exons can be
used as an indicator of transcript quality. Multi-exonic transcripts are less likely to result from
spurious transcription and genomic noise. The presence of introns is also indicative of robust
and consistent transcription boundaries. Introns have less frequent terminal repeats and trans-
posable elements in comparison to intergenic regions, suggesting that lincRNAs have additional
conservation in splicing [29]. Finally, the axiomatic length-based filter, 200bp, eliminates any
non-coding sequences that fall into the current small RNA categorie [30]. The filtering steps
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described above are often implemented through a pipeline with a series of cut-offs or a decision
tree to interrogate multiple features involved in classifying lincRNA [24].
In recent years, machine learning based classification approaches have been used to detect
lincRNAs [17, 26, 31–33]. For example, iSeeRNA interrogated coding potential based on a
variety of factors mentioned above, in addition to nucleotide composition. It was trained to
differentiate protein coding genes and lncRNAs with an area under the curve (AUC) of 0.9 [26].
LncRNA-MFDL is another tool that uses a deep learning method and the fusion of multiple
features to classify lincRNAs with an accuracy of 97.1 [32].
2.3.4 lincRNA databases
LincRNAs identified from exploratory studies are a valuable resource for accumulating informa-
tion about these relatively unknown transcripts. Information such as location, splice junction,
and tissue specificity are important features. There are quite a few specialized databases that
provide comprehensive annotations for lincRNAs or lncRNAs. These include The Broad in-
stitute’s Human Body Map projec [8], NONCODE [34] and Lncipedi [5]. Other large gene
annotation sets such as GENCODE [35, 36], UCSC’s known genes [37] or Rfam [38] RNA
family databases are not specific to non-coding RNAs, but nevertheless contain large sets of
annotations and information on lincRNAs.
The UCSC ENCODE project provides a feature-rich resource to describe the transcriptional
landscape in a variety of tissues from the GENCODE databas [39]. The Ensembl Geneome
Browser is another resource that identifies and annotates transcripts within their large database
using transcriptional evidence as well as chromatin mark-up [35]. The Ensembl project uses the
GENCODE database, and contributes multiple sources to GENCODE through an automated
annotation pipeline in combination with the large Havana annotation by the Sanger Institut
[35]. While GENCODE is one of the most comprehensive databases for mammalian species, it
does not include lincRNAs found by RNA-Seq ab initio alignment methods, such as those in
the Human Body Map. Neither is it as comprehensive as specialized databases.
More specialized lncRNA databases, such as NONCODE and Lncipedia, enumerate a much
larger number of lncRNAs (Table 1). These databases have been created to facilitate functional
analyses by integrating multiple data sources such as expression, chromatin markups, microRNA
binding sites and mutational data with known lncRNAs. Not surprisingly, the overlap of those
data sets can differ greatly, largely due to the selection criteria of particular lncRNAs or the
tissue origins where lincRNAs were initially detected.
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2.3.5 Genomic assays to study lincRNA regulations
2.3.5.1 Methods to elucidate the functions
of individual lincRNAs have made much slower progress compared to large-scale genomic as-
says. In this section we survey the increasing number of genome-scale molecular interaction
studies to investigate the cellular functions of lincRNAs. Several genomic approaches have been
reported to identify specific functions of lincRNAs. One popular technique is the protein-centric
RNA immunoprecipitation (RIP), which selects a particular protein or a group of proteins to
co-precipitate RNAs and determines functional relationships based on physical interaction [40].
This allows one to ascribe functions of the protein(s) with co-precipitated lincRNAs. For ex-
ample, Shi et al. used RIP to identify novel functional lincRNAs involved in the regulation of
TNF expression through binding to PRC [41], and found that PRC2 binds to thousands of RNA
species. Thus, protein-centric methods focusing on PRC2 have provided us critical insights into
the genome-wide regulation by lincRNA [42].
Conversely, another approach is to purify certain RNA molecules and then capture the associ-
ated proteins (RNA-centric methods); the associated proteins can then be identified via mass-
spectroscop [40]. This approach works by complementary base pairing of the RNA sequence
to oligonucleotide probes labelled with streptavidin or bioti [43]. However, in comparison to
protein-centric methods where the RNA targets can be amplified by PCR, RNA-centric meth-
ods do not have a means of amplifying the protein targets. Therefore, RNA-centric methods
work best when large quantities of protein are availabl [40].
Additionally, there have also been a handful of “DNA-centric” methods for studying lincRNAs.
Methods that investigate DNA modification or the 3D structure of chromosomes have greatly
advanced our understanding of gene regulatio [44]. For example, Ma et al. developed a novel
method called Dnase Hi-C that determines the interactions of lincRNA promoters with DNA en-
hancer region [44]. Their method involves cross-linking nearby DNA strands, followed by DNAse
I digestion, proximity ligation between the cross-linked strands and DNA sequencing. Rather
than using restrictive enzyme (RE) as done in conventional Hi-C, which generates predictable
and consistent fragment ends, DNase I produces a heterogeneous mixture of fragment ends that
greatly improves the efficiency and resolution. They were able to fine-map cell specific 3D or-
ganization of 998 lincRNA promoters. They demonstrated that lincRNA expression is tightly
controlled by complex mechanisms including super-enhancers and PRCs. Known functions and
mechanisms of lincRNAs
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Historically, lincRNAs have been shown to have a greater likelihood to be functionally associated
with their nearest neighbouring protein-coding genes. However, more recent analyses show that
the expression correlation between a lincRNA and its closest coding gene is not statistically
significant when compared to the correlation between two neighbouring protein-coding gene [8,
45]. While complementary base pairing may be the mechanism of action for some small RNAs
such as microRNAs, lincRNAs by their nature are unlikely to exert their regulatory function
solely through sequence pairing. Instead, lincRNAs have been shown to mediate the interplay
between many molecular species simultaneousl [46]. LincRNAs affect gene expression by many
different mechanisms – from chromatin remodelling and epigenetic regulation, to transcriptional,
post-transcriptional, and protein-level control. So far, no unifying genome-wide theme has been
found to explain all the complexities of lincRNA regulation. We review the handful of competing
theories that attempt to address this problem.
a. LincRNAs involved in chromatin remodelling
Epigenetics is a vital means of DNA patterning to regulate gene expressio [47]. PRCs exert
gene silencing epigenetically by histone modifications and DNA chemical alterations such as
methylation [42]. Recruitment of PRCs to certain genomic locations is mediated by specific
lincRNAs. Thus, the differential expression of certain lincRNAs (such as HOTAIR) can lead to
activation or deactivation of transcription on the genom [48]. The vital role of gene suppres-
sion due to lincRNAs has been implicated in the pathology of cancers, where dysregulation of
individual lincRNAs release cell cycle control resulting in an increase in cell proliferatio [49].
Complicating matters, thousands of lincRNAs were found bound by PRC2 within various cell
types [4], suggesting the widespread interaction of lincRNAs with the epigenetic modification
machinery.
b. LincRNAs as transcription co-factors
Many lincRNAs are known to act as transcription co-factors. In some cases, the act of transcrip-
tion of a lincRNA may positively or negatively affect expression of nearby genes [50]. Dimitrova
et al. showed that lincRNA-p21 acts as a transcriptional coactivator and was required for re-
cruitment of ribonucleoproteins to promoter elements associated with pre-mRN [51]. MALAT1
is also known to act as a transcription co-factor. This lincRNA is well characterized as one
of the most highly expressed mammalian lincRNAs. It is also known to significantly affect
the metastasic process in lung adenocarcinoma, by enhancing the expression of cell motility
genes [52]. It was found that MALAT1 acts as a molecular scaffold to allow gene expression
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by promoting the interaction among unmethylated PRC2, E2F1 transcription factor, histone
markers, and the other transcriptional co-activator complexe [53]. Interestingly, this protein
sequestration mechanism of ncRNA is not unique to eukaryotes, and it also occurs in bacteri
[54].
c. Competing endogenous RNA hypothesis of lincRNAs
The competing endogenous RNA (ceRNA) hypothesis is a theory that lncRNAs (including
lincRNAs) regulate gene expression by acting as microRNA sponge [55]. The inhibition of
specific mRNA translation is modulated by microRNA depletion through lncRNAs harbouring
microRNA binding sites. By effectively competing for the same microRNA, these lncRNAs
exert a level of competitive inhibition. Based on this hypothesis, Liu et al developed a database
of lincRNAs that were predicted to have functional associations with protein-coding genes [56].
Some exemplary lincRNAs that function as ceRNAs are the HUL [57] and LINC-RO [33]. HULC
was shown to be the molecular sponge of a series of microRNAs including miR-372, which induces
phosphorylation of CREB in liver cancer [57], and LINC-ROR shares the microRNA response
elements with core transcription factors Oct4, Sox2, and Nanog and thus increases expression
of these genes by competing for microRNAs [58]. Although some lincRNAs act as ceRNAs, it
is unclear how prevalent this mechanism is among all lincRNAs.
d. LincRNAs as evolutionary reservoirs
While lincRNAs have less sequence conservation than protein-coding genes, they have a greater
degree of secondary motif conservation compared to mRNA [59]. These elements may explain
the origins of lincRNAs, which provide a reservoir of evolutionarily constrained RNA motif
[59, 60] to supply extra genetic modules for evolutionary tinkering. It is also known that
Retrotransposon and tandem repeat sequences are more common within lincRNAs compared
to protein-coding gene [61]. Embedded microRNAs and the hypothesized ceRNA mechanism
mentioned earlier may be accounted for by such duplication events, as modulating copy number
of an embedded microRNA or target site would allow for fine-tuned regulatio [55, 62].
Computational methods for lincRNA target prediction
There have been many attempts to computationally identify the function of lincRNAs. Given
the length of lincRNA sequences and the complexity of their potential 3D structures along
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with the RNA and protein partners, this is a very challenging task. We review the different
computational approaches in the following.
a. Correlation with protein coding genes and biological processes
One of the simplest approaches to determine the function of lincRNAs is to examine their
correlations with protein coding genes [63]. However, this is a “black box” approach that
identifies neither causality nor lincRNA functions at the molecular level. Another naive approach
is to relate the function of lincRNAs to the nearby protein coding gene [64]. Many lincRNAs
have been found to exert regulatory activity on protein coding genes in cis [44, 51]. However,
Khalil et al. found that knockdown of six different lincRNAs did not affect the expression of
level of nearby gene [4]. This suggests that lincRNAs can work in trans as well, and that the
correlation between a lincRNA and its nearby protein coding genes may not necessarily be a
causative relationship, but rather a result of sharing a region of active transcription.
b. Relation between lincRNAs with microRNAs and other small non-coding RNAs
Other more sophisticated tools have been developed to identify more succinct functions. Boerner
and McGinnis constructed a pipeline to seek functions of lncRNAs in Zea May [31]. Using
BLAST search, they found that the majority of lncRNAs have strong homology to small RNA
molecules. They hypothesized that many lncRNAs are simply unprocessed pre-cursors to small
non-coding RNAs, such as microRNA, shRNA and siRN [31]. Based on the “ceRNA hypothesis”
mentioned earlier, Liu et al developed “linc2GO”, a software for identifying mRNA and lincRNA
pair [56]. Using predicted microRNA targets from miRanda, TargetScan and PITA software,
they predicted microRNA targets on both mRNAs and lincRNAs; The mRNAs and lincRNAs
that had statistically significant target sites for a particular microRNA were proposed to have
a “competing endogenous” relationship.
c. Machine learning approaches to target and functional prediction
Machine learning methods have been used successfully to classify whether transcripts are coding
or non-coding. However, machine learning methods to identify the targets of lincRNAs have
not seen much success. Comparatively, there has been much more success in using supervised
learning approaches to identify microRNA targets, such as TargetSca [65], SvMicr [66] and
mirMar [67]. Still progress is being made towards lincRNA functional prediction. Glazko et
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al. used support vector machines (SVM) to predict lncRNA and PRC2 binding using human
lincRNA associated with PRC2 as training data. With the classification model, they were able
to predict 59.4% of lncRNAs which bind to PRC2 in mice [68]. The model was based off of
the dataset by Khalil et al. [4] which found roughly 20% of lincRNAs to associate with PRC2.
However, it remains unclear whether the associations were spurious or led to sequence specific
chromatin regulation.
d. LincRNA functional prediction through the higher-order structure
Perhaps the least explored lincRNA prediction approach is functional prediction through tertiary
and quaternary structure. As the structure of RNA molecules are related to their functions,
predicting the structure of complexes between RNA-RNA, and RNA-protein interactions could
elucidate functional properties. Several RNA-RNA interaction prediction tools are available,
usually based on free-energy, such as RNAhybri [69] and RNADuple [SEBASTIANFast].
RNA-protein interaction prediction tools exist as well, such as RPIseq which uses a Random
Forest classification approac [70] or RNApred, which uses an SVM approac [71]. However,
there have not been many attempts for lincRNA functional prediction. Many of the protein
complexes interacting with lincRNAs do not fall into common binding motif [40]. Furthermore,
functional prediction is complicated by the “n-body problem”, since protein, RNA and DNA
can be complexed with lincRNAs simultaneously.
e. Downstream target prediction through directed graphs
Reverse engineering of gene regulatory networks has been an area of research before the explosion
of next generation sequencing and lincRNA researc [72]. Approaches such as Bayesian networks,
information-theoretic approaches and ordinary differential equations have shown strong perfor-
manc [73]. Generally, a perturbation of the system (such as gene knockout, overexpression or
drug treatment) is performed which forces a node (i.e., a gene) on a regulatory network graph
to be forcibly turned on or turned off. This perturbation produces direct causative (rather
than correlative) downstream effects that can be captured through microarrays and quantita-
tive methods. Recently, Jiang et al. published a database (lncRNA2Target) describing lncRNA
knockdown and overexpression experiments, followed by gene quantification by microarray or
qPC [74]. These types of experiments can be a valuable resource for elucidating a lincRNA’s
targets and pathways.
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2.4 Conclusion
Statistical evaluation studies for lincRNAs are urgently needed, as datasets produced by these
various methods have thus far shown only modest overlaps in their identified lincRNAs [14]
Besides lack of sequence conservation among lincRNAs, another major issue hindering functional
prediction is the lack of validated data. While there are many well-studied lincRNAs, there are
massively more unannotated lincRNAs. Machine learning methods often require a large training
dataset to produce accurate results. Several functional lincRNA/lncRNA databases exist (such
as lncrnaDB), however the number of entries are very low and do not categorize the function
of the lncRNAs in a systematic manne [75]. As more and more lincRNAs become functionally
validated, comprehensive and regularly updated databases would be a great source to build
good prediction methods. Perhaps even more important is the advancement of experimental
techniques to provide quality data required for the prediction. Currently, most experimental
techniques focus on a single protein or a small number of proteins (protein-centric) or a single
lincRNA or family of lincRNAs (RNA-centric [40]. New methods are required that can provide
high-throughput protein and RNA targets of thousands of lincRNAs in parallel.
2.5 Acknowledgements
This work was supported by grants K01ES025434 awarded by NIEHS through funds provided
by the trans-NIH Big Data to Knowledge (BD2K) initiative (www.bd2k.nih.gov), P20 COBRE
GM103457 awarded by NIH/NIGMS, and Medical Research Grant 14ADVC-64566 from Hawaii
Community Foundation to L.X. Garmire.
2.6 Competing interests
The authors declare that they have no competing interests.
2.7 Authors’ contributions
LXG planned the work. TC, JM, JW and LXG all wrote parts of the manuscript. TC and LXG
designed and finalized the manuscript.
Chapter 2: LincRNA review 20
References
1. Hangauer, M. J., Vaughn, I. W. & McManus, M. T. Pervasive transcription of the human
genome produces thousands of previously unidentified long intergenic noncoding RNAs.
PLoS genetics 9, e1003569. issn: 1553-7404 (2013).
2. Ezkurdia, I., Juan, D., Rodriguez, J. M., Frankish, A., Diekhans, M., Harrow, J., Vazquez,
J., Valencia, A. & Tress, M. L. Multiple evidence strands suggest that there may be as
few as 19 000 human protein-coding genes. Hum Mol Genet. issn: 1460-2083 (Electronic)
0964-6906 (Linking). doi:10.1093/hmg/ddu309 (2014).
3. Joyce, G. F. The antiquity of RNA-based evolution. Nature 418, 214–221. issn: 0028-0836
(2002).
4. Khalil, A. M., Guttman, M., Huarte, M., Garber, M., Raj, A., Morales, D. R., Thomas,
K., Presser, A., Bernstein, B. E. & van Oudenaarden, A. Many human large intergenic
noncoding RNAs associate with chromatin-modifying complexes and affect gene expres-
sion. Proceedings of the National Academy of Sciences 106, 11667–11672. issn: 0027-8424
(2009).
5. Volders, P.-J., Verheggen, K., Menschaert, G., Vandepoele, K., Martens, L., Vandesom-
pele, J. & Mestdagh, P. An update on LNCipedia: a database for annotated human
lncRNA sequences. Nucleic acids research 43, D174–D180. issn: 0305-1048 (2015).
6. Ulitsky, I., Shkumatava, A., Jan, C. H., Sive, H. & Bartel, D. P. Conserved function of
lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell
147, 1537–50. issn: 1097-4172 (Electronic) 0092-8674 (Linking) (2011).
7. Guttman, M., Russell, P., Ingolia, N. T., Weissman, J. S. & Lander, E. S. Ribosome
profiling provides evidence that large noncoding RNAs do not encode proteins. Cell 154,
240–251. issn: 0092-8674 (2013).
8. Cabili, M. N., Trapnell, C., Goff, L., Koziol, M., Tazon-Vega, B., Regev, A. & Rinn,
J. L. Integrative annotation of human large intergenic noncoding RNAs reveals global
properties and specific subclasses. Genes Dev 25, 1915–27. issn: 1549-5477 (Electronic)
0890-9369 (Linking) (2011).
9. Iyer, M. K., Niknafs, Y. S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., Barrette, T. R.,
Prensner, J. R., Evans, J. R. & Zhao, S. The landscape of long noncoding RNAs in the
human transcriptome. Nature Genetics. issn: 1061-4036 (2015).
Chapter 2: LincRNA review 21
10. Mercer, T. R., Gerhardt, D. J., Dinger, M. E., Crawford, J., Trapnell, C., Jeddeloh, J. A.,
Mattick, J. S. & Rinn, J. L. Targeted RNA sequencing reveals the deep complexity of the
human transcriptome. Nat Biotechnol 30, 99–104. issn: 1546-1696 (Electronic) 1087-0156
(Linking) (2012).
11. Sauvageau, M., Goff, L. A., Lodato, S., Bonev, B., Groff, A. F., Gerhardinger, C., Sanchez-
Gomez, D. B., Hacisuleyman, E., Li, E. & Spence, M. Multiple knockout mouse models
reveal lincRNAs are required for life and brain development. Elife 2, e01749. issn: 2050-
084X (2013).
12. Ge, X., Chen, Y., Liao, X., Liu, D., Li, F., Ruan, H. & Jia, W. Overexpression of long
noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal
cancer. Medical oncology 30, 1–6. issn: 1357-0560 (2013).
13. Guttman, M. et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse
reveals the conserved multi-exonic structure of lincRNAs. Nature Biotechnology 28, 503–
U166. issn: 1087-0156 (2010).
14. Marques, A. C. & Ponting, C. P. Catalogues of mammalian long noncoding RNAs: modest
conservation and incompleteness. Genome Biol 10, R124 (2009).
15. Ning, S., Wang, P., Ye, J., Li, X., Li, R., Zhao, Z., Huo, X., Wang, L., Li, F. & Li, X. A
global map for dissecting phenotypic variants in human lincRNAs. European Journal of
Human Genetics 21, 1128–1133. issn: 1018-4813 (2013).
16. Guttman, M. et al. Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature 458, 223–7. issn: 1476-4687 (Electronic) 0028-
0836 (Linking) (2009).
17. Garmire, L. X., Garmire, D. G., Huang, W., Yao, J., Glass, C. K. & Subramaniam, S. A
global clustering algorithm to identify long intergenic non-coding RNA–with applications
in mouse macrophages. PLoS One 6, e24051. issn: 1932-6203 (Electronic) 1932-6203
(Linking) (2011).
18. Djebali, S. et al. Landscape of transcription in human cells. Nature 489, 101–8. issn:
1476-4687 (Electronic) 0028-0836 (Linking) (2012).
19. Yang, L., Lin, C., Liu, W., Zhang, J., Ohgi, K. A., Grinstein, J. D., Dorrestein, P. C.
& Rosenfeld, M. G. ncRNA- and Pc2 methylation-dependent gene relocation between
nuclear structures mediates gene activation programs. Cell 147, 773–88. issn: 1097-4172
(Electronic) 0092-8674 (Linking) (2011).
Chapter 2: LincRNA review 22
20. He, Y., Vogelstein, B., Velculescu, V. E., Papadopoulos, N. & Kinzler, K. W. The antisense
transcriptomes of human cells. Science 322, 1855–7. issn: 1095-9203 (Electronic) 0036-
8075 (Linking) (2008).
21. Kawaji, H., Lizio, M., Itoh, M., Kanamori-Katayama, M., Kaiho, A., Nishiyori-Sueki, H.,
Shin, J. W., Kojima-Ishiyama, M., Kawano, M. & Murata, M. Comparison of CAGE
and RNA-seq transcriptome profiling using clonally amplified and single-molecule next-
generation sequencing. Genome research 24, 708–717. issn: 1088-9051 (2014).
22. Ulitsky, I. & Bartel, D. P. lincRNAs: genomics, evolution, and mechanisms. Cell 154,
26–46. issn: 0092-8674 (2013).
23. Tahira, A. C., Kubrusly, M. S., Faria, M. F., Dazzani, B., Fonseca, R. S., Maracaja-
Coutinho, V., Verjovski-Almeida, S., Machado, M. C. & Reis, E. M. Long noncoding
intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer.
Mol Cancer 10, 141. issn: 1476-4598 (Electronic) 1476-4598 (Linking) (2011).
24. Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C.,
Laxman, B., Asangani, I. A., Grasso, C. S. & Kominsky, H. D. Transcriptome sequencing
across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated
in disease progression. Nature biotechnology 29, 742–749. issn: 1087-0156 (2011).
25. Kong, L., Zhang, Y., Ye, Z. Q., Liu, X. Q., Zhao, S. Q., Wei, L. & Gao, G. CPC: assess the
protein-coding potential of transcripts using sequence features and support vector ma-
chine. Nucleic Acids Res 35, W345–9. issn: 1362-4962 (Electronic) 0305-1048 (Linking)
(2007).
26. Sun, K., Chen, X., Jiang, P., Song, X., Wang, H. & Sun, H. iSeeRNA: identification of
long intergenic non-coding RNA transcripts from transcriptome sequencing data. BMC
genomics 14, S7. issn: 1471-2164 (2013).
27. Jalali, S., Jayaraj, G. G. & Scaria, V. Integrative transcriptome analysis suggest pro-
cessing of a subset of long non-coding RNAs to small RNAs. Biol Direct 7, 25. issn:
1745-6150 (Electronic) 1745-6150 (Linking) (2012).
28. Sakharkar, M. K., Chow, V. T. & Kangueane, P. Distributions of exons and introns in
the human genome. In Silico Biol 4, 387–93. issn: 1386-6338 (Print) 1386-6338 (Linking)
(2004).
29. Semon, M. & Duret, L. Evidence that functional transcription units cover at least half of
the human genome. Trends in Genetics 20, 229–232. issn: 0168-9525 (2004).
Chapter 2: LincRNA review 23
30. Qiu, M. T., Hu, J. W., Yin, R. & Xu, L. Long noncoding RNA: an emerging paradigm of
cancer research. Tumour Biol 34, 613–20. issn: 1423-0380 (Electronic) 1010-4283 (Link-
ing) (2013).
31. Boerner, S. & McGinnis, K. M. Computational identification and functional predictions
of long noncoding RNA in Zea mays. PloS one 7, e43047. issn: 1932-6203 (2012).
32. Fan, X.-N. & Zhang, S.-W. lncRNA-MFDL: identification of human long non-coding
RNAs by fusing multiple features and using deep learning. Molecular BioSystems (2015).
33. Wang, Y., Xu, Z., Jiang, J., Xu, C., Kang, J., Xiao, L., Wu, M., Xiong, J., Guo, X. &
Liu, H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in
human embryonic stem cell self-renewal. Dev Cell 25, 69–80. issn: 1878-1551 (Electronic)
1534-5807 (Linking) (2013).
34. Xie, C., Yuan, J., Li, H., Li, M., Zhao, G., Bu, D., Zhu, W., Wu, W., Chen, R. & Zhao, Y.
NONCODEv4: exploring the world of long non-coding RNA genes. Nucleic acids research
42, D98–D103. issn: 0305-1048 (2014).
35. Flicek, P. et al. Ensembl 2012. Nucleic Acids Res 40, D84–90. issn: 1362-4962 (Electronic)
0305-1048 (Linking) (2012).
36. Harrow, J. et al. GENCODE: the reference human genome annotation for The ENCODE
Project. Genome Res 22, 1760–74. issn: 1549-5469 (Electronic) 1088-9051 (Linking)
(2012).
37. Hsu, F., Kent, W. J., Clawson, H., Kuhn, R. M., Diekhans, M. & Haussler, D. The UCSC
known genes. Bioinformatics 22, 1036–1046. issn: 1367-4803 (2006).
38. Griffiths-Jones, S., Moxon, S., Marshall, M., Khanna, A., Eddy, S. R. & Bateman, A.
Rfam: annotating non-coding RNAs in complete genomes. Nucleic acids research 33,
D121–D124. issn: 0305-1048 (2005).
39. Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome.
Nature 489, 57–74. issn: 1476-4687 (Electronic) 0028-0836 (Linking) (2012).
40. McHugh, C. A., Russell, P. & Guttman, M. Methods for comprehensive experimental
identification of RNAa-protein interactions. Genome Biol 15, 203 (2014).
41. Shi, L., Song, L., Fitzgerald, M., Maurer, K., Bagashev, A. & Sullivan, K. E. Noncoding
RNAs and LRRFIP1 regulate TNF expression. J Immunol 192, 3057–67. issn: 1550-6606
(Electronic) 0022-1767 (Linking) (2014).
42. Goff, L. A. & Rinn, J. L. Poly-combing the genome for RNA. Nature structural & molec-
ular biology 20, 1344–1346. issn: 1545-9993 (2013).
Chapter 2: LincRNA review 24
43. Gong, C. & Maquat, L. E. Affinity Purification of Long Noncoding RNA-Protein Com-
plexes from Formaldehyde Cross-Linked Mammalian Cells 81–86. isbn: 1493913689 (Springer,
2015).
44. Ma, W., Ay, F., Lee, C., Gulsoy, G., Deng, X., Cook, S., Hesson, J., Cavanaugh, C.,
Ware, C. B. & Krumm, A. Fine-scale chromatin interaction maps reveal the cis-regulatory
landscape of human lincRNA genes. Nature methods. issn: 1548-7091 (2014).
45. Wright, M. W. A short guide to long non-coding RNA gene nomenclature. Human Ge-
nomics 8. issn: 1473-9542. doi:Doi10.1186/1479-7364-8-7 (2014).
46. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into
functions. Nature Reviews Genetics 10, 155–159. issn: 1471-0056 (2009).
47. Di Croce, L. & Helin, K. Transcriptional regulation by Polycomb group proteins. Nat
Struct Mol Biol 20, 1147–55. issn: 1545-9985 (Electronic) 1545-9985 (Linking) (2013).
48. Loewen, G., Zhuo, Y., Zhuang, Y., Jayawickramarajah, J. & Shan, B. lincRNA HOTAIR
as a novel promoter of cancer progression. Journal of Cancer Research Updates 3, 134–
140. issn: 1929-2279 (2014).
49. Gutschner, T. & Diederichs, S. The hallmarks of cancer: a long non-coding RNA point of
view. RNA Biol 9, 703–19. issn: 1555-8584 (Electronic) 1547-6286 (Linking) (2012).
50. Wilusz, J. E., Sunwoo, H. & Spector, D. L. Long noncoding RNAs: functional surprises
from the RNA world. Genes Dev 23, 1494–504. issn: 1549-5477 (Electronic) 0890-9369
(Linking) (2009).
51. Dimitrova, N., Zamudio, J. R., Jong, R. M., Soukup, D., Resnick, R., Sarma, K., Ward,
A. J., Raj, A., Lee, J. T., Sharp, P. A. & Jacks, T. LincRNA-p21 activates p21 in cis to
promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell
54, 777–90. issn: 1097-4164 (Electronic) 1097-2765 (Linking) (2014).
52. Wang, K. C. & Chang, H. Y. Molecular Mechanisms of Long Noncoding RNAs. Molecular
Cell 43, 904–914. issn: 1097-2765 (2011).
53. Yang, L., Duff, M. O., Graveley, B. R., Carmichael, G. G. & Chen, L.-L. Genomewide
characterization of non-polyadenylated RNAs. Genome Biol 12, R16 (2011).
54. Duss, O., Michel, E., Yulikov, M., Schubert, M., Jeschke, G. & Allain, F. H. T. Structural
basis of the non-coding RNA RsmZ acting as a protein sponge. Nature 509, 588–+. issn:
0028-0836 (2014).
55. Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A ceRNA hypothesis: the
Rosetta Stone of a hidden RNA language? Cell 146, 353–8. issn: 1097-4172 (Electronic)
0092-8674 (Linking) (2011).
Chapter 2: LincRNA review 25
56. Liu, K., Yan, Z., Li, Y. & Sun, Z. Linc2GO: a human LincRNA function annotation
resource based on ceRNA hypothesis. Bioinformatics 29, 2221–2222. issn: 1367-4803
(2013).
57. Wang, J., Liu, X., Wu, H., Ni, P., Gu, Z., Qiao, Y., Chen, N., Sun, F. & Fan, Q. CREB up-
regulates long non-coding RNA, HULC expression through interaction with microRNA-
372 in liver cancer. Nucleic Acids Res 38, 5366–83. issn: 1362-4962 (Electronic) 0305-1048
(Linking) (2010).
58. Wang, Y., Li, Y., Wang, Q., Lv, Y., Wang, S., Chen, X., Yu, X., Jiang, W. & Li, X.
Computational identification of human long intergenic non-coding RNAs using a GA-
SVM algorithm. Gene 533, 94–99. issn: 0378-1119 (2014).
59. Kapusta, A. & Feschotte, C. Volatile evolution of long noncoding RNA repertoires: mech-
anisms and biological implications. Trends in Genetics 30, 439–452. issn: 0168-9525
(2014).
60. Smith, M. A., Gesell, T., Stadler, P. F. & Mattick, J. S. Widespread purifying selection
on RNA structure in mammals. Nucleic acids research 41, 8220–8236. issn: 0305-1048
(2013).
61. Kelley, D. & Rinn, J. Transposable elements reveal a stem cell-specific class of long
noncoding RNAs. Genome Biology 13. issn: 1474-7596. doi:Doi10.1186/Gb- 2012-
13-11-R107 (2012).
62. Labialle, S. & Cavaille, J. Do repeated arrays of regulatory small-RNA genes elicit genomic
imprinting? Bioessays 33, 565–573. issn: 1521-1878 (2011).
63. Guo, X., Gao, L., Liao, Q., Xiao, H., Ma, X., Yang, X., Luo, H., Zhao, G., Bu, D. &
Jiao, F. Long non-coding RNAs function annotation: a global prediction method based
on bi-colored networks. Nucleic acids research 41, e35–e35. issn: 0305-1048 (2013).
64. Ma, H., Hao, Y., Dong, X., Gong, Q., Chen, J., Zhang, J. & Tian, W. Molecular mech-
anisms and function prediction of long noncoding RNA. The Scientific World Journal
2012 (2012).
65. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. cell 120,
15–20. issn: 0092-8674 (2005).
66. Liu, H., Yue, D., Chen, Y., Gao, S.-J. & Huang, Y. Improving performance of mammalian
microRNA target prediction. BMC bioinformatics 11, 476. issn: 1471-2105 (2010).
Chapter 2: LincRNA review 26
67. Menor, M., Ching, T., Zhu, X., Garmire, D. & Garmire, L. X. mirMark: a site-level and
UTR-level classifier for miRNA target prediction. Genome biology 15, 500. issn: 1465-
6906 (2014).
68. Glazko, G. V., Zybailov, B. L. & Rogozin, I. B. Computational prediction of polycomb-
associated long non-coding RNAs. PloS one 7, e44878. issn: 1932-6203 (2012).
69. Kruger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and
flexible. Nucleic acids research 34, W451–W454. issn: 0305-1048 (2006).
70. Muppirala, U., Lewis, B. A. & Dobbs, D. Computational tools for investigating RNA-
protein interaction partners. J Comput Sci Syst Biol 6, 182–187 (2013).
71. Kumar, M., Gromiha, M. M. & Raghava, G. P. SVM based prediction of RNA-binding
proteins using binding residues and evolutionary information. Journal of Molecular Recog-
nition 24, 303–313. issn: 1099-1352 (2011).
72. Murphy, K. & Mian, S. Modelling gene expression data using dynamic Bayesian networks
Report (Technical report, Computer Science Division, University of California, Berkeley,
CA, 1999).
73. Bansal, M., Belcastro, V., Ambesi-Impiombato, A. & Di Bernardo, D. How to infer gene
networks from expression profiles. Molecular systems biology 3. issn: 1744-4292 (2007).
74. Jiang, Q., Wang, J., Wu, X., Ma, R., Zhang, T., Jin, S., Han, Z., Tan, R., Peng, J.
& Liu, G. LncRNA2Target: a database for differentially expressed genes after lncRNA
knockdown or overexpression. Nucleic acids research 43, D193–D196. issn: 0305-1048
(2015).
75. Galperin, M. Y., Rigden, D. J. & Fernandez-Suarez, X. M. The 2015 Nucleic Acids Re-
search Database Issue and Molecular Biology Database Collection. Nucleic acids research
43, D1–D5. issn: 0305-1048 (2015).
C
h
a
p
ter
2
:
L
in
cR
N
A
review
27
Table 1: Summary of lncRNA/lincRNA databases
Project Name Species Purpose
Human Body Map Human A reference set of lincRNAs
ChIPBase Various (incl. Human and Mouse) A resource for lncRNA transcrip�onal regula�on and expression proﬁles of ncRNA (lncRNA, microRNAs, etc.)
NONCODE Various (incl. Human and Mouse) A large lncRNA database integra�ng various databases and references
lncRNAdb
Various (incl. Human and 
Mouse) A database of lncRNAs having biological func�on or regulatory roles
ncRNA expression 
database (NRED)
Human and Mouse Expression database for human and mouse lncRNAs
LNCipedia Various (incl. Human and Mouse) A large database of lncRNA transcripts and annota�on
LncRNADisease Human A database of lncRNAs associated with human diseases
DIANA-LncBase Human and Mouse A database of experimentally veriﬁed and predicted microRNA targets on lncRNAs
lncRNA2Target Human and Mouse A collec�on of lncRNA knockout experiments and downstream regula�on
starBase 2.0 Human, Mouse and C. 
elegans
A collec�on of lncRNA and predicted microRNA targets; lncRNA expression proﬁles from TCGA data
lncRNAMap Human A resource for exploring lncRNA expression proﬁles and interac�on with small RNAs (siRNA, microRNAs, etc.)
lncRNAWiki Human An open wiki style lncRNA database
MONOCLdb Mouse A mouse noncoding database detailing func�onal enrichment of lncRNA in response to respiratory disease caused by inﬂuenza and SARS-CoV
lncRNome Human A searchable database for long noncoding RNAs in humans and various proper�es, such as predicted structure, SNPs and epigene�c modiﬁca�ons
PLncDB Arabidopsis thaliana A database dedicated to A. thaliana plant lncRNA transcriptome, including informa�on on epigene�c modiﬁca�on
Func�onal lncRNA 
Database
Human, Mouse and Rat A database of experimentally validated func�onal lncRNAs
lnCeDB Human A database of lncRNA ac�ng as ceRNA
Linc2GO Human A database of lncRNA ac�ng as ceRNA and biological processes based on GO annota�on
lncRNASNP Human and Mouse A database cataloging micro-RNA interac�ons and SNPs in lncRNAs and their impact on secondary structure
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2.8 Chapter summary
In this chapter, we review the current state of lincRNA research from the perspective of compu-
tational genomics. How has high throughput sequencing and subsequent computational analysis
changed the study of non-coding RNAs? Through sequencing methods such as CLIP-Seq and
RNA-Seq, thousands of novel lincRNAs have been identified in recent years. The goal of this
dissertation is the application of these methods to investigate lincRNA relation to cancer re-
search.
Thus, better understanding the field has helped accomplish the research in later chapters. For
example, in chapter 4 and chapter 7, we used genomic annotation derived from early lincRNA
studies in order to quantify lincRNAs in RNA-Seq samples. Through extensive literature review,
we find that there remains many additional challenges to lincRNA genomic research. Such chal-
lenges include better understanding the both the breadth and depth of the lincRNA molecular
mechanisms, better predicting their roles in biological pathways and building better databases
related to lincRNA function and metadata.
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3.1 Preface
It is crucial for researchers to optimize RNA-seq experimental designs for differential expres-
sion detection. Currently, the field lacks general methods to estimate power and sample size
for RNA-Seq in complex experimental designs, under the assumption of the negative binomial
distribution. We simulate RNA-Seq count data based on parameters estimated from six widely
different public datasets and calculate the statistical power in paired and unpaired sample ex-
periments. We comprehensively compare five differential expression analysis packages: DESeq,
edgeR, DESeq2, sSeq and EBSeq, and evaluate their performance by power, receiver opera-
tor characteristic (ROC) curves and other metrics including Areas Under the Curve (AUC),
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Matthews Correlation Coefficients (MCC) and F-measures. DESeq2 and edgeR tend to give
the best performance in general. In terms of increasing statistical power, however increasing
sample size is more potent than sequencing depth, especially when the sequencing depth reaches
20 million reads. Long intergenic non-coding RNAs (lincRNA) yields lower power relative to
the protein coding mRNAs, given their lower expression level in the same RNA-Seq experi-
ment. On the other hand, paired-sample RNA-Seq significantly enhances the statistical power,
confirming the importance of considering the multi-factor experimental design. Finally, a local
optimal power is achievable for a given budget constraint, and the dominant contributing factor
is sample size rather than the sequencing depth. In conclusion, we provide a power analysis tool
that captures the dispersion in the data and can serve as a practical reference under the budget
constraint of RNA-Seq experiments.
3.2 Introduction
RNA-Seq is a new approach to transcriptome analysis based on next generation sequencing
(NGS) technology. It is quickly replacing microarrays as the platform for gene expression
profiling, owing to the advantages of high repeatability but low noise level. Beyond revealing
gene expression patterns, the information gained from RNA-Seq has already greatly enhanced
our understanding in many other areas, such as mechanisms of alternative splicing and the
discovery of many novel isoforms of mRNA transcripts [1, 2]. Furthermore, it has led to the
discovery of many novel RNA transcripts, as well as the massive amount of newly discovered
long intergenic non-coding RNAs (lincRNAs) relative to the small number of lincRNAs identified
before RNA-Seq became popula [1–4].
RNA-Seq data are discrete counts, and the Poisson distribution had previously been used to an-
alyze RNA-Seq data [5–10]. Several earlier RNA-Seq studies have attempted to use the Poisson
distribution to perform power analysis and sample size estimation using algebraic manipulation
of Wald statistics and likelihood ratio methods [11, 12]. Chen et al. studied several test statistics
(Wald test, likelihood ratio test, Fishera’s exact test, variance stabilized test and conditional
binomial test) on Poisson distribution simulations and compared their performances in terms of
statistical power [12]. They justified the use of the Poisson distribution in the simulation data
by arguing that the Poisson distribution can be used when there are only technical replicates.
However, the much larger variation from biologic replicates [13] was not addressed in the pa-
per. Moreover, it was found that the Poisson distribution does not fit the empirical data due
to the over-dispersion mainly caused by natural biological variation [8, 14]. As a result, the
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negative binomial distribution has become widely used to analyze RNA-Seq data which allows
more flexibility in assigning between-sample variation.
It is very challenging to estimate power and satisfactory sample size for the RNA Seq differential
expression (DE) tests. One issue is that analytical solutions may not always exist for RNA-Seq
sample size and power calculations [7, 15, 16], due to the complexity of the negative binomial
model. Instead, numerical methods such as Monte Carlo simulations have been employed to
analyze the properties of negative binomial models [9, 15–19]. Other issues involved in power
estimation include the combination of multiple hypotheses testing (MHT), p-value calculation,
and various ways to estimate dispersion and normalization factors for library sizes. In RNA-Seq
analysis, tens of thousands of genes are analyzed for statistical significance simultaneously. A
naive approach would analyze each individual gene independently without consideration of the
entire dataset. However, since correlations exist among different genes within the same sample
as well as the same genes among related samples, more accurate results can be obtained by
making sensible assumptions regarding such information. This strategy has been implemented
in recent RNA-Seq DE packages such as DESeq, DESeq2, edgeR, EBSeq and sSeq [20–24].
Several studies examined differences between statistical packages of RNA-Seq DE analysis [18,
23, 25, 26]. Nookaew et al. evaluated the differences in DE using the experimental data of yeasts
in different growth conditions. Conversely others [18, 23, 25, 27] calculated true positive rate
(TPR) and false positive rate (FPR) using simulated datasets under varying parameters. In this
report, we took a unique combination of simulated and experimental data approaches, where
the parameters in the simulations were based on six different experimental data sets that span
a wide range of conditions and samples. This approach is solidly grounded upon realistic RNA-
Seq data, yet it is very flexible and can realistically reveal the relationships among parameters
relevant to the power analysis. We analyzed the entire simulated datasets as well as sub datasets
that are stratified by log2 fold changes (LFC) or expression levels, so that we could detect DE
limits given varying parameters in the model. To follow the most recent progress in the RNA-
Seq DE area as well as to present results with minimal bias, we selected two widely used
methods (DESeq and edgeR) and three recent DE analysis packages released within the past
year (DESeq2, EBSeq and sSeq). DESeq2, the most recent derivative of DESeq, was reported
to have better power compared to the DESeq package [28]. EBSeq displayed robustness and
better performance in analyzing isoform-level expression, yet comparable to other methods in
analyzing gene-level expression [21]. Additionally, sSeq package was chosen as it achieved better
sensitivity for experiments with small sample sizes [29]. Through comprehensive comparison
among all these methods, we aimed to reveal the true relationships between statistical power
and its contributing factors.
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3.3 Methods
In this study, we evaluated two different types of experimental designs: paired (two-factor) and
unpaired (single-factor) designs. In unpaired experimental designs, samples or individuals in
one condition are compared to independent samples in another condition. Paired design is a
special case of multi-factor (eg. two-factor, three-factor etc.) designs which consider factors
that affect the expression level of each sample. Specifically, in paired experiments each sample
has two conditions (such as cancer tissue and cancer adjacent normal tissue) that both yield
RNA-Seq data. In this study, we used the paired experimental design as a demonstration of the
multi-factor design, where the pairing information was treated as the second factor that affects
the expression level of each gene.
In our simulated data, we used a general linear model (GLM) with negative binomial distri-
bution. We estimated their parameters from public datasets employed in this study. For the
unpaired datasets of two groups, the counts for a particular gene in a sample i were modeled by
the formula:
logµi = x
T
i + logNi (1)
Here µi is the counts for sample i, Ni is the normalized library size for sample i, I is the vector
of coefficients for the two different experimental conditions, and xi is a vector of length two
indicating whether sample i belongs to condition one or condition two in the experiment. The
LFC was then determined by the difference of the two elements of I. For paired-sample designs,
the counts for a gene were modified from (1) with the following formula:
logµi = x
T
1iβ + x
T
2i + logNi (2)
Here a new vector of coefficients P of length n/2 is introduced to represent the relative expression
level for each pair of samples. The other new vector x2i denotes which pair a particular sample
belongs to.
The GLM parameters for each gene in each real dataset were estimated by the glm function
in R, using a log link function for the count data. The family of negative binomial distri-
butions was calculated by the negative.binomial function in the MASS package. The amount
of dispersion per gene was estimated using the Cox-Reid approximate conditional maximum
likelihood (CR-APL) method [30] . This method modifies the maximum likelihood estimate of
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dispersion by accounting for the experimental design through the Fisher’s Information Matrix
in the log-likelihood function [30]. CR-APL is implemented as the dispCoxReidInterpolateTag-
wise function in the edgeR package, and it is also used in DESeq to estimate the dispersion in
multi-factor experimental designs.
3.3.1 Generation of simulated count data
The count data were generated from the negative binomial distribution. For each gene, the
count Yi was given by:
Yi ∼ NB(mean = µi, var = µi(1 + µiφi)) (3)
Here, φi is the per-gene dispersion calculated by the CR-APL method, and the expected value
µi is a function of the library size. The library size of each simulated sample was generated from
a uniform distribution whose parameters were estimated from the maximum and minimum of
the real dataset.
We used five statistical packages for DE testing: DESeq (version 1.14.0) and edgeR (version
3.4.2) methods, as well as three newer packages released within the past year: DESeq2 (version
1.2.9), EBSeq (version 1.3.1) and sSeq (version 1.0.0). All packages are implemented in the
Bioconductor/R platform. We determined the truth data for DE in the simulation as the
overlapping DE genes detected from all five statistical packages used in the study, using the
original real datasets. This approach is similar to other studies [23, 27]. In the simulation, the
LFC of DE genes was determined by the equation 1 and 2. We set the LFC of genes that are
not differentially expressed to zero in the generation of the simulated count data, as done by
others [27].
3.3.2 Description of public datasets used in the study
The six public datasets are listed in Table 1 (see Results). We enumerate the parameters of
each dataset in the following:
Bottomly – We used this published data set to compare gene expression between C57BL/6J
and DBA/2J mouse strains [31]. An average of 22 million reads was generated for 21 mice (10
C57BL/6J and 11 DBA/2J). Count data were downloaded from the ReCount project [32].
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Bullard – Ambion’s human brain reference RNA (brain) and Stratagene’s Universal Human
Reference(UHR) RNA were compared [33]. An average of 12.5 million reads was generated
from 7 brain and 7 UHR technical replicates. Count data were also downloaded from ReCount
project [32].
Huang a- Differentiated embryonic stem cells were compared with fetal head tissues of 14.5
days post coitum. Four biological samples were compared using various rRNA removal methods,
in order to analyze coding and non-coding RNAs [34]. Twenty-two technical replicates were
used with an average of 17.7 million reads per sample. Short Read Archive (SRA) reads were
downloaded from GEO (GSE22959) and aligned with tophat to mm10 reference genome. Count
data were generated using HTSeq [35].
Montgomery-Pickrell (M-P) – RNA-seq data from 60 individuals of European descent [36]
and 69 individuals of Nigerian descent [37] were sequenced with an average sequencing depth of
17 million reads per sample. The datasets were used to analyze DE between the two populations.
Count data were downloaded from the ReCount project [32].
Tuch – Three paired tumor and non-tumor tissues from oral squamous cell carcinoma patients
were sequenced for an average of 205 million reads per sample [38]. Count data were downloaded
from Table S1 of the original publication.
Qian – West Nile Virus (WNV) transfection of macrophage cells from 10 healthy donors were
compared to mock transfection of the same cell culture with a total of 28 million reads per
sample [39]. Raw SRA read data were downloaded from GEO (GSE40718) and aligned with
tophat to Hg19 Refseq genes downloaded from UCSC Genome Browser. Count data were also
generated using HTSeq.
3.3.3 Detection of DE in unpaired (single-factor) experimental designs
We aimed to calculate p-values, sensitivity (power) and specificity over the range of parame-
ters. Toward these aims, we performed standard analyses with functions implemented in the five
RNA-Seq analysis packages DESeq2, DESeq, edgeR, sSeq and EBSeq. Specifically, in DESeq the
count data were analyzed using newCountDataSet, followed by estimateSizeFactors, estimate-
Dispersions and nbinomTest functions. For DESeq2, DESeqDataSetFromMatrix was used, fol-
lowed by estimateSizeFactors, estimateDispersions and nbinomWaldTest functions. For edgeR,
count data were analyzed using DGEList followed by calcNormFactors, estimateCommonDisp,
estimateTagwiseDisp and exactTest functions. For EBSeq, the libraries were first normalized
using MedianNorm and then DE genes were detected using the EBTest function. For sSeq,
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DE genes were detected using nbTestSH function. In packages where p-value adjustment was
needed, the p.adjust function in R with method=“BH” (Benjamini and Hochberg FDR option)
was employed.
3.3.4 Detection of DE in paired-sample (two-factor) experimental designs
Similar to the unpaired or single-factor designs, we performed standard analyses for the paired-
sample experimental designs. We calculated p-values, sensitivity (power) and specificity over
the range of parameters, using four statistical packages: DESeq2, DESeq, edgeR and sSeq.
We did not conduct DE gene detection using EBSeq, as it is not adapted to analyzing paired
data currently (communication with the authors). In DESeq, data were analyzed similar to
above, using the two-factor design matrix and method=“pooled-CR” for the dispersion estima-
tion, followed by fitNbinomGLMs function for both the null and alternative hypotheses, and
then by nbinomGLMTest function to calculate p-values per gene. DESeq2 was used similarly
to the single-factor analysis above, using the two-factor design matrix (condition + pairing in-
formation). For edgeR, count data were analyzed using DGEList followed by calcNormFactors,
estimateCommonDisp, estimateGLMTrendedDisp, estimateTagwiseDisp, glmFit and glmLRT
functions. For sSeq, function nbTestSH was used with pairedDesign=TRUE. P-value adjust-
ment was done the same way as in single-factor design, when needed.
3.3.5 Calculation of true positive rates (power) and false positive rates
The sample sizes in the simulated data sets varied from n=2 to n=25 and the average library
sizes varied from 1 million up to 50 million reads. Each condition was simulated 100 times using
random seeds uniformly distributed from 1 to 100 as the inputs. Given a significance threshold
of 0.05, the TPR was calculated by:
TPR (power) =
TP
TP + FN
(4)
And the FPR was calculated by:
FPR = 1− Specificity = FP
FP + TN
(5)
Two standard performance measures, Matthews correlation coefficient (MCC, also known as
the phi statistic) and F-measure are calculated by:
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MCC =
TP ∗ TN − FP ∗ FN√
(TP + FP )(TP + FP )(TN + FP )(TN + FN)
(6)
and:
F measure =
2 ∗ TP/(TP + FP ) ∗ TP/(TP + FN)
TP
TP+FP +
TP
TP+FN
(7)
Where TP = true positives, TN = true negatives, FP = false positives, and FN = false negatives.
3.3.6 Planning RNA-Seq under the budget constraint
For RNA-Seq cost calculation, we referred to Illumina Hi-Seq single-end RNA-Seq prices listed
by the Yale Center for Genome Analysis (http://ycga.yale.edu/services/illuminaprices.
aspx). The total overhead cost of each sample was estimated as $241, which includes sample
quality check and mRNA library construction. The remaining sequencing cost per lane was
$1331 based on HiSeq 2000 single-end sequencing. Simulated count data were generated as
before, by modelling gene counts through equation (1) or (2) and the negative binomial distri-
bution. The formula to calculate the budget is as follows:
Budget = overhead cost per sample ∗ number of samples
+sequencing depth per sample ∗ number of samples
/sequencing depth per lane ∗ cost per lane
(8)
All R code is available for downloading from our website: http://www2.hawaii.edu/~lgarmire/
RNASeqPowerCalculator.htm
3.4 Results
3.4.1 Estimation of parameters in the datasets
We based our simulation results on six representative RNA-Seq datasets. The description of
parameters for these datasets is summarized in Table 1. Among them, four datasets used polyA
enriched method while the other two used Ribosome depletion method. Four datasets had
unpaired experimental designs and two had paired-sample designs. The datasets have a wide
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variety of sample sizes ranging from 6 samples (Tuch) to 129 samples (M-P), as well as a variety
of experimental conditions spanning from cell-line, tissue, viral infection, cancer to population
comparisons. We chose this variety to capture the wide range of different parameters from
various types of experiments.
We estimated the parameters from each of the six datasets and fit them by GLMs with negative
binomial distribution (Table 1). For unpaired data sets, we used the five RNA-Seq analysis
packages (DESeq, DESeq2, edgeR, EBSeq and sSeq) to detect DE genes, whereas for paired
data sets, EBSeq was not used as it is not adapted to the paired-design (communications with
authors). We took a conservative approach to call DE genes by taking intersected DE genes
from all four or five RNA-Seq analysis packages (Table 2).
In summary, the library sizes (reads mapped to the transcriptome) of the six datasets range
from a log10 mean of 6.15 (Bullard) to 7.43 (Qian), the normalized median gene expressions
log2 counts per million (CPM) ranged from 3.18 (Huang) to 4.61 (Bullard), and the median
LFCs of DE genes range from 3.33 (Huang) to 0.751 (M-P). Among them, the Bullard dataset
which compared between brain tissue and the UHR RNA library had the highest percent DE
(59.3%) and a median LFC (2.13). The samples for this dataset were technical replicates and
thus the median dispersion is extremely low (0.000391). In contrast, the M-P data that com-
pared Caucasian to African populations have a much lower percent DE (21.5%) and the highest
median dispersion (0.231). These results indicate that comparisons at tissue levels (eg. Huang
and Bullard) have more significant differences between conditions, whereas comparisons at the
population level (eg. M-P) have a very small significant change due to the large heterogeneity
among populations.
3.4.2 Effects of experimental parameters on power of RNA-Seq analysis
Due to the cost of RNA-Seq experiments, it is imperative to know prior to an experiment
the number of biological replicates required to achieve the desirable power among genes of
interest (e.g., specific expression levels and/or fold change range). We used the negative binomial
distribution and approximate parameters from six RNA-Seq public datasets to create simulated
data for unpaired and paired experiments. We performed 100 simulations per condition to
calculate the statistical power for five categories of DE genes: all DE genes, DE genes with low
expression, high expression, low fold change (FC) and high FC that are separated by quartiles.
Fig. 1 and S1 show the comparisons among the six data sets, five DE categories and five DE
detection methods. We observed the following patterns: (1) In general, higher power is achieved
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as the number of replicates increases. However, beyond a certain replicate number, the gain in
power gain is negligible. This saturation replicate number is dependent on dispersion and median
LFC of the data: the smaller the dispersion or the bigger median LFC, the smaller the number
of replicates is to reach saturation. However, EBSeq showed lower power at higher replicates in
the subset of genes with high expression for the Huang dataset, potentially due to a problem
to handle large counts in the simulation (communications with authors); (2) higher power is
achieved as the sequencing depth increases, however beyond 5-20 million reads, depending on
the data set, the gain in power gain is minimal (Fig. S1). Similar to sample size, the smaller
the dispersion or the bigger median LFC (Bullard and Tuch data), the smaller the sequencing
depth is to reach saturation; (3) High FC and high gene expression quartiles generally show
increased power over low LC and low gene expression quartiles, before the saturation point of
replicates; (4) Power is highly affected by the experimental conditions, and (5) No single DE
program shows consistently the highest power across all datasets. The relationships among
power, sample size and datasets are complicated. However, some general trends emerge: when
the dispersions are small (Bottomly, Bullard, M-P, Qian and Tuch data), edgeR and DESeq2
generally give higher power estimations, especially when the replicates i ≤ 5. However when
the dispersion is large (M-P data), sSeq yields the highest power. Generally, DESeq estimates
power more conservatively, confirming the results of Robles et al. [18].
Given that power is highly dependent on the dataset, we examined the relationships among
power, dispersion, and sample size further (Fig. 1 and Table 1). Simulations based on the
Bullard and Tuch data show that all programs achieve very high power close to 1 (e.g., 100%
detection of DE genes). In the Bullard dataset, the estimated median dispersion parameter
is extremely low (0.000391). This is likely due to that fact that the samples in this dataset
are technical replicates rather than biological replicates. Thus all DE analysis packages used
here could easily detect differences between the two groups. In the Tuch data, the high power
was achieved largely due to the high median FC of DE genes (2.13, Table 1) and pair-designed
samples. On the opposite side, the M-P data consist of transcriptomes from 129 individuals.
The M-P dataset had the highest median dispersion of 0.231 and the lowest median FC=0.751
(Table 1). Only DESeq2, edgeR and sSeq were able to achieve a power of 0.8 or greater at a
sample size of 25 replicates per condition (Fig. 1).
3.4.3 Performance analysis of other metrics
In addition to statistical power (sensitivity), specificity (complement of FPR) is also an im-
portant factor to assess the performance of each DE program. To evaluate them together, we
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generated Receiver Operator Characteristic (ROC) curves based on the results of the simulated
data with 4 replicates per condition (Fig. 2A). The most optimal ROC curve jointly displays
high levels of TPR and FPR. DESeq2 and edgeR had similar and the best ROC curves for all
datasets. DESeq performed similarly to DESeq2 and edgeR, except for the M-P data. However,
EBSeq and sSeq generally did not perform as well as the others. EBSeq sometimes yields a large
increase in FPR with little corresponding increase in TPR, suggesting its limitation to control
the type I error. We also evaluated the different programs with other performance metrics: Area
Under the Curve (AUC) of ROC curves, Matthews Correlation Coefficient (MCC) which takes
into account all true and false positives and negatives, and F-measure which is the weighted
average of the precision and sensitivity (Fig. 2B). Although we see that no single package
consistently performs the worst or the best in all data sets, we did observe similar results as
in the ROC curves: DESeq2 and edgeR generally have similar and the best AUC, MCC and
F-measure, except for the M-P data in which sSeq has the best MCC and F-measure (Fig. 2B,
Fig. S2 and S3; Table S1).
3.4.4 Improved statistical power by the paired-sample design
In the experimental design, multiple conditions or factors can be set up to affect the expression
level of each biological sample. For example, in paired-design experiments, each biological
sample has two conditions (such as cancer tissue and cancer adjacent normal tissue) to generate
RNA-Seq data. In this study, we used the paired-sample design as a demonstration of multi-
factor design, and treated the pairing information as the second factor that affects the expression
level of each gene. We used a GLM with negative binomial distribution to estimate the effects
of the experimental condition and pairing information, based on parameters estimated from
the two paired datasets (Qian and Tuch data). Fig. 3 shows the comparisons among the four
DE categories in these two datasets, under either single-factor (unpaired) or paired statistical
model. It is clear that by considering the pairing information, the statistical power is increased,
especially for the Qian data. The Qian dataset has a lower median LFC (0.929) relative to
the Tuch dataset (2.13), as well as a lower median dispersion (roughly 40% lower than Tuch).
This suggests a big advantage to better differentiate genes by introducing additional pairing
restrictions, when the overall LFC among genes is not very large. Similar to Fig. 1 and
regardless of single-factor or paired-sample model, we observed that DESeq2 and edgeR give
the highest power estimations when the number of replicates is small; however sSeq quickly
catches up when the number of replicates increases. Again DESeq gives the most conservative
estimation of power among the four DE test methods.
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3.4.5 Differences in experimental power based on transcript type
Depending on the subsets of transcripts of interest, there might be differences for achievable
power. For example, lincRNA are generally expressed at low or medium levels relative to mRNAs
from protein coding genes [40, 41]. Thus the mRNA transcriptome and lincRNA transcriptome
may yield different levels of power, even when they are generated from the same RNA-Seq
experiments and the same biological samples. To test this, we conducted simulations based on
the Huang dataset. This dataset was chosen because it used ribosomal RNA depletion method
rather than poly-A selection, so that lincRNA detection was enhanced. To show the internal
difference of the two types of RNAs, we divided the dataset by the type of transcripts and
summarized the parameters (Table 3). Indeed the most striking difference between the two
types of RNAs is the median expression level: the mRNA has a median expression measured
in log2 CPM of 4.63, whereas the lincRNA only has a median log2 CPM of 1.25. As expected,
the analysis of protein coding genes had higher power compared to the analysis of lincRNA
transcripts when the number of replicates i≤3, which is often the limit for many experimental
labs (Fig. 4). DESeq is most conservative in power estimation and showed the largest difference
in power between the two types of transcripts, especially when the number of replicates is low.
At four replicates per condition, lincRNAs had a power of 0.65 compared to protein coding
genes power of 0.75. However, when the number of replicates is sufficient, this difference of
power becomes minimal.
3.4.6 Optimize sample size and sequencing depth under the budget con-
straint
In real-world RNA-Seq experimental design, the budget constraints usually exist and can signif-
icantly affect the trade-off decision between the sample size and sequencing depth. To demon-
strate the practical application of RNA-Seq power analysis, we conducted 100 simulations per
condition to approximate the optimal sample size and sequencing depth, exemplified by several
different budget constraint scenarios ($3000, $5000, $10,000). The cost of RNA-Seq per sample
is dependent on the cost of constructing the RNA-Seq library, as well as the cost of sequencing
depth (or library size) per sample under the multiplex arrangement, where multiple samples
will be barcoded to share one lane of the flow cell. We used an estimated cost of $241 for library
construction and $1331 for single-end sequencing cost per lane. Since that not all reads map to
the transcriptome, we used a mapping percentage of 20%. We determined the optimal power,
corresponding sample size and sequencing depth based on the parameters estimated from the
six datasets (Fig. 5 and S4). As demonstrated by the Bottomly data in Fig. 5, the higher
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the budget cap is, the more biological replicates are needed (Fig. 5 A and C) to reach the
optimal power (Fig. 5 A and B); however the sequencing depth does not change much relative
to biological replicates and stays around 20 Million, estimated from most DE methods (Fig.
5D). The highest power was achieved by sSeq, followed closely by DESeq2 and edgeR (Fig. 5 A
and B). However, sSeq also showed larger standard deviations in the estimated power compared
to the other programs (Fig. 5A). DESeq, DESeq2 and edgeR tend to give rise to less skewed
power curves across number of replicates, relative to EBSeq and sSeq (Fig. 5A). EBSeq tends to
yield lower optimal power estimation and skews towards fewer replicates but higher sequencing
depths, whereas sSeq favors more replicates and lower sequencing depth (Fig. 5 A and D).
3.5 Discussion
RNA-Seq technology is gradually replacing microarray as the method to detect transcriptome
level gene expression, therefore it is a critical time to address the problem of desirable statistical
power in the RNA-Seq experimental design. There have been a few papers on power and sample
size estimation in RNA-Seq experiments; however, these methods need improvement to capture
the dispersion in the data and serve as a practical guideline given budget constraints. Busby et
al. (Busby et al. 2013) measured power as the percentage of genes with 2-fold count change (by
default) that were correctly detected based on the statistical t-test, without realistically cap-
turing the underlying data structure. Hart et al. performed analysis on 127 RNA-Seq samples
in human versus fish 2 organisms [42]. They derived a first order closed form approximation of
GLM to compute required sample size and desired power, by taking into account of the vari-
ance, expected expression level and fold change. Alternatively, Li et al. proposed an exact test
to replace hyper-geometric probabilities with the negative binomial distribution [43]. However,
neither of their methods considered these complexities: (1) more complicated multi-factor exper-
imental designs, (2) the various ways to estimate dispersion through different analysis packages
(they only used edgeR package), and (3) practical optimization of experimental design given
a budget cap. The trade-off between sequencing depth and the number of biological samples
was recently studied [44]. The authors discovered that adding biological replicates increases the
power to detect DE genes better than the strategy of increasing sequencing depth. However,
they did not provide a direct solution for optimization given the fixed budget. Moreover like the
others, they did not consider multiple DE analysis packages, multi-factor experimental design,
or large scale RNA-Seq experiments such as in the population-based studies.
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Compared to these earlier studies, we have made a major leap-forward, rather than incremental
progress towards providing first-hand and comprehensive references in consideration of RNA-
Seq experimental design. We systematically evaluated five popular or more recent DE packages,
and conducted simulations based on 212 RNA-Seq samples from six different datasets that span
a wide range of experimental conditions, from cell-line, tissue, viral infection, cancer and popu-
lation comparisons. We chose the truth data based on more coherent criterion, the intersection
of DE genes that are consistent from all different RNA-Seq analysis packages, rather than the
more arbitrary LFC threshold like others (Robles et al. 2012; Kvam et al. 2012). Moreover,
we provided a reference framework to analyze paired-sample, or more general multi-factor ex-
periments, using the GLM approach. Last but not least, we have provided a tool to enable
researchers to determine the sample size that optimizes the power, when the budget is limited.
Our study provides many aspects of practical guidance towards the RNA-Seq experimental de-
sign. First, dispersion shows a striking impact on power. In datasets with very low dispersions,
such as the Bullard data, a power of 0.8 is easily reached with very low sample size and se-
quencing depth. On the other hand, in datasets with high dispersion, such as M-P data, a
power of 0.8 is hardly achievable except at the highest limits of simulation parameters. Due to
the strong effect of dispersion, it is clear that statistical tests based on the Poisson distribution
(i.e., assuming dispersion = 0) are not capable of handling situations with significant biological
variation. Dispersion is primarily due to biological variation, however it can also be attributed
from technical variability such as lane differences and the “shot noise” of the random process
[13]. Genes with lower expression have high variance [14], and the subset of DE genes in this
group are more likely to have higher fold change [45]. All of these factors lead to the challenge
of proper estimation of dispersions in the RNA-Seq experiments.
Different RNA-Seq DE testing packages estimate dispersion differently, making the systematical
comparisons of these packages worthwhile. We compared the power and other metrics, such
as AUC of the ROC curve, MCC and F-measures in five popular or most recent packages.
For most datasets, DESeq2 and edgeR give the highest estimate of power, closely followed by
DESeq (except the M-P data). DESeq (by default) estimates dispersion by pooling all samples
together, fitting them to a parametric distribution and conservatively taking the maximum. This
conservative approach may explain why DESeq gives a relatively lower power, as also noted by
others [18]. DESeq2 is the new update to DESeq, and it uses shrinkage estimation for dispersion:
the first round of dispersion-mean relationship is obtained by maximum likelihood estimates
(MLE), and this fit is then used as a prior to estimate the maximum a posteriori estimate
for dispersion in the second round. EdgeR estimates dispersion differently, it moderates the
dispersion per gene towards a common value across all genes, or towards a local estimate with
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genes of similar expression. For paired-sample designs, the DESeq package recommends using
the Cox-Reid approximate conditional maximum likelihood (CR-APL) method [20]. DESeq2
likewise uses the CR-APL method to derive dispersion per gene, and then shrinks the dispersion
towards a parametric fit assuming a prior distribution of log dispersion [46]. edgeR also uses
CR-APL and then shrinks the dispersion estimate using empirical Bayes [24]. On the other
hand, EBseq estimates dispersion by the method of moments, and then uses Bayes posterior
probabilities as the measure of statistical significance. While EBSeq generally does not perform
as well as other packages, it could outperform others on analyzing isoform level expression [21],
rather than gene level expression which is the focus of this report. sSeq estimates dispersion
by pooling all the samples together using the method of moments, and then shrinking the per-
gene estimates through minimizing the mean-square error [23]. Although the authors of sSeq
stated that sSeq compared favorably to other popular packages in low sample sizes regarding
sensitivities and specificities, using an external gold standard [29], we found that it did not
yield the highest powers in the Bottomly and Tuch datasets when the replicates are i≤5. This
indicates that the performance of sSeq is affected by the data sets or the choice of truth measure.
Two other important factors that influence power are the number of replicates and sequencing
depth. In general, more biological replicates and greater sequencing depth help to achieve
greater statistical power to a certain extent. Sequencing depth is closely related to the expected
counts of genes. As sequencing depth increases within the range of 5-20 million reads, genes
with lower expression levels, lower fold change and higher dispersions become detectable [47].
However, above 20 million reads, the contribution of sequencing depth to power gain becomes
minimal. Combined with preliminary data, sequencing depth can be used for investigating genes
of certain expression strengths. For example, if one were interested in estimating the statistical
power for lincRNAs, which are on average transcribe 10-fold lower than mRNA transcripts [40],
one would not be as concerned about the FDR adjustment for the entire dataset. It is therefore
possible to enumerate the power and sample size for transcripts of a specific type (e.g., genes
with low versus high expression) or over a certain range of parameters (e.g., low LFC versus
high LFC). Based on our results, we would recommend a minimum of 5 replicates in order to
diminish the power difference between protein coding mRNA and lincRNAs for the sequencing
depth of around 20 million reads.
We also aimed to generalize the potential uses of two-factor analysis by estimating parameters
from two paired-sample datasets: The Tuch dataset is a paired cancer and normal tissue exper-
iment, and the Qian dataset is a paired West Nile Virus and mock transfection of cell cultures.
We compared the power to detect DE genes in these two sets using paired analysis versus one-
factor analysis, and showed that two-factor models can substantially increase detection limit
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and hence power in RNA-seq analysis. Furthermore, DESeq, DESeq2 and edgeR are capable
of arbitrary design matrices, including scenarios such as time series and blocking design that
reduces known variability in confounding factors.
We demonstrated the optimization of RNA-Seq experiments under the budget constraint, a
real-world problem for investigators. We showed that a local optimum of power is achievable for
a particular samples size. More importantly, we found that the dominant contributing factor
to reach optimal power at specific a budget constraint is sample size, rather than sequencing
depth which is around the 20M reads range for most DE detection packages. This conclusion
is consistent with Liu et al [44], in that biological replicates are more important than read
depth for DE detection, although we investigated differently from the power perspective with
budget constraints. DESeq, DESeq2 and edgeR presented more symmetrical curves of sample
size versus power, whereas EBSeq and sSeq seemed to be more skewed. Correlating to the ROC
curves and earlier power estimation without budget constraints, DESeq2 and edgeR appear to
be the better choices of software for their overall performances.
As RNA-Seq technology matures and sequencing becomes cheaper, complex experiments with
more replicates and greater sequencing depth will become more prevalent and there will be an
increasing need to design RNA-Seq experiments more thoughtfully. Our approach reported here
can be applied more generally to complex multi-factor designs that can be modelled through
the GLM framework, such as time series, multi-level designs and blocking designs. We have also
demonstrated how optimal sample size and power can be calculated, given a budget constraint.
It is our expectation that researchers will find our methods useful and valuable in designing
RNA-Seq differential expression experiments.
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Figure 1: Power curves based on the number of replicates per condition for the six public datasets and five RNA-Seq differential expression
analysis packages. Genes were further subcategorized by gene expression and fold change (FC) levels. All genes: the proportion of detected
DE genes. High vs. low FC: upper vs. lower quartile based on FC of DE genes. High vs. low expression: upper vs. lower quartile based
on expression level of DE genes. Library sizes were estimated from the gene counts of the real datasets. FC and expression levels were
estimated through a general linear model with negative binomial distribution. Per-gene dispersion was estimated through the Cox-Reid
adjusted profile likelihood. The four unpaired-sample datasets (Bottomly, Bullard, Huang, M-P) were analyzed with edgeR, DESeq,
DESeq2, EBSeq and sSeq. The paired-sample datasets (Tuch and Qian) were analyzed with edgeR, DESeq, DESeq2 and sSeq. Note that
EBSeq is not included as it is currently not adapted to analyzing paired-sample data.
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Figure 2: Performance comparison with Receiver Operator Characteristics (ROC) curves and other metrics for the six public datasets and
five RNA-Seq differential expression analysis packages. Sensitivity and 1-specificity were estimated in each simulation for n=4 replicates
per condition. The simulations were conducted as in Fig. 1. A. ROC curve comparison. True Positive Rate (TPR) vs. False Positive Rate
(FPR) was plotted. B. Other performance metrics. Area under the curve (AUC) was measured up to FPR = 0.5 of the ROC curves in A.
Matthew Correlation Coefficient (MCC) and F-measure were measured at the threshold of alpha = 0.05.
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Figure 3: Paired vs. single-factor power analysis of paired-sample datasets (Qian and Tuch). The datasets were evaluated with pairing
information (paired analysis, solid line) or without pairing information (single-factor analysis, dashed line), using the standard analysis
pipelines for the respective packages as in Fig. 1. Note that EBSeq is not included as it is currently not adapted to analyzing paired-sample
data.
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Fig. 4: Power of protein coding genes vs. long non-coding RNA (lincRNA) transcripts. The comparison was made using the Huang
dataset, which used ribosomal RNA removal for RNA library construction. The transcriptome was separated into protein coding genes
(solid line) or lincRNA (dashed line) categories. Power was estimated in each simulation for these two categories, using the standard
analysis pipelines for the respective packages as in Fig. 1.
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Fig. 5: Optimization of power given a budget constraint. The cost of RNA-Seq per sample is dependent on the cost of constructing the
RNA-Seq library and the cost of single-end sequencing under the multiplex arrangement, where multiple samples could be barcoded to
share one lane of the HiSeq flow cell. Both sequencing depth and sample size are variables under the budget constraint. A: power curves
relative to replicates, exemplified by increasing budgets of $3000, $5000 and $10000 among five RNA-Seq differential expression analysis
packages. B: Optimal powers achieved for given budget constraints. C: Biological replicates required to obtain optimal powers for given
budget constraints. D: Sequencing depths required to obtain optimal powers for given budget constraints.
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Table 1: Description of the six public RNA-Seq datasets and estimation of dataset parameters
Dataset RNA selec�on Descrip�on Experimental Design Organism
Number of 
samples
median expression 
(log2 counts per 
million)
Bo�omly Poly-A enrichment Expression comparison between 
two cell lines
one factor Mouse 21 3.96 (1.66 - 6.16)
Bullard Poly-A enrichment
Comparison of brain �ssue to 
reference RNA library (2 biological 
samples, 7 technical replicates)
one factor Human 14 4.72 (2.72 - 6.65)
Huang Ribozyme deple�on
Comparison of CCE cells vs. Fetal 
Head cells (4 biological samples)
one factor Mouse 22 4.37 (1.54 - 6.1)
M-P Poly-A enrichment Comparison between Caucasian 
and Nigerian popula�ons
one factor Human 129 4.05 (1.08 - 6.61)
Qian Ribozyme deple�on
WNV/Mock transfec�on 
comparison
paired samples Human 20 4.3 (1.57 - 6.14)
Tuch Poly-A enrichment Cancer/Normal Tissue comparison paired samples Human 6 5.22 (4.11 - 6.3)
Dataset median log2 fold 
change of DE genes
median dispersion Percent DE
Mean Library Size 
(sum of total 
counts, log 10)
Average 
sequencing 
depth 
(log10)
Percent map to 
transcriptome (a�er 
ﬁltering)
Bo�omly 0.99 (0.615 - 1.69) 0.035 (0.0153 - 0.0756) 4.29% 6.67 +/- 0.02 7.34 21.3%
Bullard 2.13 (1.28 - 3.85) 0.000391 (0.000391 - 0.00488) 59.30% 6.11 +/- 0.00134 7.10 10.3%
Huang 3.33 (2.28 - 4.67) 0.128 (0.0594 - 0.25) 15.64% 6.16 +/- 0.143 7.25 8.2%
M-P 0.751 (0.575 - 1.1) 0.231 (0.11 - 0.724) 21.50% 6.17 +/- 0.0341 7.23 8.8%
Qian 0.929 (0.627 - 1.51) 0.0454 (0.0167 - 0.0959) 44.23% 7.00 +/- 0.00312 7.45 35.7%
Tuch 2.13 (1.68 - 2.94) 0.0776 (0.0285 - 0.173) 7.97% 6.97 +/- 0.031 8.31 3.4%
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Table 2: DE genes (FDR ¡ 0.05) detected by the different analysis packages
Dataset Total Genes DESeq2 DESeq edgeR sSeq EBSeq Intersec�on Percent DE
Bo�omly 10645 1348 588 1221 1200 579 457 4.29%
Bullard 9100 7573 7381 7667 6371 5973 5396 59.30%
Huang 17872 9842 3306 10062 12291 8308 2795 15.64%
Montgomery-Pickrell 9217 5014 2964 5264 3553 3018 1982 21.50%
Qian 17110 9670 8098 9404 16442 N/A 7567 44.23%
Tuch 15668 2072 1340 1903 5011 N/A 1248 7.97%
Table 3: Estimated parameters of protein-coding genes vs. lincRNA transcripts
Total 
Number
Diﬀeren�ally 
Expressed
median gene expression (log2 
counts per million + 1)
median log2 fold change 
of DE genes
median dispersion percent DE
All genes 17872 2795 4.37 (1.54 - 6.1) 3.33 (2.28 - 4.67) 0.128 (0.0594 - 0.25) 0.15638988
Protein coding 15834 2623 4.63 (2.05 - 6.23) 3.34 (2.27 - 4.67) 0.126 (0.0599 - 0.242) 0.16565618
lincRNA 603 79 1.18 (-1.43 - 2.71) 3.32 (2.57 - 4.58) 0.139 (0.0406 - 0.285) 0.13101161
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3.7 Appendix
3.7.1 Supplementary figures and tables
Figure S1: Power curves based on the sequencing depths for the six public datasets and
different RNA-Seq differential expression analysis packages. Power was compared in 10, 5 and
3 replicates respetively. The four unpaired datasets (Bottomly, Bullard, Huang, and M-P) were
analyzed with edgeR, DESeq, DESeq2, EBSeq and sSeq. The paired datasets (Tuch and Qian)
were analyzed with edgeR, DESeq, DESeq2 and sSeq. Note that EBSeq is not included as it is
currently not adapted to analyzing paired-sample data.
Figure S2: Extended performance comparison with Receiver Operator Characteristics (ROC)
curves for the five categories of DE genes from six public datasets using five RNA-Seq differential
expression analysis packages. True Positive Rate (TPR) vs. False Positive Rate (FPR) was
plotted. All genes: the proportion of detected DE genes. High vs. low FC: upper vs. lower
quartile based on FC of DE genes. High vs. low expression: upper vs. lower quartile based on
expression level of DE genes.
Figure S3: Extended performance comparison with other metrics (AUC, MCC and F-measure)
for the five categories of DE genes from six public datasets using five RNA-Seq differential
expression analysis packages. Area under the curve (AUC) was measured up to FPR = 0.5
of the ROC curves in Fig. S2. Matthew Correlation Coefficient (MCC) and F-measure were
measured at the threshold of alpha = 0.05.
Figure S4: Power curves relative to replicates, given budget constraints for all six datasets.
Power curves are demonstrated by increasing budgets of $3000, $5000, $10000 and $20,000,
estimated by five RNA-Seq differential expression analysis packages.
Table S1: the AUC, MCC and F-measure values for the six public datasets and five RNA-Seq
differential expression analysis packages.
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Figure S3
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Figure S4.1
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Figure S4.2
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Figure S4.3
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Table S1.1
Dataset Program Subset AUC (up to FPR = 0.5)
MCC (alpha = 
0.05)
F-measure 
(alpha = 0.05)
Bo�omly DESeq2 All Genes 0.433285586 0.492072291 0.509437612
Bo�omly DESeq2 High FC 0.432672461 0.539585716 0.75993514
Bo�omly DESeq2 Low FC 0.433343466 0.507926519 0.529210806
Bo�omly DESeq2 High Expression 0.421926238 0.549428279 0.595823996
Bo�omly DESeq2 Low Expression 0.450197884 0.699839292 0.736084121
Bo�omly DESeq All Genes 0.433018354 0.464943779 0.452827987
Bo�omly DESeq High FC 0.433224208 0.358488855 0.505883503
Bo�omly DESeq Low FC 0.43305405 0.472623674 0.458263206
Bo�omly DESeq High Expression 0.427292061 0.493080913 0.477964953
Bo�omly DESeq Low Expression 0.448442893 0.527663428 0.501146308
Bo�omly edgeR All Genes 0.436827938 0.506603199 0.526849195
Bo�omly edgeR High FC 0.436528332 0.525229544 0.73854712
Bo�omly edgeR Low FC 0.436896646 0.521751225 0.544730491
Bo�omly edgeR High Expression 0.435917098 0.601260875 0.637098197
Bo�omly edgeR Low Expression 0.439051199 0.642226971 0.686862027
Bo�omly sSeq All Genes 0.363107949 0.330670032 0.356730264
Bo�omly sSeq High FC 0.353354491 0.331423003 0.497065088
Bo�omly sSeq Low FC 0.364012207 0.342940416 0.369225195
Bo�omly sSeq High Expression 0.388655872 0.489209554 0.472868457
Bo�omly sSeq Low Expression 0.330667672 0.360105406 0.427199933
Bo�omly EBSeq All Genes 0.278989459 0.394290591 0.420182659
Bo�omly EBSeq High FC 0.280569174 0.393898242 0.585249365
Bo�omly EBSeq Low FC 0.278997527 0.406843497 0.43392693
Bo�omly EBSeq High Expression 0.236929017 0.410739265 0.462168925
Bo�omly EBSeq Low Expression 0.344721108 0.588723372 0.58121893
Bullard DESeq2 All Genes 0.450341286 0.620665066 0.859118012
Bullard DESeq2 High FC 0.45123677 0.60783282 0.965112805
Bullard DESeq2 Low FC 0.450106257 0.640893014 0.92134452
Bullard DESeq2 High Expression 0.364495656 0.412906325 0.950322021
Bullard DESeq2 Low Expression 0.471612474 0.684164971 0.939992895
Bullard DESeq All Genes 0.454003092 0.673753018 0.87700467
Bullard DESeq High FC 0.454728643 0.623272766 0.962878883
Bullard DESeq Low FC 0.453817133 0.68114862 0.927751429
Bullard DESeq High Expression 0.381739538 0.41331528 0.946373396
Bullard DESeq Low Expression 0.471638353 0.733697942 0.946729776
Bullard edgeR All Genes 0.454098772 0.591592976 0.849528091
Bullard edgeR High FC 0.454982887 0.594981406 0.965372338
Bullard edgeR Low FC 0.453875701 0.617177574 0.917326981
Bullard edgeR High Expression 0.383010239 0.401253813 0.951084936
Bullard edgeR Low Expression 0.471563072 0.667083276 0.937664847
Bullard sSeq All Genes 0.441209514 0.70548017 0.878297797
Bullard sSeq High FC 0.441344849 0.525771882 0.921195625
Bullard sSeq Low FC 0.441687067 0.664368423 0.904548261
Bullard sSeq High Expression 0.49278953 0.640243022 0.929741084
Bullard sSeq Low Expression 0.387562656 0.514681108 0.888396762
Bullard EBSeq All Genes 0.423757506 0.685959677 0.862252614
Bullard EBSeq High FC 0.424343874 0.482043907 0.8970692
Bullard EBSeq Low FC 0.42344753 0.629520633 0.883233346
Bullard EBSeq High Expression 0.356588323 0.363562391 0.885268112
Bullard EBSeq Low Expression 0.439068102 0.639188789 0.892477647
Huang DESeq2 All Genes 0.432693774 0.4600306 0.516492629
Huang DESeq2 High FC 0.433360662 0.691315035 0.916415628
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Table S1.2
Huang DESeq2 Low FC 0.432704065 0.495532439 0.575773073
Huang DESeq2 High Expression 0.427995157 0.536140975 0.661774779
Huang DESeq2 Low Expression 0.458054312 0.706752199 0.853507246
Huang DESeq All Genes 0.432590661 0.62154443 0.685277416
Huang DESeq High FC 0.433419322 0.621192688 0.844780359
Huang DESeq Low FC 0.432586626 0.644332982 0.717377624
Huang DESeq High Expression 0.433476842 0.683047814 0.770911087
Huang DESeq Low Expression 0.45356313 0.723982986 0.831414237
Huang edgeR All Genes 0.442319802 0.49663027 0.546295247
Huang edgeR High FC 0.443389363 0.721115613 0.921528845
Huang edgeR Low FC 0.442258301 0.532975541 0.604370763
Huang edgeR High Expression 0.445031728 0.59011258 0.701076832
Huang edgeR Low Expression 0.453226345 0.704131542 0.841659537
Huang sSeq All Genes 0.420638113 0.375267652 0.441088419
Huang sSeq High FC 0.420523618 0.61754034 0.897222985
Huang sSeq Low FC 0.420561831 0.407533294 0.501061211
Huang sSeq High Expression 0.432390622 0.485172724 0.625693779
Huang sSeq Low Expression 0.421399021 0.553533932 0.765882962
Huang EBSeq All Genes 0.353430082 0.422430661 0.501939494
Huang EBSeq High FC 0.353407647 0.562501785 0.868726144
Huang EBSeq Low FC 0.3534716 0.453516988 0.557669298
Huang EBSeq High Expression 0.330557595 0.458555023 0.624160627
Huang EBSeq Low Expression 0.423916185 0.724793125 0.85198609
M-P DESeq2 All Genes 0.251015458 0.208860567 0.211581765
M-P DESeq2 High FC 0.252003023 0.16071344 0.221112221
M-P DESeq2 Low FC 0.250841952 0.207119946 0.215472482
M-P DESeq2 High Expression 0.242131288 0.19718241 0.218327689
M-P DESeq2 Low Expression 0.26139684 0.130610037 0.221911536
M-P DESeq All Genes 0.165780296 0.027414877 0.006561726
M-P DESeq High FC 0.16607886 0.025467023 0.006578483
M-P DESeq Low FC 0.165595508 0.027715166 0.006568194
M-P DESeq High Expression 0.162036359 0.031145416 0.006578285
M-P DESeq Low Expression 0.172543932 0.038447598 0.006578384
M-P edgeR All Genes 0.255088872 0.114953176 0.07574754
M-P edgeR High FC 0.255954002 0.095571342 0.077327306
M-P edgeR Low FC 0.254840444 0.116588966 0.076406918
M-P edgeR High Expression 0.228334476 0.110183172 0.077261255
M-P edgeR Low Expression 0.281337751 0.131511948 0.077126519
M-P sSeq All Genes 0.244551405 0.230438039 0.340876536
M-P sSeq High FC 0.245193945 0.221263833 0.407081818
M-P sSeq Low FC 0.244467183 0.244204886 0.366639837
M-P sSeq High Expression 0.257695521 0.300111673 0.41040791
M-P sSeq Low Expression 0.251448588 0.233443921 0.378137459
M-P EBSeq All Genes 0.223569194 0.196150379 0.219533557
M-P EBSeq High FC 0.223935579 0.172279563 0.236457136
M-P EBSeq Low FC 0.22329616 0.201461103 0.226370552
M-P EBSeq High Expression 0.236394182 0.151892643 0.231735111
M-P EBSeq Low Expression 0.263541891 0.253033705 0.236150428
Qian DESeq2 All Genes 0.444051105 0.737859031 0.838512035
Qian DESeq2 High FC 0.443740005 0.494005715 0.855675801
Qian DESeq2 Low FC 0.444170163 0.702946998 0.846409898
Qian DESeq2 High Expression 0.441003056 0.543703994 0.854315978
Qian DESeq2 Low Expression 0.45793853 0.658687765 0.855743089
Qian DESeq All Genes 0.444985522 0.637771086 0.730564227
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Table S1.3
Qian DESeq High FC 0.444629608 0.376091854 0.735206263
Qian DESeq Low FC 0.445130108 0.5889196 0.732705396
Qian DESeq High Expression 0.453206186 0.422273459 0.735227273
Qian DESeq Low Expression 0.453913422 0.528529092 0.735229127
Qian edgeR All Genes 0.441164028 0.723253842 0.818593973
Qian edgeR High FC 0.440845566 0.470537391 0.830404718
Qian edgeR Low FC 0.441251095 0.683795474 0.824004371
Qian edgeR High Expression 0.448369579 0.518472209 0.830317115
Qian edgeR Low Expression 0.440657485 0.631465766 0.827682341
Qian sSeq All Genes 0.372126128 0.566493446 0.751034542
Qian sSeq High FC 0.371833136 0.382458144 0.816156676
Qian sSeq Low FC 0.37203309 0.548945601 0.779590543
Qian sSeq High Expression 0.428449434 0.485557003 0.821261729
Qian sSeq Low Expression 0.366759882 0.506482001 0.796306927
Tuch DESeq2 All Genes 0.493792209 0.815019767 0.823454026
Tuch DESeq2 High FC 0.49356017 0.889981969 0.973280236
Tuch DESeq2 Low FC 0.49378378 0.824926127 0.835003755
Tuch DESeq2 High Expression 0.49333735 0.896626091 0.91905443
Tuch DESeq2 Low Expression 0.493581205 0.923279101 0.955114143
Tuch DESeq All Genes 0.494273431 0.910104034 0.917351558
Tuch DESeq High FC 0.49301075 0.825494182 0.950691461
Tuch DESeq Low FC 0.494291613 0.912625422 0.920227758
Tuch DESeq High Expression 0.494625502 0.927928968 0.942156802
Tuch DESeq Low Expression 0.492590769 0.908701127 0.943808992
Tuch edgeR All Genes 0.496622751 0.907957823 0.914823411
Tuch edgeR High FC 0.496391957 0.907276573 0.976998305
Tuch edgeR Low FC 0.496631139 0.9128054 0.92009337
Tuch edgeR High Expression 0.497462851 0.954263613 0.964124675
Tuch edgeR Low Expression 0.493046637 0.930734649 0.959381215
Tuch sSeq All Genes 0.458072739 0.36269168 0.337614694
Tuch sSeq High FC 0.460482487 0.768541612 0.95163797
Tuch sSeq Low FC 0.457828518 0.375211241 0.357664747
Tuch sSeq High Expression 0.47550779 0.598056121 0.66456535
Tuch sSeq Low Expression 0.396962457 0.515187054 0.725999942
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3.8 Chapter summary
In this chapter, we compare different statistical methods for finding differentially expressed
genes. In finding differentially expressed genes, generally, one must consider two measures:
statistical power (i.e., true positive rate) with false discoveries (i.e., non-differential genes that
are incorrectly detected). These two measures can be balanced through summary statistics,
such as area under the reciever operator curve (AUC), Matthew’s correlation coefficient and
F1-measure. As a result, we prove that two methods stand above other competitors. These two
methods are implemented in software packages DESeq2 and edgeR.
Understanding of RNA-Seq and its downstream analysis is essential for studying lincRNAs
from high throughput sequencing. We use these packages as a means of obtaining normalized
lincRNA expression between samples and finding differentially expressed lincRNAs in order to
achieve the specific aims.
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4.1 Preface
Long intergenic noncoding RNAs (lincRNAs) are a relatively new class of non-coding RNAs
that have the potential as cancer biomarkers. However, currently most lincRNA biomarkers are
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detected in individual cancer types, and their pan-cancer biomarker application has not yet been
reported. To seek a panel of lincRNAs as pan-cancer biomarkers, we have analyzed transcrip-
tomes from over 3300 cancer samples with clinical information. Compared to mRNA, lincRNAs
exhibit significantly higher tissue specificities that are then diminished in cancer tissues. More-
over, lincRNA clustering results accurately classify tumour subtypes. Using RNA-Seq data
from thousands of paired tumour and adjacent normal samples in The Cancer Genome Atlas
(TCGA), we identify six lincRNAs as potential pan-cancer diagnostic biomarkers (PCAN-1,
PCAN-2, PCAN-3, PCAN-4, PCAN-5 and PCAN-6). These lincRNAs are robustly validated
using cancer samples from four independent RNA-Seq data sets, and are verified by qPCR
in both primary breast cancers and MCF-7 cell line. Interestingly, the expression levels of
these six lincRNAs are also associated with prognosis in various cancers. We performed cell
line experiments on two breast cancer cell lines suggesting that growth and migration are af-
fected by the expression of these lincRNAs. In summary, our study highlights the emerging
role of lincRNAs as potentially powerful and biologically functional pan-cancer biomarkers and
represents a significant leap forward in understanding the biological and clinical functions of
lincRNAs in cancers.
4.2 Introduction
Advancement of high-throughput technologies such as RNA-Seq has recently allowed for the
identification of tens of thousands of new lincRNAs in different tissues [1–4]. The Encyclopedia
of DNA Elements (ENCODE) project found that about 62% of the entire genome is transcribed
to long (> 200 base pairs) RNA sequences [5]. Given that 3% of the genome encodes protein-
coding exons, the large majority of these transcripts are non-coding RNAs (lncRNAs). Among
these lncRNAs, about one third come from intergenic regions (lincRNAs) [5]. Unlike small
non-coding RNAs which may regulate target gene expression through simpler complementary
recognition [6], the mechanisms of lincRNAs are complex and may depend on formation of
RNA-protein complexes [7]. Attempts have been made to extrapolate the functions of lincRNAs
based on model lincRNAs, such as studies that predict lincRNAs binding to PRC2 or competing
endogenous lincRNAs (micro-RNA “sponges”) [8–12]. However, lincRNAs remain one of the
most mysterious and least understood species of non-coding RNAs [2].
Regardless of the regulatory mechanisms, lincRNAs are becoming a relatively new class of cancer
biomarker candidates. Several lincRNAs and overlapping lncRNAs have been relatively well-
studied and indicated as potential biomarkers associated with tumour initiation, progression or
prognosis, such as MALAT [13–15], HOTAI [15–17], XIS [18–20], PCAT [15, 21, 22] and CCAT
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[23]. However, most of the studies detect lincRNAs as candidate biomarkers of a specific cancer
type. The pan-cancer biomarker-based design of clinical trials, on the other hand, can increase
statistical power and greatly decreasing the size, expense, and duration of clinical trials [24].
Towards this, we here propose a pan-cancer based lincRNA diagnostics biomarker study, which
is aligned with the goal of TCGA analysis project that enables the discovery of novel adaptive,
biomarker-based strategies to be practiced across boundaries of different tumour type [24] . In
this study, we have taken full advantage of the rich RNA-Seq data from the TCGA consortium,
thousands of RNA-Seq and microarray data from Gene Expression Omnibus (GEO) as well as
RNA-Seq data from our own collection of breast cancer samples. By combining data-mining and
machine-learning methods with biological function validation experiments, we have highlighted
lincRNAs as a new paradigm for actionable diagnostics in the pan-cancer setting. In addition,
we have portrayed the comprehensive landscape of lincRNAs and their relationship to other
omics data in pan-cancers. We found that the lincRNAs are more tissue-specific compared to
protein-coding mRNAs, and they also convey complementary relevance to clinical information,
including tumour molecular subtypes. Moreover, we have detected and thoroughly validated 6
lincRNAs as potential pan-cancer diagnostic biomarkers in over 3300 tissue samples. Finally,
we confirmed that the lincRNAs are biologically functional, by measuring the reduction of cell
proliferation and migration in breast cancer cell lines with siRNA knockdown on two of the
homologous lincRNAs.
4.3 Methods
4.3.1 RNA-Seq datasets
TCGA datasets
We used 12 cancer datasets from TCGA incorporating RNA-Seq data files from 1240 tissue
samples (Supplementary Table I). RNA-Seq datasets were chosen from cancers in TCGA that
have at least 25 pairs of primary tumour and paired adjacent normal tissue samples. These
datasets include breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), head and
neck squamous cell carcinoma (HSNC), kidney chromophobe (KICH), kidney renal clear cell car-
cinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD),
lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), stomach adenocar-
cinoma (STAD) and thyroid carcinoma (THCA). RNA-Seq BAM files were downloaded from
UCSC Cancer Genomics Hub (https://cghub.ucsc.edu/) using the GeneTorrent progra [25].
The TCGA alignment protocol used the Mapsplice alignment progra [26] to align raw reads to
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the human genome, where loci with the same alignment score has equal probability to assign
a read. Technical replicates were combined by merging the results from the BAM files. Ref-
Seq genes and lincRNAs were quantified using featureCounts [27, 28] from the Subread package
(version 1.4.5-p1). RefSeq annotation was obtained from Illumina hg19 iGenomes and lincRNAs
were obtained from Broad Institute Human Body Map project, so that we can directly compare
the tissue specificity results between TCGA samples and those in Cabili et al [1]. All align-
ments were conducted on the New Hampshire INBRE (IDeA Network of Biomedical Research
Excellence) grid computing system. DESeq [29, 30] (version 1.6.1) was used for calculating nor-
malized count data and FPKM data. A combination of independent RNA-Seq and microarray
datasets were used for verification, and the summary of the datasets is listed in Supplementary
Table I.
GEO datasets
A comprehensive search of GEO RNA-Seq database was performed to find additional datasets
for verification. Datasets with tumour and normal samples with good read quality (read map-
ping rate and low duplication rates) were selected. These included GSE25599 (liver cancer),
GSE58135 (breast cancer) and GSE50760 (colon cancer). In addition, normal breast tissue
samples were taken from GSE52194, GSE45326 and GSE30611 for comparison with our cancer
samples. GEO datasets were aligned to the UCSC hg19 genome using Tophat2 with default
parameters for either single-end or paired-end protocols. LincRNA count quantification and
FPKM data were generated as above. Microarray datasets from GEO with tumour and nor-
mal samples were selected based on platforms that had probes mapping to the six lincRNAs of
interest.
Our own dataset
Our primary breast cancer samples were extracted with RNeasy Mini Kit (Qiagen), followed by
quality control with RNA 6000 chips (Agilent Bioanalyzer). RNA species with RIN values >
7 were sent to the Genomics Core of Yale Stem Cell Centre. Ribo-depleted RNA-Seq was con-
ducted with 100 bp read length. The read count quantification and FPKM data were generated
as above. The RNA-Seq reads of our samples will be deposited to GEO upon publishing of this
manuscript. Tissue specificity
To analyze tissue specificity, Jensen-Shannon divergence score (JS score) was calculated from
tumour and normal samples of each tissue, and the two distributions of JS scores were compared
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following the method of Cabili et al [1]. Briefly, fragments per kilo bases of exons for per million
mapped reads (FPKM) were first calculated from the normalized count data from each sample.
Then the mean FPKM for each tissue type was calculated and log transformed. The vector e
that represents the distribution of expression is given by:
e =
log2(FPKM + 1)∑n
i=1 log2(FPKM i + 1)
(9)
The JSt score is the JS score for each tissue type t, calculated by the following:
JSt(e, e
t) = 1−
√
H (e+ et)− H (e) +H (e
t)
2
(10)
Where H is the Shannon entropy and et is the hypothetical distribution when a lincRNA is
expressed in only one tissue type:
et = (e1, ..., ei, ..., en), where ei =
1 if i = t0 if i 6= t (11)
The JS score for a lincRNA is then defined as the maximum JSt score across all tissue types.
4.3.2 Differential expression
Each of the 12 TCGA cancer datasets was tested for differential expression (DE) using DESeq
[29, 30]. Statistically significant genes were selected with a FDR adjusted p-value threshold
of 0.05 after Benjamini & Hochberg multiple hypothesis correction. As a result, six lincRNAs
were discovered to be consistently upregulated or down-regulated in all twelve TCGA cancer
datasets. These six lincRNAs were used subsequently for survival and pathway analysis.
4.3.3 Survival analysis
These six lincRNAs with pan-cancer diagnostic potential were examined for their association
with patient survival among four types of TCGA cancer types. Note that these lincRNAs were
initially selected as diagnostic biomarkers, but not prognostic biomarkers. The survival data
from the four types TCGA cancers were obtained in two approaches. LUAD, LUSC and OV
have relapse free survival information directly available from the TCGA data repository. The
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fourth cancer type BRCA has overall survival data available, per the courtesy of Volinia et al
[31]. Patients who did not have an event (death or tumour relapse, depending on the data
set) during the study were considered as censored. The expression values of the six lincRNAs
were used as predictors to fit a Cox-Proportional Hazards (Cox-PH) regression model, where
the overall survival or disease free survival was the response variable. For each patient, a
prognosis index (PI) score was generated from the Cox-PH model. The median PI score among
all patients of the same cancer type was used as the threshold to dichotomize the patients into
high vs. low risk groups, similar to other [32]. The log-rank p-value was then calculated to
assess the statistically significant difference between the Kaplan-Meier curves of the high vs.
low risk groups.
4.3.4 Tumour subtype classification and concordance between data types
using NMF
Non-negative matrix factorization (NMF) method was used to classify tumour subtypes with
lincRNA expression values. The optimal number of clusters was selected using the maximum
cophenetic correlation. The lincRNA clustering results were then compared to those of other
data types, using the method similar to Han et a [33]. The other data types from the TCGA in-
clude mRNA-Seq, mature microRNA-Seq, methylation and reverse phase protein array (RPPA)
for each cancer typ [34], all obtained from the Broad institute Genomic Data Analysis Center
(GDAC). The concordances from the chi-square tests between lincRNA and other data types
were used to assess the correlations between clustering.
Additionally, lincRNA clustering was compared with another standard method, the PAM50
clustering [35], using the TCGA breast cancer samples. The correlation between these two
clustering approaches was calculated using the concordance as mentioned above. Similarly,
cluster correlation was computed for subtypes based on ER+/- information from the GSE58135
breast cancer dataset.
4.3.5 LincRNA sequence coding potential and homology characterization
To predict the coding potential of the sequences, iSeeRNA [34] and Coding-Potential Assessment
Tool (CPAT) [36] were used. The two programs are trained on long non-coding RNAs to assess
the coding potential of transcripts. For iSeeRNA, the coordinates of lincRNA transcripts and
exons were used as inputs in the form of GFF files. For CPAT, lincRNA sequences were used
as inputs in the form of fasta files. To test for homology between transcripts, NCBI’s command
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line BLAST+ suite [37] was used. Pairwise BLAST was performed on all isoforms of the six
differentially expressed lincRNAs. We calculated the percentages of homology by the number
of matching base pairs divided by the total number of base pairs in the query sequence. Due to
the high homology between three of the discovered lincRNAs (PCAN-2, PCAN-3 and PCAN-5),
downloaded RNA-Seq reads may have slight ambiguity in counting these lincRNA expression,
since they were generated by TCGA using the Mapsplice alignment progra [26].
4.3.6 Quantitative RT-PCR (qRT-PCR) analysis
Total RNA from MDA-MB-231 and MCF-7 cell lines was isolated using RNeasy Mini Kit
(Qiagen). Pooled total RNA from five healthy normal breast cancer patients was ordered from
Biochain (Total RNA – Human Adult Normal Tissue 5 Donor Pool: Breast, catalog# R1234086-
P). To match these healthy controls, total RNA was isolated from five in-house breast cancer
patient samples.
High Capacity cDNA Reverse Transcription kit (Life Technologies, Thermo Scientific) was used
for random-primed first-strand complementary DNA synthesis. Real time quantitative PCR
(qPCR) was performed with SYBR Green (Life Technologies) with primers against selected linc
RNAs (primer sequences are listed in Supplementary Table VI). Amplification and real time
measurement of PCR products was performed with 7900HT Fast Real-Time PCR System (Life
Technologies). The comparative Ct method [38] was used to quantify the expression levels of
lincRNAs. Beta-glucuronidase (GUS) gene expression served as the internal control. GUS was
selected as the internal control, as its expression level has been found to be comparable in range
to the expression of linc RNAs and is stable in a wide variety of cancers [39, 40].
4.3.7 RNA interference
The siRNA oligos were synthesized by GE Dharmacon. The target sequences are as follows:
control siRNA #1: 5’-UGGUUUACAUGUCGACUAA-3’
control siRNA #2: 5’-UGGUUUACAUGUUGUGUGA-3’
control siRNA #3: 5’-UGGUUUACAUGUUUUCUGA-3’
control siRNA #4: 5’-UGGUUUACAUGUUUUCCUA-3’
lincRNA siRNA #1: 5’-UUCCUUUAGACCCAUUCUCUU-3’
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lincRNA siRNA #2: 5’-PGAACCCACCACUGCUUCUC-3’
This lincRNA siRNA targets PCAN-2 and PCAN-3 lincRNAs. Cells were transfected in a
6-well plate format with siRNA oligos at 40nM (for cell proliferation assays) or 60nM (for
migration assays) concentration, using DharmaFECT 1 Transfection Reagent (Dharmacon).
The knockdown efficiency was determined by qRT-PCR 24 hours post transfection.
4.3.8 Cell growth and migration assays
Cell proliferation analysis was done using CellTiter-Glo Luminescent Cell Viability Assay Kit
(Promega). Briefly, MDA-MB-231 cells were transfected in biological triplicates with siRNA
constructs (control siRNA and linc RNA siRNA). After 24 hours, 400 cells of each condition were
seeded in triplicates into 96-well plates and allowed to grow for another 48 hours. Cells number
estimation at different time points was based on the quantification of the present ATP using
SpectraMax Gemini XPS microplate reader (Molecular Devices). Cell migration was analysed
using well established wound-healing assa [41]. Scratches in cell monolayer were made 30 hours
post siRNA transfection (3 scratches in each of the 3 biological replicates). Cell migration
was analysed by time-lapse microscopy using IX81 Olympus microscope, with 10x objective
(for MDA-MB-231 cells) and 4x objective with additional 1.6x magnification (for MCF-7 cells).
Images were taken every 5 minutes over time period of 24 hours. Migration rates and cell
tracking were analysed using the Metamorph software.
4.4 Results
4.4.1 Overview of the workflow
To detect genes differentially expressed between healthy and tumour tissues, we employed a
two-factor (cancer/normal, and source of samples) experimental design in which patients with
tumour samples and matched normal sample were selected. This approach allowed sufficient
statistical power by reducing the variation of data [42]. In total, we downloaded 1240 paired
cancer and adjacent normal RNA-Seq samples in 12 different cancer types.
The 12 different cancer types include breast invasive carcinoma (BRCA), colon adenocarcinoma
(COAD), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kid-
ney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hep-
atocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma
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(LUSC), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD) and thyroid car-
cinoma (THCA). Details on the number of samples in each cancer type, sequencing strategies,
total mappable reads, and detected lincRNAs are listed in Supplementary Table I. For lincRNA
genomic coordinates, we used the UCSC genome browser’s “lincRNA transcript track”, which
is based on both the Broad Institute Human Body Map including the annotations of transcripts
of uncertain coding potential (TUCP) [1]. We quantified lincRNA expression with normal-
ized fragments per kilobase per million (FPKM) values. Computationally, we have performed
various analyses to study the biological and clinical relevance of lincRNAs to pan-cancer, in-
cluding differential expression (DE), tissue specificity and molecular subtype analyses, as well
as construction and verification of the diagnostic and survival models (Supplementary figure
1). Experimentally, we have verified the gene expression differences of a panel of 6 lincRNAs,
which have pan-cancer diagnostic biomarker potential. Most importantly, we demonstrated the
phenotypic changes of two of the over-expressed lincRNAs by siRNA knockdown experiments
in two breast cancer cell lines MCF-7 and MDA-MB-231.
4.4.2 The high tissue specificities of lincRNAs are diminished in cancers
To investigate the expression patterns of the lincRNA transcripts among different tissue types,
we conducted principal component analysis (PCA) for lincRNA expression on adjacent normal
and cancer samples separately from 12 TCGA datasets (Figure 1). As expected, the normal
samples are clearly clustered by tissue type based on lincRNA expression (Figure 1a). How-
ever, the cancer samples become less separable by tissue type (Figure 1b). The less precise
distinction of cancer samples in the PCA plot suggests a degree of de-differentiation of tumor
cells. The possibility of confounding due to heterogeneity of tumours of the same type can be
excluded, since the latter would lead to more spreading, rather than less spreading observed on
the PCA plot. We therefore reason it as the loss of tissue specificity in cancers. Supporting
this observation, the first three principal components of PCA account for less variance in cancer
samples compared to those in the adjacent normal tissues, suggesting deregulation of lincRNAs
in cancers (Figure 1). We replicated the same analysis for protein-coding genes between tumour
and adjacent normal tissues, and found the same trend of losing tissue specificity in the tumour
samples (Supplementary figure 2).
To further analyze the tissue specificity of lincRNAs, we calculated the tissue specificity scores
(JS scores) as defined in Cabili et al1, where a higher JS score indicates more tissue specificity.
We compared the distributions of these JS scores in tumour and adjacent normal tissue, for
both lincRNAs and RefSeq protein coding genes (Figure 2). Consistent with the PCA plots,
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lincRNAs in cancer tissues are significantly less tissue specific than those in adjacent normal
tissues (t-test, p < 2.2e-16) (Figure 2a, c and d). Moreover, in comparison with RefSeq protein
coding genes (Figure 2b, e and f), lincRNAs have a much higher average JS score (t-test,
p < 2.2e-16). Subsequently, we defined a subset of lincRNAs that are highly tissue specific
with JS score greater than 0.75 and are expressed in at least 5% of the total normal samples
(Supplementary Table II). To confirm that the tissue-specific lincRNAs defined by TCGA pan-
cancer analysis are accurate, we then compared the tissue type assigned to lincRNAs by Cabili
et al1to the tissue types assigned to the same lincRNAs based on the TCGA data. We observed
statistically significant correlations (2-test, all p < 0.0001) between the two studies in all tissue
categories (Supplementary figure 3). In addition, we plot the tissue specific JS score for each
tissue type (JSt score) and plotted their distributions (Supplementary figure 4). As expected,
significant amounts of lincRNA have zero JS scores, as many lincRNAs are not expressed in
certain tissues.
4.4.3 LincRNA clustering accurately predicts molecular subtypes of tumours
Given the tissue specificity of lincRNAs, we hypothesized that lincRNAs can accurately separate
tumours by molecular subtype. To identify a representative cancer type, we first used consensus
non-negative matrix factorization (CNMF) to cluster the patient samples from each of the 12
types of cancer. We then calculated the correlations between the clustering result based on
lincRNAs and those based on four other high-throughput data types: mRNA expression, micro-
RNA expression, DNA methylation and reverse phase protein array (RPPA) obtained from
the Broad Institute Genomic Data Analysis Center (GDAC) [24] (Broad, 2014) (Broad, 2014)
The majority of lincRNA and GDAC clustering results are statistically significantly correlated
(Figure 3a). As expected, lincRNA and mRNA expression are the most highly correlated among
all four high-throughput data types. Among the 12 cancer datasets, the BRCA dataset has the
best agreements between lincRNAs and the other data types. We therefore focused on the
correlation between lincRNA and molecular subtypes in breast invasive carcinoma.
We first applied CNMF to the TCGA BRCA dataset and used cophenetic correlation [34] to
determine the optimal cluster number to be 5, the same number of clusters as in PAM50 based
classification. We then compared the result of CNMF clustering to PAM50 based subtypes,
which include basal-like, HER2-enriched, luminal A, luminal B and normal-like subtypes [35]
(Figure 3c). The concordance score based on the 2-test is highly significant (p < 2.2e-16), and
the overall accuracy to clinical types is 71.6%, as measured by rand measure, a metric for the
percentage of agreement on a pair of samples belonging to the same group. Interestingly, the
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first CNMF cluster has the strongest correlation with the basal-like subtype among all molecular
subtypes, with an accuracy of 95% based on rand measure. Additionally, we examined the
GSE58135 breast cancer dataset that has primary tumour samples in ER+/HER2- and triple
negative subtypes (Figure 3b). The unsupervised CNMF clustering on these cancer samples
yields highly accurate separation between ER+/HER2- and triple negative samples (2-test p <
2.2e-16, and rand measure 84.5%). These results show that lincRNAs are well correlated with
the molecular subtypes of tumours.
4.4.4 Transcriptome analysis reveals a pan-cancer panel of six lincRNAs
To seek a panel of lincRNAs as pan-cancer diagnostic biomarkers, we performed differential
expression analysis on the above 12 TCGA datasets and detected thousands of differentially ex-
pressed lincRNAs in each TCGA dataset (Supplementary figure 5). Among them, six lincRNAs
are consistently and significantly altered in all 12 cancers, with five of them being up-regulated
and one down-regulated (Figure 4a, Supplementary figure 6 and Supplementary Table III). On
the contrary, when we applied the same selection criteria to protein coding genes, we identified
47 mRNAs. The much larger number of mRNAs is presumably due to the less tissue specificity
of mRNAs and more annotated mRNAs compared to lincRNAs at the time of investigation.
4.4.5 Analysis of known lincRNA markers
Several other lincRNAs, such as PCAT1, MALAT1, HOTAIR, have previously been reported to
associate with a variety of cancers [13, 21, 22, 43]. We re-analyzed their expression in our pan-
cancer data set (Supplementary figure 7). These three lincRNAs are not pan-cancer lincRNAs,
but the TCGA results confirmed the previous findings based on several cancer types. PCAT1
was discovered in prostate cancer [22], and is indeed extremely significant in the TCGA PRAD
data. MALAT1 is known to be primarily associated with liver cancer, lung cancer and kidney
cancer [13], and it is recapitulated in the TCGA data. HOTAIR is also known to be highly
upregulated in many different TCGA cancer types [44].
To confirm that the six lincRNAs are indeed associated with pan-cancers, we processed ad-
ditional 833 samples from a wide range of resources including three public RNA-Seq datasets
and eleven microarray datasets (Supplementary Table I). All three public RNA-Seq datasets
(GSE58135 breast cancer, GSE50760 colon cancer, and GSE25599 liver cancer) show consistent
directions of fold change for all six lincRNAs (Figure 4b). Although the microarray platforms
are not designed to detect lincRNAs, some probes are nevertheless overlapped with non-coding
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RNAs as shown by others [45], and thus they can be another source of empirical verification.
Among the various microarray platforms examined, 24 of the 29 microarray probe sets have
the same overall directions of fold changes as those in the RNA-Seq datasets (Supplementary
figure 8). Moreover, the expression levels of the six lincRNAs in 28 breast cancer cell lines from
the GSE58135 dataset and 5 breast cancer cell lines from the Cancer Cell Line Encyclopedia
(CCLE) are all comparable with those from the TCGA BRCA samples (Supplementary figure
9), further supporting the robustness of these lincRNAs as potential pan-cancer biomarkers.
To verify this lincRNA panel experimentally, we performed additional RNA-Seq and qPCR
experiments on our own breast cancer samples. First, we sequenced fresh frozen primary tumour
samples from 10 individual patients using the ribosomal depletion RNA-Seq method. We then
compared them to normal breast tissue RNA-Seq data from GEO (GSE52194, GSE45326 and
GSE30611). All six lincRNAs have the same trends of changes as in the other GEO RNA-Seq
datasets (Figure 4c) and five of them are significantly differentially expressed. We followed up
with the qPCR validation and designed seven PCR primer pairs for selected transcripts in the
lincRNA panel (supplementary table IV). The qPCR results in pooled breast tumour samples
(n=5), pooled normal breast samples (n=5) and MCF-7 cell lines are shown in Figure 4d. In
all cases, the expression levels show statistically significant differential expression in the same
directions as the RNA-Seq data, both between primary tumour and normal sample pools and
between normal and MCF-7 cancer cell lines.
4.4.6 Sequence features among the six-lincRNA biomarkers
To confirm the non-coding nature of the lincRNA transcripts, we used the iSeeRN [34] and
Coding-Potential Assessment Tool (CPAT) [36]. Both programs are specifically trained on long
non-coding RNAs to assess the non-coding potential of RNA transcripts. Out of the 52 isoforms
from the lincRNA panel, iSeeRNA predicted 49 to be non-coding. For the three transcripts that
are ambiguous, we used a second tool, CPAT, to obtain further evidence for the coding or non-
coding nature of these transcripts. CPAT classifies all three of them as non-coding RNAs.
In contrast, both CPAT and iSeeRNA correctly classified all isoforms of house-keeping genes
GUS and GAPDH as protein coding. Overall, both programs provide strong evidence for the
non-coding nature of the six lincRNAs (Supplementary Table V).
To examine the relationship between the six lincRNAs, we first checked the correlations of their
expression values in all TCGA samples. Three of the lincRNAs, PCAN-2, PCAN-3 and PCAN-
5, are highly correlated with spearman correlation coefficients of approximately 0.92 between
them (Supplementary figure 10). The high correlations among expression prompted us to check
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if sequence similarities exist. Thus, we tested the pairwise homology among all transcripts of
the six lincRNAs, using NCBI’s BLAST+ suit [37] (Supplementary figure 11). Indeed, the
three lincRNAs mentioned above are highly homologous, and some of the annotated transcripts
are 99% identical. Two of the lincRNAs, PCAN-2 and PCAN-3, are in the tandem locations
on chromosome 14 and the third lincRNA PCAN-5 is located on chromosome 22, suggesting
potential gene duplication events from a common origin.
4.4.7 The lincRNA biomarker panel robustly and accurately predicts pan
cancers
To quantitatively assess the value of the six lincRNAs as pan-cancer diagnostic biomarkers,
we built a classification model upon them (Figure 5a). First, we split the TCGA pan-cancer
data into 80% training and 20% holdout testing sets. Given that some lincRNAs are highly
correlated (Supplementary figure 10) and thus potentially redundant as biomarker predictors, we
used correlation feature selection (CFS) method to select the most relevant and least redundant
subset of lincRNAs among them. As a result, five of the lincRNAs were chosen: PCAN-1,
PCAN-2, PCAN-3, PCAN-4, and PCAN-6.
We then compared the classification results on the training dataset using four widely used
machine-learning algorithms: Random Forest (RF), Linear Support Vector Machines (LSVM),
Gaussian Support Vector Machines (GSVM) and Logistic Regression with L2 regularization (L2-
LR). As shown by the receiver operator characteristics (ROC) curves on the TCGA training
data set, RF has the best AUC of 0.947 (95% confidence interval, or CI: 0.9343-0.9603) on
the training data among the four methods (Supplementary figure 12). We thus selected the
RF model to test the classification performance on additional 496 samples from the hold out
test set. As expected, the trained RF model has very similar prediction result on the TCGA
hold-out testing set, with an AUC=0.947, sensitivity=0.817 and specificity=0.970 (Figure 5d).
To further verify the robustness of the five-lincRNA panel, we tested the TCGA data based
RF model on four independent RNA-Seq datasets: GSE58135 breast cancer, GSE50760 colon
cancer, GSE25599 liver cancer and our breast cancer dataset (Figure 5b, c and d). Impressively,
this model predicts the other four independent data sets very well, with AUCs of 0.972 (95% CI:
0.95-0.9946), 0.841(95% CI: 0.6875-0.9946), 0.970 (95% CI: 0.9108-1) and 0.950 (95% CI: 0.867-
1) for GSE58135, GSE50760, GSE25599 and our dataset, respectively (Figure 5c and d). Other
model evaluation metrics including Sensitivity, Specificity, Precision, Matthew’s Correlation
Coefficient, F-score and Accuracy in the validation datasets further demonstrate the excellent
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performance of the model (Supplementary Table VI). We therefore conclude that the panel of
six lincRNAs are potential biomarkers for pan-cancer diagnosis.
4.4.8 The lincRNA panel is associated with prognosis in cancer patients
Although the six lincRNAs were detected as potential diagnosis markers for pan-cancer, we
were curious if they might be associated with the prognosis of cancer patients as well. Thus we
performed survival analysis on 1201 samples from four TCGA datasets: namely BRCA, LUAD,
LUSC datasets, and additionally the TCGA ovarian cancer (OV) dataset which was not used
in the lincRNA signature discovery phase due to lack of normal samples (Supplementary figure
13). Since only overall survival information is available in TCGA in BRCA and OV datasets,
we fit the overall survival with Cox-PH regression models and categorized the patient risks by
prognosis index (PI) [32]. The resulting Kaplan-Meier survival curves show that the lincRNA
panel is able to separate patients into higher and lower risk groups by median PI, with log-
rank tests p-values of 0.012 and 0.010 for BRCA and grade 3 OV, respectively (Supplementary
figure 13a and b). On the other hand, the more preferable relapse free survival (RFS) in
LUAD and LUSC datasets are available, thus we fit RFS with Cox-PH models, and obtained
significant p-values of 0.0416 and 0.013 for differential survivals of LUAD and LUSC samples,
respectively (Supplementary figure 13c and d). In summary, although the lincRNA panel was
not purposely discovered as prognosis markers but rather diagnostic markers, their expression
values are associated with the prognosis outcomes in various types of cancers.
4.4.9 Biological relevance of lincRNAs explored by cell culture experiments
To explore the relationship between the lincRNAs panel and tumourigenic phenotypes, we con-
ducted experiments using two breast cancer and colon cancer cell lines as examples. Given
the extremely high homology between PCAN-2 and PCAN-3, we intentionally designed siRNAs
that target both of them so as to observe phenotypes. In non-aggressive MCF-7 and highly
metastatic MDA-MB-231 cell lines, we efficiently knocked down two lincRNAs PCAN-2 and
PCAN-3 (Figure 6a). Transient knockdown allowed us to analyse cell proliferation and cell
migration rate. Interestingly, the growth rate of fast proliferating MDA-MB-231 cells signifi-
cantly decreased upon transfection with lincRNAs siRNA (Figure 6b). To assess cell migration
rates we employed the well-established wound-healing assay and followed the cell movement
with time-lapse microscoopy over the time of 24 hours. As expected, the migration rate was
significantly inhibited upon lincRNAs knockdown (Figure 6c, d). The effect of lincRNA down-
regulation on cell migration was more pronounced in a highly aggressive MDA-MB-231 cell line
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(0.349 versus 0.059 mm over 24 hours for control and lncRNA siRNA, respectively) but it was
also observed in much slower migrating MCF-7 cells (0.127 versus 0.096 mm over 24 hours for
control and lncRNA siRNA, respectively). We repeated the cell migration experiment on MDA-
MB-231 with another less effective siRNA, and observed similar significantly slower (P<0.0001)
migrating rate (Supplementary figure 14).
Furthermore, we repeated these experiments in another HCT116 colon cancer cell line with the
more efficient siRNA (supplementary figure 15). Using the same experimental procedures, we
observed significant differences in both cell proliferation (p<0.0001) and migration (p=0.036),
between the lincRNA knockdown and the siRNA scrambled control. These results suggest that
down-regulation of cancer cell abundant PCAN-2 and PCAN-3 lincRNAs weakens the typical
cancer phenotypic features, such as proliferation and migration.
4.5 Discussion
Since 2012, a community effort has launched towards TCGA pan-cancer analysis across many
different tumour type [33, 46], where the main focus has been the mutational landscap [47].
Pan-Cancer Initiative aims to enable the discovery of novel intervention strategies that can be
tested clinically, including developing novel adaptive biomarker-based clinical trials that cross
boundaries between tumour type [24]. One can expect that in the future, a pan-cancer screening
biomarker panel from blood or other body fluids could become a useful, routine, and economical
screening too [24] applied before the patients have typical cancer symptoms that indicate late-
stage character of the disease. Once an individual is identified as high-risk in the test, he or
she can be followed up with more confirmative tests, such as imaging scanning. In the field of
cancer biomarkers, although many lincRNAs and other lncRNAs have recently been implicated
in cancer initiation and progressio [33, 48, 49], the clinical potential of lincRNAs remains under-
explored across different tumour types. In this study, our goals were to (1) depict the landscape
of lincRNAs in pan-cancers, (2) demonstrate their relevance to clinical outcomes, such as tumour
subtype, diagnosis and patient survival; and (3) explore the utilities of lincRNAs as pan-cancer
diagnostic biomarkers.
Towards these goals, we have performed a new dimension of pan-cancer analysis using the lin-
cRNA transcriptome. In total, we analyzed 3354 patient RNA-Seq samples from 12 types of
cancers in TCGA (13 including OV in survival analysis) as well as an additional 15 independent
datasets (three RNA-Seq datasets from GEO, one in-house RNA-Seq breast cancer dataset and
11 microarray datasets from GEO). To our knowledge, this study is the most comprehensive
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endeavour to analyze lincRNAs in the context of pan-cancer. By systematically analyzing 12
types of RNA-Seq datasets in TCGA, we show that lincRNAs are more tissue specific than
protein-coding genes. The loss of tissue specificity due to cancer is greater for lincRNAs com-
pared to protein-coding genes. This suggests that lincRNAs can potentially be more sensitive
biomarkers than protein coding genes. In addition, unsupervised clustering results of lincR-
NAs demonstrate significant correlations with molecular subtypes. CNMF clustering based on
lincRNAs almost perfectly divided the Triple Negative and ER+/Her2- breast cancers into dis-
tinct groups in GSE58135 data set. Furthermore, CNMF clustering of TCGA BRCA samples
detected 5 distinct clusters that highly correspond to the five widely used molecular subtypes
based on the PAM50 signatures.
Although others have suggested that lincRNAs have potential as biomarker [22, 34], our study
is the first to pinpoint a promising six-lincRNA pan-cancer diagnostics panel quantitatively,
rigorously and robustly. Despite all the potential issues including population heterogeneity
and sample size limitation in high throughput dataset [50], the six-lincRNA biomarker model
performs well overall with AUCs ranging from 0.972 to 0.841. Moreover, we verify the alteration
of these lincRNAs with eleven additional microarray gene expression data sets. Our most
unexpected finding is that the six lincRNA diagnostic signature is also associated with the
survival prognosis of cancer patients, based on the TCGA datasets (BRCA, OV, LUAD and
LUSC). Furthermore, we have demonstrated that the lincRNAs have biological functions, by
knocking-down experiments on two of them, PCAN-2 and PCAN-3. Our preliminary results
indicate that downregulation of only two out of six panel lincRNAs is sufficient to partially
revert some of the typical physiological hallmarks of cancer cells including fast proliferation and
more importantly, migration.
Developing a pan-cancer biomarker model based on the lincRNA signatures could be very signif-
icant clinically, providing complementary values to protein-coding gene based biomarker panels.
We plan to continue our translational investigations in this direction. Yet our next challenge is
to understand how each of the identified lincRNA biomarkers function in tumourigenesis and
progression. Although lincRNAs do not encode proteins, it’s clear that they play important
roles in cellular biology. Currently, multiple hypotheses exist on how lincRNAs regulate cellular
functions [2], which include functioning as scaffold structure [23, 51], sponge of small regulatory
RNA [10, 11] or direct interaction with proteins to modulate localization and activit [52]. To
better understand the phenotypic effects of the six lincRNAs, we will proceed with experiments
that address the physiological functions of these lincRNAs as well as molecular mechanisms by
which they promote tumourigenesis and/or malignancy. We are aware that the repertoire of
lincRNAs is evolving and thus we may miss some newly identified lincRNAs, such as reported
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recentl [48]. However, given the fact that the six lincRNAs in this report have reached very
high and robust accuracy in pan-cancer data, the addition of other new lincRNAs is expected
to not increase the robustness of the current panel.
In summary, our initial pan-cancer analysis has demonstrated that lincRNAs accurately classify
cancer subtypes through supervised as well as unsupervised methods. The panel of six lincRNAs
is a highly accurate diagnostic biomarker signature with additional prognostic value. These
results highlight lincRNAs as a new paradigm for actionable pan-cancer diagnosis and prognosis.
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Figure 1: Principal component analysis of lincRNA expression in 12 TCGA datasets. The first three principal components (PCs) were
plotted using the log FPKM values of lincRNA expression in (a) normal adjacent tissue and (b) cancer samples. The variances associated
with each of the first 10 principal components are plotted alongside each graph (Scree Plot).
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Figure 2: Tissue specificities of lincRNAs and protein coding genes. (a-b) Maximum JS scores for were used to measure tissue specificity
in primary tumours and adjacent normal samples, based on either lincRNAs (a) or protein coding genes (b). A value of 1 indicates that
the lincRNA is expressed in only one tissue. (c-f) Fractional expression of lincRNAs or protein coding genes in each tissue was plotted in
the adjacent normal or cancer samples.
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Figure 3: Correlation of lincRNAs with other data types and cancer subtypes. (a) The concor-
dance between clustering results of lincRNAs and other high throughput data types in TCGA
based on chi-square statistical test. (b) CNMF was used to determine the clustering of lincRNAs
in the GSE58135 Breast Cancer dataset. The concordance of the clustering with the tumour
subtypes in the dataset is significant (chi-square, p < 2.2e-16). (c) CNMF was used to deter-
mine the clustering of lincRNA in the TCGA BRCA dataset. The concordance of the CNMF
clustering with the tumour subtypes in the dataset is significant (chi-square, p < 2.2e-16).
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Figure 4: Differentially expressed pan-cancer lincRNAs. (a) Six lincRNAs are consistently differentially expressed in 12 TCGA datasets.
Each of the six lincRNAs shown is either significantly upregulated or significantly downregulated across the various cancers. The six
lincRNAs in three independent RNA-Seq datasets from GEO (b), our own breast cancer dataset (c) and qPCR of pooled 5 normal tissues,
pooled 5 tumours and the MCF-7 cell line (d).
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Figure 5: The pan-cancer diagnostic model for the lincRNA panel. (a) The classification of the lincRNA panel was based on a com-
putational RNA-Seq pipeline. The TCGA data were split into 80% training and 20% testing subsets. Five out of the six lincRNAs
were selected as predictive features using Correlation Feature Selection (CFS). Pan-cancer diagnostic models were constructed using four
standard classification machine learning methods: Random Forest (RF), Linear Support Vector Machines (LSVM), Gaussian Support
Vector Machines (GSVM) and Logistic Regression (L2-LR). The best model was chosen based on various metrics of the Receiver operating
characteristic (ROC) curves, including Area Under the Curve (AUC), F-score, Matthew’s correlation coefficient (MCC) and Accuracy. (b)
The performance of the classifier was analysed with the ROC curves on the TCGA hold-out testing data, based on the four classification
methods mentioned above and (c) ROC curves of the top Random Forest model on four independent RNA-Seq validation datasets. (d)
AUCs were calculated on the TCGA hold-out testing data in and the four validation datasets.
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Figure 6: The effect of lincRNAs downregulation on cell proliferation and migration. (a) PCAN-
2 and PCAN-3 lincRNAs can be efficiently knocked down in MDA-MB-231 and MCF-7 cell lines.
Bars represent RT-qPCR results of the lincRNA expression. siRNA lincRNA bars show mean
expression (n=3) with S.D. normalized to the control condition. (b) Transient knockdown of
PCAN-2 and PCAN-3 inhibits the growth rate of MDA-MB-231 cells. 30 hours after transfection
400 cells were seeded in 96-well plates and processed for luminescent cell viability assay at
indicated time points. Data points represent mean value (n=3), error bars, S.D. *, P<0.05,
**P<0.01. (c) lincRNA knockdown inhibits migration of MDA-MB-231 and MCF-7 cells in
wound-healing assay. Cells were transiently transfected 30 hours before making scratches in the
cell monolayer. Cell migration rate was analysed with time-lapse microscopy. Red lines – cells
tracks analysed over 24 hours. Size bars – 100 micrometers. (d) Quantification of MDA-MB-231
and MCF-7 cells migration distance over 24-hour time period. Bars – value of mean migration
distance, error bars +/- S.D. (n=20-25 analysed cells), ***P<0.001.
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4.9 Appendix
4.9.1 Supplementary figures and tables
Figure S1: Workflow of lincRNA pan-cancer analysis.
TCGA RNA-Seq aligned data (BAM files) and raw data (fastq and SRA files) from several
validation datasets were used in this study. Validation datasets were aligned using Tophat2.
LincRNAs were quantified using the FeatureCounts program and then normalized as FPKM
values. Tissue specificity and subtype analysis was performed on the entire lincRNA transcrip-
tome. Differential expression was analyzed with DESeq2 to obtain a list of pan-cancer lincRNA
biomarkers, followed by diagnostic classification modelling and survival analysis.
Figure S2: Principal component analysis of mRNA expression in 12 TCGA datasets.
The first three principal components (PCs) were plotted using the log FPKM values of lincRNA
expression in (a) normal adjacent tissue and (b) cancer samples. The variances associated with
each of the first 10 principal components are plotted alongside each graph (Scree Plot).
Figure S3: Comparison of lincRNA tissue specificity between TCGA data and Cabili et al1.
Each plot is composed of the group of lincRNAs specific to a certain tissue type (liver, kidney
etc), as defined in Human Body Map Project by Cabili et al. This group of lincRNAs are
reassigned to specific tissues by the JS score calculated from the TCGA data. The correlations
between studies in all tissue categories are significant.
Figure S4: JSt scores for each tissue type. Each plot shows the scores for tissue specificity
calculated for cancer and normal samples for each individual tissue type.
Figure S5: Differential expression in each cancer type in the 12 TCGA cancer datasets. The
significance threshold is set to α = 0.05afterBenjamini−Hochbergcorrection.
Figure S6: Normalized log2 FPKM expression of the panel of six lincRNAs in the 12 TCGA
cancer datasets.
Figure S7: Validation of known prognostic lincRNAs. Differential expression analysis of known
prognostic lincRNAs markers (PCAT1, MALAT1 and HOTAIR).
Figure S8: Log2 fold change of the six lincRNA panel in the supplementary microarray vali-
dation datasets.
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Figure S9: LincRNA expression in the breast cancer cell lines from CCLE and GSE58135
compared with primary tumour expression levels.
Figure S10: Correlation heatmap of expression levels among the six lincRNAs.
Figure S11: Blast homology among all transcripts of the six lincRNAs.
Figure S12: ROC of the diagnostic classifier in the TCGA training dataset.
Figure S13: The prognostic potential of the pan-cancer lincRNA panel.
(a-d) The performance of the lincRNA panel in predicting survival is plotted with Kaplan-Meier
curves. There were significant differences in overall survival for 463 BRCA patients (a), 350 OV
patients with Grade 3 tumours, the dominant grade of TCGA OV (b), as well as the relapse
free survival for 193 LUAD patients (c) and 139 LUSC patients (d). The higher and lower risk
groups are separated by high and low prognostic index (PI) categories. The PI score is based
on the Cox-Regression model of the six lincRNA panel.
Figure 14: Additional cell line experiments on MDA-231 cell line, using siRNA #2 (less efficient
siRNA).
(a) lincRNA knockdown by siRNA #2 inhibits migration of MDA-MB-231 in wound-healing
assay. Cells were transiently transfected 30 hours before making scratches in the cell monolayer.
Cell migration rate was analysed with time-lapse microscopy. Red lines – cells tracks analysed
over 24 hours. Size bars – 100 micrometers. (b) Quantification of MDA-MB-231 migration
distance over 24-hour time period. Bars – value of mean migration distance, error bars +/-
S.D. (n=60 analysed cells), ***P<0.0001.
Figure S15: Additional cell line experiments on HCT116 colon cancer cell line.
(a) PCAN-2 and PCAN-3 lincRNAs can be efficiently knocked down in HCT116 cell lines.
Bars represent RT-qPCR results of PCAN-2 (gray) and PCAN-3 (orange) expression. siRNA
lincRNA bars show mean expression (n=3) normalized to GUS. (b) Transient knockdown of
PCAN-2 and PCAN-3 inhibits the growth rate of HCT-116 cells. 72 hours after transfection.
400 cells were seeded in 96-well plates and processed for luminescent cell viability assay at
indicated time points. Data points represent mean value (n=3), error bars, S.D. *, P<0.05. (c)
Quantification of HCT116 cells migration distance over 24-hour time period. Bars – value of
mean migration distance, error bars +/- S.D. (n=60 analysed cells), *, P=0.036.
Supplementary Tables
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Table S1: Tabulation of the patients, tumour samples and normal adjacent tissue samples used
in this study.
Table S2: A list of tissue specific lincRNAs and their associated tissue type, defined by JS
score > 0.75 and expression in at least 5% of the samples.
Table S3: Genomic coordinate descriptions of the six lincRNAs and cross-reference with the
Ensemble database.
Table S4: Primer designs for quantitative real-time PCR of the lincRNA panel.
Table S5: Coding potential predictions of all isoforms of the lincRNA panel, using iSeeRNA and
Coding Potential Assessment Tool (CPAT). Additional positive controls using protein-coding
genes GAPDH and GUS are also listed.
Table S6: Classification performance metrics of the lincRNA diagnostic model across all
datasets (TCGA training, TCGA testing, GSE58135 breast cancer, GSE50760 colon cancer and
GSE25599 liver cancer). Metrics used are Area Under the Curve (AUC), Accuracy, F-score,
Matthew’s correlation coefficient (MCC), Sensitivity, Specificity and Precision.
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Figure S11
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Figure S12
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Figure S13
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Figure S14
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Figure S15
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Table S1
TCGA datasets
Dataset Primary Adjacent Paired # mapped reads
Breast invasive carcinoma 1059 111 111 193560468
Colon adenocarcinoma 444 41 41 44872617
Head and Neck squamous cell carcinoma 498 43 41 57516555
Kidney Chromophobe 66 25 25 42982445
Kidney renal clear cell carcinoma 531 72 72 94701140
Kidney renal papillary cell carcinoma 226 32 32 48960010
Liver hepatocellular carcinoma 210 50 50 46819687
Lung adenocarcinoma 489 58 57 69621821
Lung squamous cell carcinoma 489 50 50 86702630
Prostate adenocarcinoma 419 52 52 98002347
Stomach adenocarcinoma 285 32 30 65146435
Thyroid carcinoma 498 59 59 127022122
Subtotal 5214 625 620 975908277
Samples used for survival analysis Cancer
Breast invasive carcinoma 463
Ovarian serous adenocarcinoma 406
Lung adenocarcinoma 193
Lung squamous cell carcinoma 139
Samples used for subtype analysis Cancer
Breast invasive carcinoma 521
Validation Datasets
sliateD lanoitiddArecnac-noNrecnaCnoissccA
)VBH( recnaC reviL ,pb 63 ,dne elgniS010199552ESG
recnaC tsaerB ,pb 001 ,deriaP654853185ESG
recnac noloC ,pb 001 ,deriaP636306705ESG
Our BRCA dataset 10 6 Single end, 100 bp, BRCA; normal samples: GSE52194, GSE45326, GSE30611
Whole Human Genome Oligo Microarray G4112A sliateD lanoitiddArecnac-noNrecnaC
GSE12428 amonoicrac llec suomauqs gnul ,yarraorciM8243
Aymetrix Human Exon 1.0 ST Array sliateD lanoitiddArecnac-noNrecnaC
recnac hcamots ,yarraorciM030372703ESG
recnac llec raelc yendik ,yarraorciM020223074ESG
recnac citaercnap ,yarraorciM65179332ESG
recnac etatsorp ,yarraorciM9205143012ESG
recnac hcamots ,yarraorciM525259131ESG
recnac gnul ,yarraorciM426163221ESG
recnac nairavo ,yarraorciM11965192ESG
sliateD lanoitiddArecnac-noNrecnaCyarrA 0.2 sulP 331U emoneG namuH xirtemyffA
selpmas dioryht ,yarraorciM997643ESG
amonicrac laro ,yarraorciM273265013ESG
sliateD lanoitiddArecnac-noNrecnaCyarraorciM K06x8 EG namuH 3G tnirPeruS
selpmas recnac tsaerb ,yarraorciM8874433ESG
ER+/HER2- Triple Negative
GSE58135 subtype analysis 42 42
Total unique biological samples 3354
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Table S2
lincRNA JS_Score Associated_Tissue
XLOC_010690 0.766204217 kidney
XLOC_007596 0.857703592 liver
XLOC_003732 0.752100476 colon
XLOC_010399 0.768482652 kidney
XLOC_008645 0.758646776 lung
XLOC_011257 0.763064551 liver
XLOC_001387 0.77810803 liver
XLOC_007597 0.824089647 liver
XLOC_000947 0.903394197 adipose+breast
XLOC_011275 0.911613639 liver
XLOC_004719 0.941948946 kidney
XLOC_013795 0.781746482 adipose+breast
XLOC_004102 0.873732325 kidney
XLOC_004360 0.785572253 adipose+breast
XLOC_003239 0.775039257 lung
XLOC_008455 0.770565259 adipose+breast
gnul1771400_COLX
XLOC_001901 0.760514635 liver
XLOC_004836 0.754396243 adipose+breast
XLOC_004514 0.794355439 liver
XLOC_004801 0.906048522 adipose+breast
XLOC_004261 0.817042521 adipose+breast
XLOC_000224 0.799618236 kidney
XLOC_004269 0.867461193 kidney
XLOC_008454 0.792515074 adipose+breast
XLOC_004515 0.752963989 liver
XLOC_005515 0.767317503 thyroid
XLOC_008260 0.902906732 lung
XLOC_001704 0.848966352 liver
XLOC_013779 0.756769238 head+neck
XLOC_007883 0.926395141 liver
XLOC_006805 0.772086177 kidney
yendik1644800_COLX
XLOC_003315 0.791869141 colon
XLOC_012693 0.755588854 liver
XLOC_000857 0.760980892 kidney
XLOC_009690 0.763803004 lung
XLOC_001425 0.900101922 kidney
XLOC_005607 0.808412113 liver
XLOC_010419 0.779716586 thyroid
XLOC_013465 0.754345459 prostate
XLOC_007017 0.773648455 adipose+breast
XLOC_008602 0.767872806 liver
XLOC_007405 0.804291982 prostate
XLOC_014355 0.762921632 prostate
XLOC_013037 0.768622905 prostate
XLOC_001378 0.862077396 kidney
XLOC_005775 0.817266832 kidney
XLOC_000430 0.936023257 liver
XLOC_l2_000357 0.767464299 lung
XLOC_l2_013883 0.914582666 prostate
XLOC_l2_001548 0.763547727 adipose+breast
XLOC_l2_004342 0.768931463 prostate
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Table S3
lincRNA Human Body Map ID Chromosome lincRNA strand lincRNA start lincRNA width lincRNA end
PCAN-1 XLOC_002996 chr3 + 195367106 10516 195377622
PCAN-2 XLOC_l2_004121 chr14 + 19650018 45163 19695181
PCAN-3 XLOC_l2_004340 chr14 - 19856361 68973 19925334
PCAN-4 XLOC_l2_007509 chr2 + 114298969 29137 114328106
PCAN-5 XLOC_l2_009441 chr22 - 16101370 91857 16193227
PCAN-6 XLOC_l2_013931 chr7 - 97503667 98000 97601667
Closest Gene Distance Gene start Gene width Gene end Ensembl gene match Ensembl Annotation (GRCh37)
detatonnanU ,ANRcniLA/N7701135914055137559259192065DOPA
POTEG 65075 19553365 31578 19584943 AL589743.1 LincRNA, Unannotated
POTEM 58620 19983954 36319 20020273 CTD-2314B22.3 LincRNA, Unannotated
nanU ,enegoduesP dessecorPA/N8278524117602166652411142041L4DXOF notated
POTEH 63105 16256332 31606 16287938 AP000525.9 LincRNA, Processed Transcript, Unannotated
tatonnanU ,enegoduesP dessecorPA/N5581057962402924184792181SNSA ed
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Table S4
Assay Label LincRNA target Primers
4121_1: PCAN-2 (XLOC_l2_004121) F: 5’-AGCTTCGGAGAAGCAGTGGT-3’
R: 5’-TTCTTTCCGCGGAGACCT-3’
4340_4 PCAN-3 (XLOC_l2_004340) F: 5’-ACAGATGAACCGCGGAGAC-3’
R: 5’-AGCTTCGGAGAAGCAGTGGT-3’
2996_3 PCAN-1 (XLOC_l2_002996) F: 5’-TAAGGGTCATGGAGCTGGAG-3’
R: 5’-ATCAGCTCCTCCCCGAGTAT-3’
7509_4 PCAN-4 (XLOC_l2_007509) F: 5’-GAAGTTTAATGTTGCCAATGGA-3’
R: 5’-GCCTTTGCACAGACTGACCT-3’
13931_6 PCAN-6 (XLOC_l2_013931) F: 5’-ATCCAGAACTGCAGCCAGTC-3’
R: 5’-AGAAGTACATGGGGGTGTGG-3’
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Table S5 part 1
h�p://lilab.research.bcm.edu/cpat/calculator_sub.php
Reference: CPAT: Coding-Poten�al Assessment Tool using an alignment-free logis�c regression model.  Nucleic Acid Research
PCAN-1 (XLOC_002996)
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
TCONS_00006377 6659 633 0.5291 0.173947044 0.760142576 yes
TCONS_00006378 1716 135 1.0111 0.171563902 0.080769211 no
TCONS_00007073 211 96 0.6124 -0.376596856 0.000483433 no
TCONS_00007074 1586 153 1.1382 0.213026381 0.17417223 no
PCAN-2 (XLOC_l2_004121)
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
TCONS_L2_00008289 768 117 0.7464 0.041918727 0.013971842 no
TCONS_L2_00008290 549 192 0.8298 0.048534387 0.042017289 no
TCONS_L2_00008291 2102 276 0.484 -0.012649119 0.021810528 no
TCONS_L2_00008292 1406 327 0.639 -0.180683866 0.021204847 no
TCONS_L2_00008293 2391 267 0.42 -0.077650944 0.010473072 no
TCONS_L2_00008294 4116 267 0.42 -0.077650944 0.009441453 no
TCONS_L2_00008295 1060 342 0.5027 -0.119244657 0.02480705 no
TCONS_L2_00008296 990 342 0.5027 -0.119244657 0.024910079 no
PCAN-3 (XLOC_l2_004340)
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
TCONS_L2_00007970 5950 459 0.6599 0.112352222 0.336164826 no
TCONS_L2_00008343 1169 144 0.6051 -0.107657632 0.004404995 no
TCONS_L2_00008346 4142 267 0.42 -0.077650944 0.009426701 no
TCONS_L2_00008347 1405 327 0.639 -0.180683866 0.021206108 no
TCONS_L2_00008348 570 168 0.904 -0.068320034 0.019342915 no
PCAN-4 (XLOC_l2_007509)
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
TCONS_L2_00013918 2879 270 0.6819 -0.343879747 0.004149952 no
TCONS_L2_00013919 547 192 1.0539 0.129150962 0.131216094 no
TCONS_L2_00013920 2179 270 0.6819 -0.343879747 0.00432936 no
PCAN-5 (XLOC_l2_009441)
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
TCONS_L2_00017847 609 150 0.8864 -0.136597695 0.009670352 no
TCONS_L2_00017848 880 168 0.868 -0.07522081 0.016248197 no
TCONS_L2_00017849 913 168 0.868 -0.07522081 0.016216201 no
TCONS_L2_00017850 763 168 0.868 -0.07522081 0.016362141 no
TCONS_L2_00017851 757 144 0.6203 -0.079415711 0.005701195 no
TCONS_L2_00017852 631 168 0.868 -0.07522081 0.016491637 no
TCONS_L2_00017853 359 93 0.9437 -0.087655495 0.008776281 no
TCONS_L2_00018290 1174 144 0.6051 -0.107657632 0.004403664 no
TCONS_L2_00018291 4136 267 0.42 -0.077650944 0.009430103 no
TCONS_L2_00018292 2102 276 0.484 -0.012649119 0.021810528 no
TCONS_L2_00018293 1394 327 0.6533 -0.197474682 0.019892986 no
TCONS_L2_00018294 413 144 0.6051 -0.107657632 0.004610957 no
TCONS_L2_00018295 871 102 0.8213 -0.089455015 0.006323578 no
TCONS_L2_00018296 551 258 0.6655 0.081717204 0.062360503 no
PCAN-6 (XLOC_l2_013931)
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
TCONS_L2_00026766 1676 459 0.484 0.100992688 0.259495691 no
TCONS_L2_00026767 809 591 0.702 0.137974424 0.795810077 yes
TCONS_L2_00026768 376 252 1.047 0.176429194 0.280760562 no
TCONS_L2_00026769 453 153 1.0189 0.316429065 0.23511127 no
TCONS_L2_00026770 4110 396 0.618 -0.361689179 0.010864527 no
TCONS_L2_00026771 1215 267 1.1441 0.363689952 0.67084369 yes
TCONS_L2_00026773 1150 267 1.1441 0.363689952 0.671714583 yes
TCONS_L2_00026774 1091 267 1.1441 0.363689952 0.672504065 yes
TCONS_L2_00026775 829 267 1.1441 0.363689952 0.675998075 yes
TCONS_L2_00026776 930 327 1.2265 0.349269552 0.823711195 yes
TCONS_L2_00026777 1119 267 1.1441 0.363689952 0.672129517 yes
TCONS_L2_00026778 582 267 1.1441 0.363689952 0.679274184 yes
TCONS_L2_00026779 1167 267 1.1441 0.363689952 0.671486925 yes
TCONS_L2_00026780 659 135 0.3685 -0.40494765 0.00027646 no
TCONS_L2_00026781 400 156 0.6087 -0.431469675 0.000628962 no
TCONS_L2_00026782 255 246 0.4729 -0.16219555 0.006446424 no
TCONS_L2_00026783 287 204 0.9136 0.316628344 0.279341985 no
TCONS_L2_00026784 1549 210 1.0844 0.305066245 0.377734015 yes
TCONS_L2_00027441 929 426 0.4914 0.202855179 0.339790484 no
Protein coding gene controls
GAPDH
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
ENST00000229239.5 1875 1008 1.2926 0.519960341 0.999962146 yes
ENST00000396861.1 1348 1008 1.2926 0.519960341 0.999963338 yes
ENST00000396858.1 1292 882 1.2952 0.533919114 0.999870952 yes
ENST00000396859.1 1256 1008 1.2926 0.519960341 0.999963542 yes
ENST00000396856.1 1266 783 1.315 0.548545855 0.999679465 yes
GUSB
Sequence Name RNA Size ORF Size Ficket Score Hexamer Score Coding Probability Coding Label
ENST00000304895.4 2300 339 1.2668 0.277977644 0.776289336 yes
ENST00000421103.1 1742 339 1.2668 0.277977644 0.782118123 yes
ENST00000345660.6 2027 285 1.1446 0.333726267 0.659495687 yes
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Table S5 part 2
Results from iSeeRNA: h�p://137.189.133.71/iSeeRNA/
PCNA-1 (XLOC_002996)
ID C/NC NONCODING SCORE
TCONS_00007074 noncoding 0.9837
TCONS_00007073 noncoding 0.996
TCONS_00006377 noncoding 0.9873
TCONS_00006378 noncoding 0.9828
PCAN-2 (XLOC_l2_004121)
ID C/NC NONCODING SCORE
TCONS_l2_00008295 noncoding 0.8142
TCONS_l2_00008296 noncoding 0.7723
TCONS_l2_00008290 noncoding 0.9384
TCONS_l2_00008289 noncoding 0.9267
TCONS_l2_00008292 noncoding 0.9812
TCONS_l2_00008294 noncoding 0.9769
TCONS_l2_00008291 noncoding 0.9582
TCONS_l2_00008293 noncoding 0.9681
PCAN-3 (XLOC_l2_004340)
ID C/NC NONCODING SCORE
TCONS_l2_00008348 noncoding 0.9764
TCONS_l2_00008347 noncoding 0.9819
TCONS_l2_00008343 noncoding 0.8167
TCONS_l2_00008346 noncoding 0.9733
TCONS_l2_00007970 noncoding 0.9729
PCAN-4 (XLOC_l2_007509)
ID C/NC NONCODING SCORE
TCONS_l2_00013919 coding 0.208638
TCONS_l2_00013920 noncoding 0.9405
TCONS_l2_00013918 noncoding 0.6351
PCAN-5 (XLOC_l2_009441)
ID C/NC NONCODING SCORE
TCONS_l2_00017847 noncoding 0.6722
TCONS_l2_00017848 noncoding 0.9813
TCONS_l2_00017849 noncoding 0.9852
TCONS_l2_00017850 noncoding 0.9341
TCONS_l2_00017851 noncoding 0.9674
TCONS_l2_00017852 noncoding 0.8795
TCONS_l2_00017853 noncoding 0.984
TCONS_l2_00018290 noncoding 0.8125
TCONS_l2_00018291 noncoding 0.9676
TCONS_l2_00018292 noncoding 0.9702
TCONS_l2_00018293 noncoding 0.9803
TCONS_l2_00018294 noncoding 0.9135
TCONS_l2_00018295 noncoding 0.9988
TCONS_l2_00018296 noncoding 0.9808
PCAN-6 (XLOC_l2_013931)
ID C/NC NONCODING SCORE
TCONS_l2_00026774 noncoding 0.6841
TCONS_l2_00026769 coding 0.0722
TCONS_l2_00026766 coding 0.2569
TCONS_l2_00026779 noncoding 0.8778
TCONS_l2_00026780 noncoding 0.8494
TCONS_l2_00026781 noncoding 0.9237
TCONS_l2_00026767 noncoding 0.7907
TCONS_l2_00026771 noncoding 0.872
TCONS_l2_00026778 noncoding 0.6522
TCONS_l2_00026776 noncoding 0.7908
TCONS_l2_00026777 noncoding 0.605
TCONS_l2_00027441 coding 0.141
TCONS_l2_00026784 noncoding 0.8035
TCONS_l2_00026768 noncoding 0.8508
TCONS_l2_00026773 noncoding 0.8681
TCONS_l2_00026770 noncoding 0.6034
TCONS_l2_00026783 noncoding 0.7266
TCONS_l2_00026782 noncoding 0.5388
TCONS_l2_00026775 noncoding 0.8405
Protein coding gene controls
GAPDH
ID C/NC NONCODING SCORE
ENST00000229239.5 coding 0
ENST00000396861.1 coding 0
ENST00000396858.1 coding 0.002
ENST00000396859.1 coding 0
ENST00000396856.1 coding 0.0038
GUSB
ID C/NC NONCODING SCORE
ENST00000304895.4 coding 0
ENST00000421103.1 coding 0
ENST00000345660.6 coding 0
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Table S6
Area under curve
TCGA_training TCGA_tes�ng GSE58135_breast_cancer GSE50760_colon_cancer GSE25599_liver_cancer Our BRCA dataset
019.0728.0545.0939.0649.0MVSG 0.750
588.0697.0869.0719.0819.0MVSL 1.000
079.0148.0279.0249.0749.0tseroF modnaR 0.950
093.0014.0646.0509.0109.0noissergeR citsigoL 0.550
Max accuracy
TCGA_training TCGA_tes�ng GSE58135_breast_cancer GSE50760_colon_cancer GSE25599_liver_cancer Our BRCA dataset
058.0168.0347.0309.0498.0MVSG 0.773
058.0338.0129.0158.0658.0MVSL 1.000
009.0168.0639.0598.0788.0tseroF modnaR 0.909
006.0936.0976.0138.0828.0noissergeR citsigoL 0.636
F-score
TCGA_training TCGA_tes�ng GSE58135_breast_cancer GSE50760_colon_cancer GSE25599_liver_cancer Our BRCA dataset
437.0237.0984.0808.0887.0MVSG 0.624
437.0486.0638.0807.0217.0MVSL 1.000
618.0237.0378.0097.0577.0tseroF modnaR 0.817
052.0203.0814.0566.0856.0noissergeR citsigoL 0.346
Matthew's correlation coecient
TCGA_training TCGA_tes�ng GSE58135_breast_cancer GSE50760_colon_cancer GSE25599_liver_cancer Our BRCA dataset
078.0848.0228.0798.0498.0MVSG 0.800
248.0428.0639.0348.0558.0MVSL 1.000
909.0848.0449.0098.0888.0tseroF modnaR 0.900
766.0766.0057.0538.0628.0noissergeR citsigoL 0.645
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4.10 Chapter summary
In this chapter, I quantify the lincRNA expression in over 3000 unique patient samples from 12
different cancer types, in both primary tumor samples and paired normal adjancent samples.
We explore how the expression of lincRNAs relate to clinical phenotypes, such as overall patient
survival, disease free sruvival and tumor subtypes. We find that there are six lincRNAs that
are consistently differentially expressed.
We show in both the TCGA samples and several validation datasets that these lincRNAs can
be used as a novel lincRNA biomarker panel that can accurately distinguish between tumor and
normal samples. The expression of these six lincRNAs also seem to be significantly correlated
with patient survival. Finally, we show that there is some change of cancer phenotypes through
knockdown of the lincRNAs on cancer cell lines.
Chapter 5
Cox-nnet: an artificial neural
network method for prognosis
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5.1 Preface
Artificial neural networks (ANN) are computing architectures with many interconnections of
simple neural-inspired computing elements, and have been applied to biomedical fields such
as imaging analysis and diagnosis. We have developed a new ANN framework called Cox-
nnet to predict patient prognosis from high throughput transcriptomics data. In 10 TCGA
RNA-Seq data sets, Cox-nnet achieves a statistically significant increase in predictive accuracy
compared to other methods, including Cox-proportional hazards regression (with LASSO, ridge,
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and mimimax concave penalty), Random Forests Survival and CoxBoost. Cox-nnet also reveals
richer biological information, at both the pathway and gene levels. The outputs from the
hidden layer node provide an alternative approach for survival-sensitive dimension reduction. In
summary, we have developed a new method for more accurate and efficient prognosis prediction
on high throughput data, with functional biological insights. The source code is freely available
at https://github.com/lanagarmire/cox-nnet.
5.2 Author Summary
The increasing application of high-througput transcriptomics data to predict patient prognosis
demand modern computational methods. With the re-gaining popularity of artificial neural
network, we asked if a refined neural network model could be used to predict patient survival,
as an alternative to the conventional methods, such as Cox proportional hazards (Cox-PH)
methods with LASSO or ridge penalization. To this end, we have developed a neural network
extension of the Cox regression model, called Cox-nnet. It is optimized for survival prediction
from high throughput gene expression data. Cox-nnet is statistically more accurate than pre-
vious algorithms. Moreover, Cox-nnet reveals much richer biological information, at both the
pathway and gene levels, by analyzing features represented in the hidden layer nodes in Cox-
nnet. Additionally, we propose to use hidden node features as a new approach for dimension
reduction during survival data analysis.
5.3 Introduction
The human brain is a neural network consisting of 1011 interconnected neurons [1]. Each neuron
receives input from other neurons, and under certain conditions it is activated and outputs its
own signals as electric pulses. Inspired by this structure, Artificial Neural networks (ANNs)
were developed in 1943 to models non-linear behavior [2]. In ANN, hidden units, termed as
neurons or nodes, may be activated or deactivated, depending on the input signals, their own
linear weight and bias parameters. The data are fed forward through the network, and for
each hidden unit, these weight and bias parameters are learned through backpropagation of the
information along the gradient of the loss function. In recent years, ANNs have caught renewed
attention, thanks to increased parallel computing power and the promise of deep learning [3].
Survival analysis is a regression problem in order to model patients survival time (or other
event time). However, unlike standard regression problems, survival analysis is complicated by
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censoring, where the subject leaves the study before the occurrence of the event. To deal with
this issue, semi-parametric proportional hazards models were developed, where the covariates
of the models explain the relative risks of the patients, termed hazard ratios. The first ANN
model to predict survival was done by Faraggi and Simon, who only used four clinical input
parameters to model prostate cancer survival[4]. However, their simple model was by no means
suitable for high throughput input data. Subsequently, other authors attempted to implement
ANN methods to predict patient survival. One study applied ANNs to high dimensional survival
data by simplifying the regression as a binary classification problem [5, 6], and another study
fit continuous variables of survival time to discrete variables through binning [5, 6]. These
approaches potentially led to loss of accuracy in prediction. Another study used time as an
additional input in order to predict patient survival or censoring status [7], with the potential
to overfit when the survival and censoring are correlated. Thus far, a genuine ANN model
based on proportional hazards designed to analyze high throughput data in the genomics era is
lacking.
Meanwhile there exist other modeling approaches for patient survival prediction. The most
common method is the Cox-PH model, a linear model based on the proportional hazards [8]. In
this manuscript, we evaluated LASSO (L1 norm), ridge (L2 norm) and MCP [9] regularizations
on Cox-PH models. CoxBoost is an iterative “gradient boosting” method modified from the Cox-
PH model[10]. Finally, Random Forests Survival (RF-S) is a tree-based, non-linear, ensemble
method [11], rather than a proportional hazards model.
To address all the issues of ANN based predictions as mentioned earlier, we have developed a
new software package, named Cox-nnet. We used Cox regression as the output layer of ANN,
rather than approximating it as a classification problem. We note three advantages of our
package. First, it has statistically significant improved predictive accuracy in comparison with
the other modeling methods described above. Secondly, it is also optimized for use with graphics
processing units (GPU) and runs approximately 10 times faster compared to running on the
central processing unit (CPU). Lastly, Cox-nnet allows feature importance scores to be defined,
so that the relative importance of specific genes to prognosis outcome can be assessed. The
hidden layer node structure in the ANN can be analyzed to reveal more useful information
regarding relevant genes and pathways in the data. Overall, Cox-nnet is a desirable survival
analysis method with both excellent predictive power and ability to elucidate biological functions
related to prognosis.
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5.4 Results
5.4.1 Cox-nnet structure and optimization
Cox-nnet is the neural network extension of the Cox-PH model. We created a package suitable
for high dimensional datasets using the Theano Python library, a package created for the com-
putation of mathematical expressions involving multi-dimensional arrays and machine learning
[12]. The neural network model used in this paper is shown in Figure 1 and an overview of
modules in the Cox-nnet package is shown in Figure S1. As a proof of concept, the current
ANN architecture is composed of the input layer, one fully connected hidden layer and an out-
put “proportional hazard” layer. The output layer of Cox-nnet replaces the linear predictors in
the standard Cox-PH model (see theoretical descriptions in Methods).
Cox-nnet performs cross-validation (CV) to find the optimal regularization parameter. Due
to the large amount of parameters and hyperparameters, overfitting is a potential problem
in ANNs. Thus for regularization, we experimented with a range of regularization methods,
including ridge, dropout [13], and the combination of ridge and dropout (see details in Methods).
We found that dropout regularization offered overall the best model (Figure S2). Additionally,
we compared Cox-nnet structures between one hidden layer and two hidden layers, and found
that a single hidden layer Cox-nnet with only dropout regularization performed slightly better
than that with two hidden layers (Figure S2). Thus, we used the single hidden-layer Cox-
nnet with dropout regularization for comparison with other survival methods for any following
analysis.
Many other functions are implemented to improve the usability of the package (Figure S1).
Among then, the optimization strategies include momentum gradient descent [14] and Nesterov
accelerated gradient [15]. A comparison of these descent methods is shown in Figure S3A,
and we chose the best Nesterov accelerated gradient search method for this report. Other
parameterization details of Cox-nnet are described in Methods. Moreover, this package can be
run on multiple threads or a Graphics Processing Unit (GPU), and it achieves slightly faster
training time compared to Random Forest and CoxBoost (Figure S3B). In all, Cox-nnet is a
modern software implementation that can achieve efficient computational time.
5.4.2 Performance comparison of survival prediction methods
We compared four methods, including Cox-nnet, Cox-PH (including Ridge, LASSO and MCP
penalizations), CoxBoost and RF-S on 10 datasets from The Cancer Genome Atlas (TCGA).
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These datasets were selected for having at least 50 death events (Table S1). For each dataset, we
trained the model on 80% of the samples, selected randomly, and determined the regularization
parameter using 5-fold CV on the training set. We evaluated the performance on the remaining
20% holdout test set. We replicated this evaluation 10 times in order to assess the average
performance of each method.
Three metrics are used to evaluate the performance of the model. The first one is Harrellas
concordance index (C-index) calculated for censored survival data [16, 17]. It evaluates the
relative ordering of the samples, comparing the prognostic index (i.e., log hazard ratio) of
each patient with the survival times. The second metric is the inverse probability of censoring
weighted (IPCW) estimate of the uncensored concordance [18]. This metric aims to overcome
the inaccuracy of C-index when censoring time is correlated with the patientas hazard. The
third metric is the log-ranked p-value from Kaplan-Meier survival curves of two different survival
risk groups. This is done by using the median Prognosis Index (PI), the output of Cox-nnet, to
dichotomize the patients into high risk and low risk groups, similar to our earlier reports [17, 19,
20]. A log-ranked p-value is then computed to differentiate the Kaplan-Meier survival curves
from these two groups. Note, the dichotomization of patients ignores the differences within each
dichotomized group, thus may lead to less accuracy compared to C-index and IPCW metrics.
The comparison of C-indices among the four methods over the 10 TCGA data are shown in Fig-
ure 2A. Overall, Cox-nnet (dropout) has higher predictive accuracy over the other three methods
(Figure 2B). Cox-PH (ridge penalization) performs the second best, followed by CoxBoost and
RF-S in descending order. Interestingly, the ensemble-based method RF-S consistently ranks
worse than Cox-nnet and Cox-PH. The comparison of the IPCW metric and the log-ranked
p-values on the dichotomized survival risk groups is shown in Figure S4 and S5 respectively.
Generally, log-ranked p-values in the 10 TCGA datasets are better in Cox-nnet, compared to
other methods. However, the dichotomization of patients ignores the differences within each
dichotomized group, thus the resulting log-ranked p-values are less consistent than C-indices on
the same data.
5.4.3 Hidden layer nodes of Cox-nnet are surrogate prognostic features
To explore the biological relevance of the hidden nodes of Cox-nnet, we used the TCGA Kidney
Renal Cell Carcinoma (KIRC) dataset as an example. We first extracted the contribution of each
hidden node to the PI score for each patient (Figure 3A). The contribution was calculated as the
output value of each hidden node weighted by the corresponding coefficient at the Cox regression
output layer. As expected, the value of the hidden nodes strongly correlated to the PI score.
Chapter 6: Neural network survival 123
However, there is still significant heterogeneity among the nodes, suggesting that individual
nodes may reflect different biological processes. We hypothesize that the top (most variable)
nodes may serve as surrogate features to discriminate patient survival. To explore this idea,
we selected the top 20 nodes with the highest variances, and presented the patients PI scores
using t-SNE (Figure 3B). t-SNE is a non-linear dimensionality reduction method that embeds
high-dimensional datasets into a low dimensional space (usually two or three dimensions). This
method has been widely used to visualize data with large number of features, by enhancing
the separation among samples[21]. The hidden nodes represent a dimension reduction of the
original data and they clearly discriminate samples by their PI scores, as shown by the t-SNE
plot (Figure 3B, left). As comparison, we performed PCA using the whole RNA-Seq gene
expression matrix, and then selected the top 20 PCA components with the highest degree of
explained variance in the data. These 20 principle components from PCA in combination with
t-SNE fail to separate the patient samples by PI score (Figure 3B, right). This drastic difference
between the t-SNE plots demonstrates that the nodes in Cox-nnet effectively capture the survival
information. Therefore, the top node PI scores can be used as features for dimension reduction
in survival analysis.
5.4.4 Biological relevance of hidden layer nodes of Cox-nnet
To further explore the biological relevance of the top 20 hidden nodes, we conducted Gene Set
Enrichment Analysis (GSEA) [22] using KEGG pathways [23], as described in the Methods sec-
tion. Briefly, we calculated significantly enriched pathways using Pearsonas correlation between
the log transformed gene expression to the output score of each node (Figure 3C and Table
S2). We compared these enriched pathways to those from GSEA of the Cox-PH (ridge) model
(Table S3), the competing model with the second best prognosis prediction. Using the fgsea
package in R [24], we calculated statistical significance of the pathways by performing 10,000
permutations, followed by multiple hypothesis testing with Benjamini Hochberg adjustment. A
total of 110 (out of 187) significantly enriched pathways (Table S2) were identified in at least
one node, including seven pathways enriched in all 20 nodes that were not found by the Cox-PH
method (Table 1). In contrast, Cox-PH only identified 30 significantly enriched pathways us-
ing the same significance threshold. We also used the genes values from CoxBoost or Random
Forest, however they did not produce any significantly enriched pathways. Among the seven
pathways enriched in all 20 nodes from Cox-nnet, the P53 signaling pathway stands out as an
important biologically relevant pathway (Figure S6), since it was shown to be highly prognostic
of patient survival in kidney cancer [25].
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Next, we estimated the predicative accuracies of the leading edge genes [22] enriched in the
GSEA from Cox-nnet vs. those enriched in Cox-PH model. Leading edge genes are those
genes in the pathway of interest that contribute positively to the enrichment score in GSEA.
We used the C-index of each leading edge gene, obtained from single-variable analysis (Figure
4). Collectively, leading edge genes from Cox-nnet have significantly higher C-index scores (p
= 5.79e-05) than those from Cox-PH, suggesting that Cox-nnet has selected more informative
features. In order to visualize these gene level and pathway level differences between Cox-nnet
and Cox-PH, we reconstructed a bipartite graph between leading edge genes for Cox-nnet or
feature genes (for Cox-PH) and their corresponding enriched pathways (Figure 5). Besides P53
pathway mentioned earlier that is specific to Cox-nnet, several other pathways, such as insulin
signaling pathway, endocytosis and adherens junction, also have many more genes enriched
in Cox-nnet. Among these genes specific to Cox-nnet, many have been previously reported to
relevant to renal carcinoma development and prognosis, such as CASP9[26], TGFBR2[27], KDR
(VEGFR)[28]. These results suggest that Cox-nnet model reveals richer biological information
than Cox-PH.
5.4.5 Evaluation of gene input relative to survival in Cox-nnet
To further examine the importance of each gene relative to the survival outcome, we calculated
the average partial derivative of each input gene feature value over all patients, with respect to
the output of the model (i.e., the log hazard ratio). As demonstrated by the leading edge genes
in seven common pathways of all nodes in Cox-nnet, the feature importance scores produce
stronger biological insight (Figure S6). For example, the feature importance for the BAI1 gene
in the P53 pathway is much higher in the Cox-nnet model compared to the Cox-PH model.
Corresponding to our finding, the BAI gene family was found to be involved in several types of
cancers including renal cancer[29] [30] [31] [32]. BAI1 acts as an inhibitor to angiogenesis and is
transcriptionally regulated by P53 [33]. Its expression level was significantly decreased in tumor
vs. normal kidney tissue, and was even lower in advanced stage renal carcinoma[32]. Mice
kidney cancer models treated with BAI1 showed slower tumor growth and proliferation [34].
Additionally, the MAPK1 gene (also known as ERK2), annotated in two pathways identified by
Cox-nnet (the Adherens Junction and Insulin Signaling pathway), has a much higher feature
importance score in Cox-nnet compared to Cox-PH. MAPK1 is one of the key kinases in intra-
cellular transduction, and was found constitutively activated in renal cell carcinoma [35]. Drugs
inhibiting the MAPK cascade have been targeted for development[36].
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Additionally, we compared the partial derivative of the hidden nodes (rather than the Cox-nnet
output), with respect to the input genes (Supplemental Figure S7) and the partial derivative
of the output with respect to the hidden nodes i.e., the output layer weights (Supplemental
Figure S8). We first calculated the gradient for each patient and calculated the average par-
tial derivatives, and replicated the GSEA analysis as for the previous analysis. However, we
found that fewer pathways are significant, and are less relevant to cancer using this approach
(Supplemental Figure S7). The authors of the GSEA algorithm stated that the input to the
method should be the “correlation of the gene with the phenotype” [22] suggesting that the
partial derivative approach may not be the appropriate metric.
5.5 Discussion
In this report, we have implemented Cox-nnet, a new ANN method, to predict patient survival
from high throughput omics data. Cox-nnet is an improved alternative to the standard Cox-PH
regression, as demonstrated by increased performance for survival prediction in 10 TCGA RNA-
Seq datasets. Moreover, Cox-nnet has the capabilities to explore the biological information.
Our analysis suggests that Cox-nnet can reveal richer biological information than Cox-PH. This
is manifested both at the pathway and gene levels. The hidden nodes in the Cox-nnet model have
distinct activation patterns, and can serve as surrogate features for survival-sensitive dimension
reduction. More significant KEGG pathways are enriched which correlate with top nodes in
Cox-nnet, as compared to those from the Cox-PH model, suggesting that Cox-nnet reveals more
relevant biological information. A critical pathway for renal cancer development, P53 pathway,
is only enriched by Cox-nnet but not Cox-PH model in TCGA KIRC. Other pathways, including
insulin signaling pathway, endocytosis and adherens junction, have many more genes enriched
by Cox-nnet. Moreover, leading edge genes obtained from these KEGG pathways enriched by
Cox-nnet (which are a fraction of the gene features considered by the model) have collectively
higher associations with survival.
Some technical details on model optimization is worth discussion. In neural networks, because
of the large amount of parameters and hyperparameters, overfitting is a potential problem.
In Cox-nnet, we experimented with three regularization approaches given previous guidelines:
ridge, dropout and combination of ridge and dropout. Ridge regularization is one of the most
common methods to reduce overfitting, recommended by Demuth et al. [37]. In this scheme,
the L2 norm of all the weights are added to the cost function of the model, leading to a “weight
decay” term in the gradient. Dropout is a recent regularization method for networks, inspired
Chapter 6: Neural network survival 126
by Bayesian analysis on weighted averages of different network architectures to improve the
model performance [13]. In dropout networks, each training iteration uses a different network
architecture; nodes are randomly removed from the network during training based on a proba-
bility hyperparameter between 0 and 1. Instead of entire models being reweighted, the output
of each node is reweighted during evaluation. This method was previously shown to perform
better than other regularization methods, such as ridge regularization [13]. Our results on Cox-
nnet confirmed this earlier conclusion. Also similar to previous study, we found that additional
complexity of combining dropout and ridge regularization does not yield better performance
[13].
Another potential risk of overfitting in Cox-nnet can come from inadvertently fitting the model
to the patient censoring. To investigate this, we ran a simulation RNA-Seq dataset (described in
the methods section) and compared C-index and IPCW metrics with censoring to uncensored
C-index (Figure S9). The uncensored performance index represents the “true” performance
of the model, i.e., if all the data were uncensored. Both the C-index and the IPCW metric
accurately estimate the uncensored performance of the simulated dataset, and neural network-
based Cox-nnet and tree-based Random Forest survival do not differ significantly from Cox-PH
models. These results suggest that overfitting may not be a significant concern in Cox-nnet,
which could have inadvertently benefited from overtuning of the hyperparameters.
As a promising new predictive method for prognosis, the current Cox-nnet implementation
has some limitations. Its architecture is relatively simple, including an input layer, one or
two hidden layer and an output Cox regression layer. It is possible to incorporate other more
sophisticated architecture into the model, such as including more layers of neurons or more
sophisticated hidden layers (although the size of current genomics data suggest deeper ANN
is not necessarily more beneficial, Figure S2). A convolutional neural network approach using
convolutional and pooling layers could also be used, as those reported in processing imaging
or other types of positional data [38]. Additionally, it is possible to embed a priori biological
pathway information into the network architecture, e.g., by connecting genes in a pathway to
a common node in the next hidden layer of neurons. In the future, we plan to further analyze
how different neural network architectures affect the performance of Cox-nnet and compare the
biological insights from the various models.
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5.6 Methods
5.6.1 Cox-PH, CoxBoost and Random Forest Survival (RF-S) models
Cox-nnet is an extension to the Cox-PH model. Individual hazard, an instantaneous measure
of the likelihood of an event, is estimated based on a set of features [8]. The hazard function is:
h(t|xi) = h0(t)exp(θi) (12)
θi = x
T
i β (13)
Where θi is the log hazard ratio for patient i. This model uses partial log-likelihood as the cost
function:
PL(β) =
∏
C(i)=1
expθi∑
tj≥ti expθj
(14)
CoxBoost, is an iterative “gradient boosting” method modified from the Cox-PH model [10].
In CoxBoost, parameters are separated into individual partitions, and the partition that leads
to the largest improvement in the penalized partial likelihood is selected for that iteration. In
subsequent boosting iteration, the model selects another block and refits those parameters by
maximizing the penalized likelihood function. In this method, the number of boosting iterations
is used as the complexity parameter in CoxBoost and optimized via cross-validation (CV).
Random Forests Survival (RF-S) is a tree-based, non-linear, ensemble method [11], rather than
a proportional hazards model. For each tree in the forest, data are bootstrapped, and nodes are
split by maximizing the log-rank statistic. At the leaf nodes, the cumulative hazard function
(CHF) is estimated and a patientas CHF is calculated as an average over all the trees in the
ensemble.
5.6.2 Theoretical considerations of Cox-nnet
Cox-nnet is a neural network whose output layer is replaced by a Cox model. In a Cox-nnet
model with one input layer of J input features and one hidden layer composed of H hidden
nodes, the linear predictor is replaced by the outputs of the hidden layer:
Chapter 6: Neural network survival 128
θi = G(W
TXi + b)
Tβ (15)
Where W is the coefficient weight matrix between the input and hidden layer with the size H
x J, is the bias term for each hidden node and is the activation function (applied element-wise
on a vector). Subsequently, the ridge (L2 norm) regression cost function is modified to:
Cost(β) = −pl(β) + λ ‖β‖2 (16)
In this manuscript, the tanh activation function is used:
G(z) =
exp(z)− exp(−z)
exp(z) + exp(−z) (17)
In addition to ridge regularization, we also employ dropout regularization [13]. This ap-
proach has been shown to reduce overfitting and improve performance over other regularization
schemes[13]. In dropout, nodes are removed during each training iteration with probability 1-p.
During evaluation, output from the nodes are multiplied by p. The optimal dropout parame-
ter, p, is determined through CV on the training set. Moreover, we also apply the combined
approach of ridge and dropout for comparison.
5.6.3 Implementation of Cox-nnet
We implement Cox-nnet using a feed forward, back propagation network with gradient descent.
The partial log likelihood is usually written as a double conditional sum (equation 3). To avoid
the computational inefficiency of calculating the partial log likelihood (equation 3) using two
nested for loops, we convert it into a formulation of matrix operations and basic sums. First we
define an indicator matrix R with elements:
Rij =
1 if ti ≤ tj0 if ti > tj (18)
We also define an indicator vector C with elements given by the censoring of each patient. An
operation using R replaces the conditional sum over tj ≥ ti, and an operation using C replaces
the conditional sum over C(i)=1 in equation 3. In Theano, the partial log likelihood is:
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pl = T.sum((theta− T.log(T.sum(T.exp(theta) ∗R, axis = 1))) ∗ C) (19)
For the models trained in this manuscript, the number of iterations was fixed at 1e4. The
learning rate was initialized at 0.1, and decayed exponentially by a factor of 0.9 if the loss did
not decrease. The number of hidden nodes in the hidden layer is chosen to be the square root
of the number of input nodes, following the aoepyramida rule of thumb [39]. The optimization
strategies used was Nesterov accelerated gradient [15].
Many functions are implemented to improve the usability of the package, including CVSearch,
CVProfile, CrossValidation, and TrainCoxMlp (Figure S1). CVSearch, CVProfile, CrossValida-
tion are methods that perform CV to find the optimal regularization parameter. TrainCoxMlp
performs optimization of coefficients on the regularized partial likelihood function.
The source code of cox-nnet can be found at: https://github.com/lanagarmire/cox-nnet,
and can be installed through the Python Package Index (PyPI). Documentation of package can
be found at http://garmiregroup.org/cox-nnet/docs/. To call Cox-nnet from R, we provide
an example here: http://garmiregroup.org/cox-nnet/docs/examples/#interfacing-and-
analysis-with-r.
5.6.4 Model evaluation
To evaluate the performance of all methods, we resampled the data 10 times. In each resampling
iteration, we trained each model on 80% of the samples for each dataset (chosen randomly) and
evaluated the performance on the 20% holdout test set. The output of Cox-PH, Cox-nnet and
CoxBoost are the log hazard ratios (i.e., Prognosis Index, or PI) for each patient. The hazard
ratio describes the relative risk of a patient compared to a non-parametric baseline. On the
other hand, the output of RF-S is an estimation of the survival time for each patient. We use
C-index, IPCW [18] and log-ranked p-values to measure the performance of each model.
C-index: is a measure of how well the model prediction corresponds to the ranking of the survival
data [40]. It is calculated for censored survival data, which evaluates a value between 0 and 1,
with 0.5 equivalent to a random process. The C-index can be computed as a summation over
all events in the dataset, where patients with a higher survival time and lower log hazard ratios
(and conversely patients with a lower survival time but higher log hazard ratios) are considered
concordant. IPCW: This metric aims to overcome the inaccuracy of C-index when censoring
time is correlated with the patientas hazard.
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log-ranked p-value: a PI cutoff threshold is used to dichotomize the patients in the data set into
higher and lower risk groups, similar to our earlier report [19, 20]. A log-ranked p-value is then
computed to differentiate the Kaplan-Meier survival curves between the higher vs. lower risk
groups. In this report, we used the median log hazard ratio as the cutoff threshold.
The cross-validated performance metric may be Harrel’s concordance index (C-index) [16] or
the “cross-validated partial likelihood” [41]. Since the contribution of each patient in the partial
likelihood is determined only in the context of all the other patients, the cross-validated partial
likelihood is calculated subtracting full partial likelihood from the training set in the CV. In
the k-th iteration of a K-fold CV, the optimal coefficients βˆλ,k are found by minimizing the
cost function on the training sub-samples. If plk(βˆλ,k) is the partial likelihood of the training
sub-samples, and pl(βˆλ,k) is the partial likelihood of the full dataset, then the cross-validated
partial likelihood is the sum of differences:
cvpl(λ) =
K∑
k=1
pl(βˆλ,k)− plk(βˆλ,k) (20)
5.6.5 Feature evaluation
For computing the importance of a feature in Cox-nnet, we use a method of partial derivatives
[42, 43]. For each patient, we compute the partial derivatives of each input with respect to the
linear output of the model (e.g., the log hazard ratio). The average of the partial derivatives
for each input across all patient samples is calculated as the feature score.
5.6.6 Datasets
In order to evaluate the performance of Cox-nnet, we analyzed 10 TCGA datasets which were
combined into a pan-cancer dataset. The TCGA datasets included the following cancer types:
Bladder Urothelial Carcinoma (BLCA), Breast invasive carcinoma (BRCA), Head and Neck
squamous cell carcinoma (HNSC), Kidney renal clear cell carcinoma (KIRC), Brain Lower
Grade Glioma (LGG), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD),
Lung squamous cell carcinoma (LUSC), Ovarian serous cystadenocarcinoma (OV) and Stomach
adenocarcinoma (STAD). RNA-Seq expression and clinical data were downloaded from the
Broad Institute GDAC [44]. Overall survival time and censoring information were extracted
from the clinical follow-up data. Raw count data were normalized using the DESeq2 R package
[45] and then log-transformed. Datasets were selected from TCGA based on the following
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criteria: > 300 samples with both RNASeq and survival data and > 50 survival events. In
total, 5031 patient samples were used (see Table S1 for a patient tabulation by individual
dataset).
5.6.7 t-SNE clustering
T-distributed stochastic neighbor embedding (t-SNE) is a non-linear dimensionality reduction
method that embeds high-dimensional datasets into a low dimensional (usually two or three)
space. Comparing to other methods with similar purposes (such as MDS), t-SNE puts more
emphasis on making sure data points that are close together in the original high-dimensional
space remain close in the dimension-reduced space. Therefore it usually preserves the clusters of
data points in the original space [21]. This method has been widely used to visualize data with
large number of features. To explore this idea, we selected the top 20 nodes of the Cox-nnet
model with the highest variances, and clustered the patient samples using t-SNE. To do this,
we used the tsne package in R [46].
5.6.8 Statistical testing between model performance
To test for statistical significance between methods using their performance metrics (C-index,
IPCW and log-rank), we use a one-tailed Wilcoxon rank sum test for each of the 10 TCGA
datasets, to compare Cox-nnet with the other methods. The p-value is adjusted using the
Benjamini Hochberg procedure.
5.6.9 Data simulation
We used the ssizeRNA package in R to generate simulated RNA-Seq data counts in R [47]. We
generated four sub-groups of 200 patients each (a total of 800 patient samples) with 1000 genes,
with 20% of the genes differentially expressed for each group. The prognosis index for patients
in each group were randomly generated based on expression of 100 randomly selected genes, and
the survival times were sampled based on the Weibull survival distribution. Censoring times
were chosen from the exponential distribution with rate = 0.05. We randomly generated this
dataset 100 times and estimated the performance metrics on 20% holdout test-sets.
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Table 1. Cox-nnet node-associated pathways. Significantly enriched pathways from common to
all 20 hidden nodes that are not found in the Cox-PH Gene Set Enrichment Analysis (Adjusted
p <0.05).
Pathway P.value P.adjusted Nodes
KEGG adherens junction 0.000 0.001 1A-20
KEGG endocytosis 0.000 0.001 1A-20
KEGG insulin signaling pathway 0.000 0.001 1A-20
KEGG lysine degradation 0.000 0.003 1A-20
KEGG p53 signaling pathway 0.000 0.003 1A-20
KEGG pyruvate metabolism 0.000 0.001 1A-20
KEGG sphingolipid metabolism 0.001 0.005 1A-20
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Figure 1. An overview of the neural network architecture used in this study.
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Figure 2. A. Boxplot of the C-index of the 10 TCGA datasets using four prognosis-predicting methods (Cox-nnet, CoxBoost, Cox-PH and
RF-S). Each dataset was randomly split into 80% training and 20% testing sets. B. Heatmap of the performance rank of each dataset.
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Figure 3. A. Hidden node activation weighted by the corresponding Cox layer coefficients of the TCGA KIRC dataset. The columns
represent individual patient scores, ordered by their Prognostic Index. The rows represent the node activations. B. t-SNE plot of the
top 20 hidden nodes and the top 20 principal components in PCA analysis of the RNA-Seq gene expressiongse. C. Gene Set Enrichment
Analysis: significantly enriched KEGG pathways of the top 20 hidden nodes (adjusted p-value <0.05).
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Figure 4. Single variable C-index scores of the leading edge genes from Cox-nnet and Cox-PH. Cox-nnet has significantly higher C-index
scores (p = 5.79e-5).
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Figure 5. Enriched pathway-gene bipartite network from the leading edge genes and significantly enriched pathways. Significantly enriched
pathways common to all 20 hidden nodes are labeled in green. Leading edge genes found uniquely in Cox-nnet are labeled in orange, and
genes found in both Cox-nnet and Cox-PH are labeled in blue.
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5.8 Appendix
5.8.1 Supplemental figures and tables
Figure S1. Overview of the structure, methods and classes in the Cox-nnet package.
Figure S2. A. Boxplot of the C-index of the 10 TCGA datasets among various penalization
approaches in Cox-nnet one hidden layer (ridge, drop-out and ridge combined with dropout),
Cox-PH (LASSO, ridge, and MCP), as well as Cox-nnet with two hidden layers. Each dataset
was randomly split into 80% training and 20% testing sets and resampled 10 times to calculate
the average performance of each approach.
Figure S3. A: comparison of descent methods on the TCGA KIRC dataset. The change in cost
function is evaluated over 100,000 iterations for three methods: gradient descent, momentum
gradient descent and the Nesterov accelerated gradient. B: Training time comparing CPU
training time vs. GPU training time on the same dataset.
Figure S4. inverse probability of censoring weighted (IPCW) performance metric boxplot of
the 10 TCGA datasets.
Figure S5. A. Bar plots of Log-rank p-values of the 10 TCGA datasets. The log rank p-values
were calculated first splitting the patients by median prognostic index in the testing data set,
and subsequently log-rank tests were performed to compare the survival distributions between
the high and low risk groups. B. Kaplan-Meier plots showing survival differences between the
high and low risk groups.
Figure S6. Variable importance of the common leading edge genes of enriched KEGG path-
ways.
Figure S7. Pathway enrichment using partial derivatives of the hidden nodes. Rather than
using gene input correlation to the hidden node output, the partial derivative of the hidden
nodes with respect to the input gene were calculated. Geneset Enrichment Aanalysis was used
in the same manner as in Figure 3B. Using this approach, fewer significant pathways were
detected.
Figure S8. Partial derivative of the output with respect to the hidden nodes compared to the
hidden node output.
Figure S9. RNA-Seq survival simulation results showing the performance over 100 simulated
datasets comparing the C-index, IPCW metric and the uncensored concordance.
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Table S1. Tabulation of TCGA patients by individual dataset.
Table S2. Significantly enriched pathways from the Cox-PH method (p < 0.05).
Table S3. Significantly enriched pathways from the Cox-nnet method (p < 0.05).
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Figure S6
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Table S1
Number of patient samples in TCGA datasets
Cancer Type Event = 0 Event = 1 Total Samples
BLCA 229 177 406
BRCA 927 150 1077
HNSC 300 219 519
KIRC 356 175 531
LGG 391 121 512
LIHC 228 130 358
LUAD 324 166 490
LUSC 277 210 487
OV 130 172 302
STAD 215 134 349
Overall 3377 1654 5031
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Table S2 part 1
Cox-nnet node-associated enriched
pathways
Signicantly enriched pathways common for all nodes (p < 0.05)
P athway P.value P.adjus ted Nodes
KE G G  adherens junction 0.000 0.001 1-20
KE G G  butanoate metabolism 0.000 0.001 1-20
KE G G  ce ll cycl e 0.000 0.001 1-20
KE G G  citrate cycl e tca  cycl e 0.000 0.001 1-20
KE G G  cytokine cytokine rece ptor interaction 0.000 0.001 1-20
KE G G  endocytosis 0.000 0.001 1-20
KE G G  endometrial ca nce r 0.000 0.001 1-20
KE G G  fatty acid metabolism 0.000 0.001 1-20
KE G G  insu lin signaling pathway 0.000 0.001 1-20
KE G G  lysi ne degradation 0.000 0.003 1-20
KE G G  p53 signaling pathway 0.000 0.003 1-20
KE G G  peroxiso me 0.000 0.001 1-20
KE G G  ppar signaling pathway 0.000 0.001 1-20
KE G G  propanoate metabolism 0.000 0.001 1-20
KE G G  prostate ca nce r 0.000 0.001 1-20
KE G G  proteaso me 0.000 0.001 1-20
KE G G  proximal tubule bica rbonate reclamation 0.000 0.001 1-20
KE G G  pyruva te metabolism 0.000 0.001 1-20
KE G G  renin angiotensin syst em 0.000 0.002 1-20
KE G G  sphingolipid metabolism 0.001 0.005 1-20
KE G G  syst emic lupus erythematosu s 0.000 0.001 1-2 0
KE G G  tight junction 0.000 0.001 1-20
KE G G  tryptophan metabolism 0.000 0.001 1-20
KE G G  va line leucine and iso leucine degradation 0.000 0.001 1-20
KE G G  va scu lar sm ooth muscl e contraction 0.000 0.001 1-20
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Table S2 part 2
Additional signicantly enriched pathways (p < 0.05)
P athway P.value P.adjus ted Nodes
KE G G  adipocytokine signaling pathway 0.001 0.005 1-19
KE G G  beta alanine metabolism 0.000 0.003 1,3-20
KE G G  colorectal ca nce r 0.000 0.001 1-13,15-20
KE G G  homologous recombination 0.000 0.001 1-14,16-20
KE G G  inositol phosphate metabolism 0.000 0.004 1-2,4-20
KE G G  neurotrophin signaling pathway 0.000 0.001 1-13,15-20
KE G G  nitrogen metabolism 0.001 0.007 1-16,18-20
KE G G  phosphatidylinositol signaling syst em 0.000 0.003 1-2,4- 20
KE G G  aldosterone regulated so dium reabso rption 0.001 0.007 1-8,10-13,15-20
KE G G  foca l adhesion 0.000 0.001 1-13,16-20
KE G G  mtor signaling pathway 0.002 0.012 1-5,7-13,15-20
KE G G  renal ce ll ca rcinoma 0.000 0.001 1-13,15-18,20
KE G G  riboso me 0.000 0.001 1-4,6-9,11-20
KE G G  pathways in ca nce r 0.000 0.001 1-13,16-18,20
KE G G  wnt signaling pathway 0.000 0.003 1-3,5-13,16-20
KE G G  cytoso lic dna se nsing pathway 0.000 0.003 1-4,6-7,9,11-17,19-20
KE G G  intestina l immune network for iga production 0.000 0.001 1-3,5,7-11,13-14,16-20
KE G G  primary immunodeficiency 0.000 0.001 1-3,5,7-13,16-20
KE G G  terpenoid backbone biosyn thesis 0.002 0.011 1,3-5,7-13,16-20
KE G G  tgf beta signaling pathway 0.000 0.001 1-13,17-18,20
KE G G  va so pressi n regulated water reabso rption 0.000 0.001 1-3,5,7-13,15,17-20
KE G G  base  excision repair 0.001 0.006 1-2,4-5,7-10,12-14,16-18
KE G G  glycolysi s gluconeogenesis 0.000 0.002 1,3-5,8,10-16,1 8-19
KE G G  nod like  rece ptor signaling pathway 0.000 0.001 2,5-7,9,11-16,19-20
KE G G  erbb signaling pathway 0.000 0.003 1-4,8-12,17-18,20
KE G G  pancreatic ca nce r 0.001 0.006 1-4,6,8,10-13,17-18
KE G G  regulation of actin cytoske leton 0.000 0.002 1-3,5-8,10,12-13,17-18
KE G G  complement and coagulation ca sca des 0.000 0.001 4-5,7-9,11,14-16,19
KE G G  dna replica tion 0.000 0.001 2,5,7,9,12-14,16,18-19
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Table S2 part 3
P athway P.value P.adjus ted Nodes
KE G G  glycosa minoglyca n biosyn thesis chondroitin su lfate 0.001 0.005 2,4,6,9,14-17,19-20
KE G G  non sm all ce ll lung ca nce r 0.002 0.012 1,3-4,6,8,10-11,15,17
KE G G  pathogenic esch erichia coli infection 0.000 0.001 2,4,6-7,9,14-16,19
KE G G  chronic myeloid leukemia 0.001 0.009 1,3,8,10-12,17-18
KE G G  pyrimidine metabolism 0.000 0.004 2,4,6-9,14,17
KE G G  thyroid ca nce r 0.006 0.023 1,3,5,8,10,12,17-18
KE G G  graft versu s host dise ase 0.000 0.0 01 7-9,11,16,19-20
KE G G  leukocyte transe ndothelial migration 0.003 0.014 1,3,5,10,12-13,18
KE G G  melanoma 0.005 0.023 1,3,8,10,12,17-18
KE G G  arginine and proline metabolism 0.004 0.019 1,3-4,8,10,12
KE G G  histidine metabolism 0.004 0.019 3-4,9,12,14,19
KE G G  oxidative phosphorylation 0.000 0.001 1,5,10,12-13,19
KE G G  long term potentiation 0.004 0.020 1,10,12,17-18
KE G G  taste transd uction 0.005 0.021 1-3,5,12
KE G G  acute myeloid leukemia 0.012 0.041 4 ,8,10,17
KE G G  allograft rejection 0.000 0.001 8-9,16,19
KE G G  arrhythmogenic right ventricular ca rdiomyopathy arvc 0.011 0.038 2-3,7,18
KE G G  glioma 0.006 0.025 1,8,10,17
KE G G  leish mania infection 0.000 0.001 9,14,16,19
KE G G  lyso so me 0.000 0.002 1,3,10,12
KE G G  natural killer ce ll mediated cytotoxicity 0.000 0.001 7,9,16,19
KE G G  o glyca n biosyn thesis 0.008 0.031 1-2,6,17
KE G G  parkinso ns dise ase 0.005 0.020 1,5,10,12
KE G G  splice oso me 0.001 0.007 6,11,14,17
KE G G  ca lcium signaling pathway 0.003 0.015 1,12,18
KE G G  gap junction 0.007 0.028 1,17-18
KE G G  hematopoietic ce ll lineage 0.000 0.001 9,16,19
KE G G  sm all ce ll lung ca nce r 0.005 0.022 8,10,17
KE G G  toll like  rece ptor signaling pathway 0.000 0.002 9,16,19
KE G G  type i diabetes mellitus 0.000 0.001 9,16,19
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Table S2 part 4
P athway P.value P.adjus ted Nodes
KE G G  ubiquitin mediated proteolysi s 0.006 0.026 1,10,17
KE G G  amyotrophic lateral scl erosis als 0.012 0.041 6,19
KE G G  antigen proce ssi ng and prese ntation 0.000 0.001 16,19
KE G G  autoimmune thyroid dise ase 0.000 0.002 16,19
KE G G  chemokine signaling pathway 0.000 0.001 16,19
KE G G  fc epsilon ri signaling pathway 0.013 0.043 4,17
KE G G  huntingtons dise ase 0.004 0.020 1,19
KE G G  jak stat signaling pathway 0.002 0.011 16,19
KE G G  long te rm depressi on 0.006 0.024 1,17
KE G G  melanogenesis 0.012 0.040 10,18
KE G G  prion dise ase s 0.006 0.025 14,19
KE G G  alzheimers dise ase 0.003 0.013 1
KE G G  asco rbate and aldarate metabolism 0.003 0.016 4
KE G G  asthma 0.003 0.016 19
KE G G  basa l ce ll ca rcinoma 0.006 0.023 4
KE G G  ce ll adhesion molecules ca ms 0.006 0.024 19
KE G G  drug metabolism  cytochrome p450 0.012 0.040 4
KE G G  fc gamma r mediated phagocytosis 0.004 0.017 19
KE G G  glycine se rine and threonine metabolism 0.009 0.033 4
KE G G  glycosa minoglyca n biosyn thesis keratan su lfate 0.010 0.035 14
KE G G  mism atch repair 0.016 0.050 7
KE G G  primary bile acid biosyn thesis 0.007 0.026 5
KE G G  purine metabolism 0.012 0.041 14
KE G G  steroid biosyn thesis 0.008 0.029 19
KE G G  t ce ll rece ptor signaling pathway 0.004 0.017 19
KE G G  viral myoca rditis 0.000 0.003 19
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Table S3 part 1
GSEA enrichment of Cox-PH associated 
cancer pathways
List of significantly enriched pathways (p < 0.05)
detsujda.Peulav.Perocs.EyawhtaP
300.0000.0704.0-elcyc llec GGEK
300.0000.0706.0elcyc act elcyc etartic GGEK
300.0000.0165.0msilobatem dica yttaf GGEK
300.0000.0014.0emososyl GGEK
300.0000.0814.0noitalyrohpsohp evitadixo GGEK
300.0000.0336.0noitamalcer etanobracib elubut lamixorp GGEK
300.0000.0775.0noitadarged enicuelosi dna enicuel enilav GGEK
500.0000.0492.0noitcudsnart yrotcaflo GGEK
500.0000.0033.0-noitcaretni rotpecer enikotyc enikotyc GGEK
500.0000.0045.0-emosaetorp GGEK
500.0000.0193.0noitcartnoc elcsum htooms ralucsav GGEK
600.0000.0514.0emosixorep GGEK
600.0000.0343.0noitcnuj thgit GGEK
900.0100.0815.0msilobatem etaonaporp GGEK
110.0100.0604.0yawhtap gnilangis rapp GGEK
110.0100.0546.0metsys nisnetoigna niner GGEK
410.0100.0773.0-susotamehtyre supul cimetsys GGEK
610.0200.0863.0recnac etatsorp GGEK
430.0300.0334.0-noitcefni iloc aihcirehcse cinegohtap GGEK
040.0400.0904.0recnac lairtemodne GGEK
240.0500.0854.0msilobatem etaonatub GGEK
KEGG epithelial cell signaling in helicobacter pylori infection 0.361 0.006 0.047
740.0600.0704.0-yawhtap gnilangis rotpecer ekil don GGEK
740.0600.0125.0msilobatem eninala ateb GGEK
740.0700.0393.0-sedacsac noitalugaoc dna tnemelpmoc GGEK
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Table S3 part 2
detsujda.Peulav.Perocs.EyawhtaP
740.0700.0724.0msilobatem nahpotpyrt GGEK
740.0700.0183.0msilobatem enilorp dna eninigra GGEK
740.0700.0272.0yawhtap gnilangis muiclac GGEK
740.0700.0333.0-emosoecilps GGEK
840.0800.0403.0esaesid snosnikrap GGEK
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5.9 Chapter summary
In this chapter, we further explore the application of machine learning methods to high through-
put RNA-Seq data. We used artificial neural networks (ANN) in order to predict cancer patient
survival. ANN is a machine learning method that is the basis for the deep innovation of self-
driving cars. Here, we create a new model, termed Cox-nnet, applying ANN to censored survival
data. Unlike the standard Cox regression method, this approach may pick up on interactions
between features (in this case, gene expression) to more accurately predict patient survival. In
addition, we show that information extracted from the hidden layer can be used to reveal useful
biological pathway information from each patient.
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6.1 Preface
Long intergenic non-coding RNAs (lincRNAs) are emerging as important components in cancer
biology. It is understood that changes and mutations in cancer driver genes effect a series
of downstream expression changes. However, because lincRNAs are a relatively new class of
transcripts compared to protein coding genes, the mutational landscape of lincRNAs has not
been as extensively studied.
Although RNA-Seq data are most commonly used to determine gene expression and analyze
alternative splicing events, a number of studies have shown that robust variant calling can be
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performed using RNA-Seq data. In the current study, we determined expressed lincRNA and
protein coding gene variations on primary tumors from 6000 patients in 12 different cancer types.
We highlight the relationship of molecular and genetic features related to lincRNA mutations
in cancer and explore the relationship of eSNVs and determine regions in the genome that have
a high frequency of lincRNA mutations.
Exploring the landscape of lincRNA somatic mutations in cancer may eventually lead to a
more fundamental understanding of the tumorigenic process of genetic mutations leading to
malignancy.
6.2 Introduction
Long intergenic non-coding RNAs (lincRNAs) are emerging as important components in can-
cer biology. The expression of thousands of lincRNAs are dysregulated in cancer, and many
lincRNAs have been shown to be robust biomarkers for tumor tissue and patient prognosis
[1–3]. There is also strong evidence that lincRNAs may serve as drivers of tumorigenesis, drug
resistance and disease progression [4–6]. It is understood that changes and mutations in cancer
driver genes effect a series of downstream expression changes [7, 8]. However, because lincR-
NAs are a relatively new class of transcripts compared to protein coding genes, the mutational
landscape of lincRNAs has not been as extensively studied.
Differences in single nucleotide positions from the reference genome may arise through genetic
inheritance (germline) or occur spontaneously in the genome of cells in the body (somatic).
Germline nucleotide differences that are shared between members of a population are termed
Single Nucleotide Polymorphisms (SNPs) [9]. In the context of cancer, somatic single nucleotide
changes not found in the germline are termed Single Nucleotide Variants (SNVs) [9]. When SNVs
are found on expressed genes or transcripts in the transcriptome, they are termed expressed
SNVs (eSNVs) [10].
Exome sequencing is a popular platform that has been extensively used to investigate genetic
differences and mutations in cancer. Exome sequencing captures targeted DNA through PCR or
other enrichment strategies, and then uses next generation sequencing platforms to determine
the nucleotide sequences of the targeted regions [11]. However, exome sequencing traditionally
interrogates only the exons of protein coding regions, and does not include the majority of non-
coding transcripts [12]. Whole genome sequencing (WGS) could potentially provide the same
information and more. However, the number of WGS sample data are far more limited compared
Chapter 7: lincRNA eSNV analysis 164
to exome sequencing and RNA-Seq data, and also do not contain expression information and
expressed allele information.
It has been emphasized that extensive heterogeneity exists between tumor samples as well as
within tumor samples. Furthermore, cellular subpopulations are mixed in tumor samples. Not
only is the expression of a gene important, but the particular isoforms and gene alleles may be
essential in characterizing the tumor heterogeneity and cancer pathways. SNVs may influence
the expression of proximal genes (in cis) or genes far away or downstream in a molecular pathway
(in trans) [13, 14]. Thus, to interrogate the effects of lincRNA mutations, we used RNA-Seq
data to perform variant calling on both lincRNA associated regions and protein coding genes.
Although RNA-Seq data are most commonly used to determine gene expression and analyze
alternative splicing events, a number of studies have shown that robust variant calling can be
performed using RNA-Seq data [10, 15, 16]. Using The Cancer Genome Atlas (TCGA) RNA-Seq
data, we determine expressed lincRNA and protein coding gene variations on primary tumors
from over 6000 patients in 12 different cancer types. We highlight the relationship of molecular
and genetic features related to lincRNA mutations in cancer and explore the relationship of
eSNVs present in lincRNA transcribed regions with their gene expression. Finally, we compare
the molecular features strongly correlated with lincRNA mutations and those in protein-coding
genes.
6.3 Methods
6.3.1 TCGA Datasets
We used 12 cancer datasets from TCGA and included 6118 primary tumor samples in this study.
These datasets include bladder urothelial carcinoma (BLCA) breast invasive carcinoma (BRCA),
head and neck squamous cell carcinoma (HSNC), kidney renal clear cell carcinoma (KIRC), Liver
hepatocellular carcinoma (LIHC), low grade glioma (LGG), lung adenocarcinoma (LUAD),
lung squamous cell carcinoma (LUSC), Ovarian serous cystadenocarcinoma (OV), and stomach
adenocarcinoma (STAD), prostate adenocarcinoma (PRAD) and thyroid carcinoma (THCA).
Both RNA-Seq BAM files and RNA-Seq fastq files were downloaded using the GeneTorrent
program from the UCSC Cancer Genomics Hub (https://cghub.ucsc.edu). Additional TCGA
samples were downloaded from NCBI Genomic Data Commons Data Portal (https://gdc-
portal.nci.nih.gov) using the GDC data transfer tool. In total, 6118 samples with both
expression data and eSNV data were used in the analysis (Table S1 and S2).
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6.3.2 Expresion quantification
LincRNA were quantified from GRCh37/hg19 aligned BAM files from TCGA using standard
procedures [2]. The FeatureCounts program [17] was used to calculate raw counts for each sam-
ple, based on lncipedia 3.1 annotation. Intergenic transcripts from lncipedia were determined
by subtracting transcripts that overlapped with the transcription coordinates of protein coding
genes from ENCODE [18]. Count data was normalized using the DESeq2 package in R [19]
and fragments per kilo bases of exons per million mapped reads (FPKM) were estimated (See
Figure S1).
For protein coding genes, raw counts were downloaded from the Broad institute firehose project
(http://gdac.broadinstitute.org). Protein coding genes were determined using the BiomaRt
R package [20], using the “gene biotype” field. Count data was normalized and FPKM was es-
timated using the DESeq2 package.
6.3.3 Exome sequencing comparison
The exome sequencing variant calls, including somatic and germline variants, were downloaded
for 7 TCGA datasets (BLCA, HNSC, KIRC, LGG, LIHC, LUAD, PRAD and STAD). For
comparison, eSNVs from the RNA-Seq dataset were filtered by the probe coverage region of the
exome sequencing data. The proportion of eSNVs also called by the exome sequencing variant
calls in each sample was used as a quality measure for the correctness of the eSNV variant
calling procedures.
6.3.4 Predicting germline and somatic mutations
Using the exome sequencing somatic and germline mutation data from TCGA, we built a Ran-
dom Forest model to classify somatic vs. germline SNVs. The Xgboost package in R was used
(version 0.6-0) with 1000 trees. Four features were used in the building of this model: dbsnp
(whether an SNV occurred at a position annotated by the dbSNP database), fa.tumor (the es-
timate allele ratio of the SNV in the tumor exome sample), conservation (PhyloP conservation
score from the UCSC genome browser) and transversion (whether the SNV was a transition or
transversion mutation). The data was split into 80 traning and 20% testing for evaluation.
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6.3.5 Expressed single nucleotide variations (eSNVs)
Raw read data was downloaded from UCSC Cancer Genomics Hub in fastq format. Reads were
first aligned to the hg19 genome reference using STAR aligner [21] in two-pass mode. Aligned
BAM files were sorted using Picard-tools’ ReorderSam function (http://broadinstitute.
github.io/picard) and reads were split based on splicing junctions using Genome Analysis
Toolkit (GATK) SplitNCigarReads function [22]. Reads were then processed through removal
of duplicates, indel realignment and base recalibration following standard protocols. Variant
calling was performed using GATK’s Haplotype caller. Data processing was performed on the
University of Hawaii high performance computing cluster (see Supplementary Methods for de-
tails). To further reduce potential false positive calls, variants were filtered based on SNV
clusters and read strand bias following recommendations from the developers. To define lin-
cRNA specific eSNVs, variants associated with lincRNAs based on the lncipedia 4.0 reference
[4] were saved for analysis. eSNVs for protein coding genes were similarly filtered based on the
Refseq transcriptome annotation.
6.3.6 Predictive models for eSNVs
We constructed classification models in order to predict eSNVs for each cancer type. These
models were built on balanced datasets, comprised of somatic eSNVs and background “negative”
eSNVs – i.e., random sites on expressed lincRNAs in each RNA-Seq sample. The molecular
features used in these models included conservation, copy number variation, histone marker
features, nucleotide composition features, etc. (Table S3). Two algorithms were employed on
these datasets: logistic regression with ridge regression (LR), a fast linear classification algorithm
using the glmnet R package (version 2.0-5) and Gradient Boosted Trees [23], a fast non-linear
tree-based classifier using the xgboost R package (version 0.6-0).
To evaluate each model, the datasets were split into 80% training and 20% testing. AUC was
calculated as performance metrics on the testing sets. To evaluate the relative importance of
each feature, we used the Gain measurement, which is the improvement of the model accuracy
on its branches in the trees for each feature.
6.3.7 Calculating mutation probabilities
Although the Boosted Trees models were built using balanced datasets, the true negative class of
the eSNV data are all mutation sites that were not called as variants. The posterior probabilities
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of the Boosted Trees models must be modified to account for the increase in type I errors that
would result from application of the models to the entire lincRNA transcriptome. In order to
calculate individual site mutation probabilities, we adjusted the posterior probabilities of the
Boosted Trees eSNV models through a Bayesian framework [24]. For each patient with RNA-Seq
data in this study, we calculated the mutation probabilities for every genomic position included
in a lincRNA. Subsequently, we calculated the log-odds mutation scores.
6.3.8 Calculating feature importance and feature mutual information
In order to determine feature importance, we calculate the Gain value of each feature. In
an ensemble forest model (Random Forest or Gradient Boosted Trees), Gain is the average
improvement of performance of the model on each tree branch that is split by the feature in the
ensemble forest [23].
To determine the correlation between features, we calculated the normalized mutual information
[25]. Mutual information is a measure of correlation between two variables [26]. It measures the
information shared between two variables based on their conditional probability distributions.
The normalized mutual information is a measure that scales mutual information by the geometric
mean of geometric mean of the two variables, and therefore ranges between 0 and 1.
6.4 Results
6.4.1 Computational pipeline accurately predicts genetic variation in tumor
RNA-Seq samples
6118 primary tumor RNA-Seq samples were selected from 12 TCGA datasets (Table S1). A
pipeline for calling mutations from bulk RNA-Seq data was implemented (Figure S1). TCGA
fastq files were aligned using STAR aligner, and then pre-processed by splitting reads along exon
junctions. These samples were then further pre-processed using the Indel Realignment and Base
Recalibration modules in GATK. Finally, VCF files were generated using the Haplotype caller
GATK module. To verify the quality of the results, we compared the variant calls from exome
sequencing for paired exome and RNA-Seq sample datasets (Figure S2). On average, 80% of
the single nucleotide variants found in RNA-Seq data were also found in the exome sequencing
variant calls, inside the regions of the exome sequencing probes (Figure S2 and S3). O’Rawe et
al. 2013 found that the concordance between sequencing platforms and variant calling software
to be about 50% [27]. Furthermore, the sensitivity of state of the art variant calling platforms
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is about 55% [28]. Thus, the high proportion of eSNVs detected in both RNA-Seq and exome
platforms suggests the variant calls from the RNA-Seq are reliable. Furthermore, we compared
the concordance between exome and RNA-Seq samples in each dataset (Figure S3). We found
that the paired Exome and RNA-Seq samples had much higher concordant SNVs compared to
samples from different patients.
6.4.2 A Random Forest model differentiates somatic and germline mutations
Using the exome sequencing data, we built a random forest model classifying the somatic muta-
tions versus the germline mutations based upon four features: dbsnp (whether the mutation is
documented in the NCBI dbSNP database), FA.tumor (the fraction of the alternate allele in the
tumor sample), conservation (PhyloP conservation score) and transversion (whether the muta-
tion is a transversion or a transition mutation). This model had an AUC of 0.988 on the exome
sequencing data and an AUC of 0.983 and 0.987 on based on the exome and RNA-Seq data re-
spectively (Figure 1A). By comparison, the logistic model had slightly lower AUCs of 0.979 and
0.985. The dbsnp and FA.tumor features had relatively high importance scores in correlation
with the outcome (somatic or germline mutation), whereas conservation and transversion were
not important features in this model (Figure 1B).
Secondly, we then applied this model to the 12 RNA-Seq datasets, and selected eSNVs which
were highly confident of being germline (posterior probability < 0.05) or somatic mutations
(posterior probability > 0.95). Using these thresholds, 170 million germline variants were de-
tected (155.4 million in protein-coding genes and 14.56 million in lincRNA genes) and 5.67
million eSNVs were detected (5 million in protein coding genes and 660,000 in lincRNA genes)
(Table S1). Within lincRNA regions, there 2.48 million somatic mutations and 19.3 million
germline mutations. Within protein coding exonic gene regions, there were 9.46 million somatic
mutations and 136.9 million germline mutations.
6.4.3 lincRNA eSNV genome-wide landscape
To explore lincRNA somatic mutations, we plotted the density of eSNVs by binning lincRNA
eSNVs in 100,000 base pair windows across the genome, and then normalizing by the exon
density of the lincRNA transcriptome (Figure 2). There are some regions that have an increased
frequency of lincRNA eSNVs. The top four regions included chr2p11.2, chr14q32.33, chr7q32.1
and chr1p36.13. In particular, chr2p11.2 is known to be heavily associated with breast cancer
[29]. In 2011, Sahin et al. found that copy number inbalances in chr2p11.2 had a significant effect
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on breast cancers detected through symptoms vs. breast cancers detected through screening [29].
They also found that the imbalance had a significant effect on disease free survival. However,
they were not able to determine any association with protein coding genes. These results suggest
that the association of this region with cancer phenotypes could be due to lincRNA mutations.
6.4.4 A gradient boosted model determines eSNV mutation likelihood
For each of the 12 TCGA cancer types, we constructed a classification model to predict mutation
likelihood. We constructed balanced dataset comprised of somatic eSNVs (positive class) and
negative “background” eSNV; e.g., random positions on expressed genes or lincRNAs which
are not mutated. We extracted nucleotide, position, gene level and tissue features relevant to
each individual eSNV (descriptions of features used are in Table S2). In addition, for eSNVs
located within protein coding genes, we extracted features related to the coding sequence frame.
Similarly, we also built models using the germline variants using the same features.
We applied three machine learning algorithms to each dataset: logistic regression (a linear clas-
sifier), a neural networks (a flexible non-linear classifier) and gradient boosted trees (a fast
tree-based non-linear classifier). In each dataset, the Boosted Trees model performed consider-
ably better than the neural network and logistic regression models. The neural network models
generally performed better than the logistic regression. Across all 12 TCGA datasets, Boosted
Trees had an average AUC of approximately 0.947 (Figure 3). The neural network and logis-
tic regression models had average AUCs of 0.876 0.839, respectively in differentiating somatic
eSNVs in lincRNA (Figure S4). For somatic mutations in protein coding genes, Boosted Trees
had an average AUC of 0.930; neural network logistic regression had average AUCs of 0.908 and
0.845, respectively (Figure 3).
By comparison, the Boosted Trees models built on predicting germline variants had AUCs of
0.886 (lincRNAs) and 0.883 (protein coding genes) (Figure S4). Similar to the eSNV models,
the neural network and logistic regression models for germline variants had significantly lower
AUCs of 0.828 and 0.772 for lincRNAs; and 0.883 and 0.815 for protein coding genes. In all
cases, the Boosted Trees models had stronger performance compared to logistic regression by
large margins. This suggests that the relationship of the features to the outcome are not linear
and may be complex and not easily understood.
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6.4.5 Molecular features correlating with somatic eSNVs differ from germline
variants and differ from protein coding genes
To evaluate the importance of each feature in the model, we used the Gain measure, which
calculates the average increase in performance for each feature in every tree in the Boosted
Trees ensemble. For the lincRNA eSNV models (Figure 4), transversion (whether the SNV was
the result of a transversion mutation), followed by conservation. For the two lung cancer datasets
(LUAD and LUSC) the histone H3k09me3 methylation feature from a lung fibroblast cell line,
Ag04450H3k09me3 pos, was the third most important feature. For other datasets, CG 0, the
nucleotide base feature, and cnv pos (the copy number variation at the SNV position) were
the next most important features. Interestingly, for protein coding gene mutations, the UTR3
feature, the location of a eSNV on the 3’UTR region, was the third most important feature,
and the CG 0 and cnv pos features were relatively less important.
For germline lincRNA variants (Figure S5), conservation was the most important feature, while
transverison was the 2nd most important. Cnv pos did not come up as an important feature.
Interestingly, several histone features were important in specific datasets. For kidney renal cell
carcinoma, LncapH3k04me3 pos and Hepg2H3k4me3 pos (the trimethylation histone signature
for a prostate and liver cancer cell line respectively) was the third and fourth most important
features. Promoter methylation signatures were relatively less important than methylation
signatures at the eSNV position. In addition, nucleotide composition upstream or downstream
of the eSNV were not as important as the nucleotide base of the eSNV position. Only the
nucleotide base at the eSNV position were determined to be important, with C/G nucleotides
being much less likely to be mutated (Figure S6). While cnv pos was an important feature,
there was not much separation between the distributions of the positive and negative classes in
the models (Figure S7), suggesting that the role of copy number variation is complex.
For protein coding somatic eSNVs, features related to the protein coding frame were also in-
cluded. Similar to the model for lincRNA eSNVs, transversion was the most important feature.
However, utr3 (whether a mutation occurred in the 3’UTR region) was the 3rd most important
feature. Cnv pos (copy number variation at the eSNV position) was less important for protein
coding genes.
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6.4.6 Feature correlation is determined through normalized mutual informa-
tion
To explore how features are related to one another, we calculated the normalized mutual informa-
tion for features used to predict somatic eSNVs (Figure 5) and performed hierarchical clustering
on the pairwise mutual information scores. There were three distinct clusters from the histone
data. H3k4 trimethylation histone features were split based on the location of measurement
(i.e., at the histone values at the promoter site or the nucleotide position). Interestingly, the
features in these two groups were only weakly correlated. Other types of methylation (H3k27,
H3k36) weakly clustered together, although the correlation between these features were much
weaker. The cnv pos and cnv promoter features were almost identical, as copy number variation
was defined for large sections of the genome. Otherwise, no other feature had strong correlation
with other features, suggesting that they had orthogonal information. Interestingly, lincRNA
gene expression (“expr”) did not strongly correlate with any feature, and only weakly correlated
with histone features at the promoter regions.
6.4.7 LincRNA tumor drivers have distinct mutation profiles
To explore the mutation landscape of lincRNAs, we calculated a summarized mutation score as
the average mutation log odds for every nucleotide position in all lincRNAs. We converted this
probability to log odds and found the mean log odds for every lincRNA in each TCGA sample.
Next we asked whether known driver lincRNAs had a different mutation profile compared non-
driver lincRNAs. We used the lnc2Cancer database of experimentally validated lncRNA drivers
[30], and found approximately 500 intergenic lincRNAs in the database. The known driver
lincRNAs showed distinct mutation and expression profiles in several cancer types (Figure 6).
Overall known driver lincRNAs had significantly lower mean log odds compared to non-drivers
(p < 2.2e-16) and higher overall expression (p < 2.2e-16) (Figure S8).
6.4.8 LincRNA eSNV profiles provides more robust clustering compared to
lincRNA expression
We hypothesized that since the eSNV data incorporates RNA-Seq, copy number variation, hi-
stone data, etc., whereas the expression data only contains RNA-Seq information, the eSNV
data would provide better clustering results. Here we performed sample link community clus-
tering [31] on the eSNV data (using summarized mutation scores) and compared the results to
the clustering based on the lincRNA expression (Figure 7). The Link Community clustering
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method purports to find robust communities on complex and overlapping clusters, based on
similarity of node edges. On average, the eSNV clustering had much stronger robustness, as
measured by the partition density, compared to the clustering determined by expression (Figure
S9). This suggests that the clusters determined by eSNV data may have a stronger signal than
the clusters determined by expression data.
6.5 Discussion
As others have previously investigated, it is possible to accurately determine somatic mutations
in cancer samples without paired normal samples [32]. In this study, we show that a simple model
can accurately separate eSNVs from germline SNPs, based on models built on exome sequencing
data and tested on RNA-Seq data. Since paired normal samples are often not available, as in
the case of older FFPE DNA samples [33], or RNA-Seq expression samples in the present case,
it is therefore useful to be able to computationally predict which variants are somatic mutations.
Based on the random forest model (Figure 3), the features dbsnp (whether a variant is found in
the dbSNP database) and allele frequency are important features in predicting which variants
are somatic. dbSNP variants are those commonly found in population germlines, and therefore
are much less likely to be somatic. Similarly, it has been noted that variants that have low
allele frequency are likely to be cancer mutations, and may even play important roles in cancer
development [34]. Thus, variants found to have 100% allele frequency in the tumor samples
are unlikely to be somatic mutations, as normal sample contamination is usually present [35].
Furthermore, even in normal sample contamination is removed, tumor samples often contain
multiple populations that may have different alleles and mutational profiles [36].
The models predicting eSNVs from the background nucleotide positions showed strong perfor-
mance (Figure 3), showing that it is possible to differentiate sites which are eSNVs from those
which are unlikely to be eSNVs. Comparing the different classification algorithms, the logistic
regression models for protein-coding gene eSNVs showed stronger performance than the logistic
regression models for lincRNA eSNVs. However, using the non-linear Boosted Trees algorithm,
the situation was reversed, and the Boosted Trees models for lincRNA eSNVs showed stronger
performance than the models for protein-coding gene eSNVs. This suggests that the prediction
of lincRNA somatic mutations may be more non-linear and more complex than the protein
coding genes. The most important feature for the lincRNA somatic model was transversion
(whether a mutation was a transversion – 1, or transition mutation – 0). Transition somatic
mutations, particularly C>T transitions, are more frequent than transversion somatic mutations
[37]. However, for particular tumor types and even specific genes (e.g., p53 somatic mutations),
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the prevalence of transversions may be higher than transitions [37, 38]. This suggests the
transversion or transition type of mutation may ultimately be important in determining a mu-
tation’s biological importance. In addition to the type of mutation, the fourth most important
feature was CG 0 (i.e., whether the reference at the mutation site was a C/G nucleotide – 1 or
a AT nucleotide – 0). These findings show that the information about the basic chemistry of
the mutation is one of the strongest indication of mutation likelihood.
Conservation is the second most important feature in the lincRNA somatic model. Although
conservation scores are determined through evolutionary homology, it has been shown that
conservation correlates with somatic mutation hot spots [39]. The germline models for lincRNAs,
in contrast, scored conservation as the most important feature. This may be expected, as
conservation itself is a direct measure of the likelihood of variation through a species’ germline
lineage. The third most important feature for most lincRNA somatic models was cnv pos (i.e.,
copy number variation at the mutation position, determined by a microarray on a corresponding
DNA TCGA sample). Previous studies have found that many somatic gene mutations are
significantly correlated with their mutation profiles and copy number alterations in cancer,
including EGFR and KRAS [40]. However, although many genes were found to be correlated,
on a global scale, many genes did not reach significance [40]. The cnv pos feature was more
important in the lincRNA models compared to the protein coding gene models, suggesting that
cnv pos may be a relatively more important feature for lincRNAs. Furthermore, cnv pos was
significantly less important in both germline models.
For the datasets with matched tissue cell line histone data, histone features related to the
lincRNA sites were determined to have a significant effect on the prediction of eSNVs sites.
Previous studies have found that chromatin modifications had a major effect on regional muta-
tion rates in cancer cells [41]. Since histone methylation and acetylation status determines the
3-dimensional conformation and openness of genomic regions, differences in histone modifica-
tions between regions may change the exposure of a region to mutagenic forces.
Several additional features related to the coding frame of protein coding genes were included
in the models predicting somatic protein coding gene eSNVs. Somatic mutations in the coding
region of genes are much less frequent compared to non-coding portions, such as the UTR
regions and introns [42]. In support of this idea, of these additional features added to the
protein coding gene models, the most important was utr3 (whether a mutation came from a
3’UTR region). We showed that the mutation and expression profile of known lincRNA driver
genes are statistically different than non-driver or unknown lincRNAs (Figure 6 and Figure S8).
Despite higher expression being correlated with a higher chance of mutation (Figure S10), the
lincRNA mutation likelihood is significantly lower for known driver lincRNAs, and the overall
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expression for known driver lincRNAs is significantly higher. This corroborates previous studies
that showed that known cancer driver mutations in non-coding regions actually have lower
somatic and germline mutation scores [43].
While using RNA-Seq to perform mutation calling is an interesting idea to couple SNVs with
expression data, false negatives may arise due to the fact that many lincRNAs and transcripts are
lowly expressed or not expressed at all in certain tissues or conditions [44]. On the other hand,
false positives may also be introduced as RNA splicing of transcripts could cause additional
read misalignment to the genome reference [10]. Similarly, since expression data and eSNVs
both come from RNA-Seq and require the presence of expressed transcripts to produce reads for
measurement, expression and eSNVs are inherently coupled. A gene that is not expressed will
also not have any detected mutations. This suggests that there may be bias towards regions of
high read coverage and therefore high expression.
However, within the TCGA RNA-Seq datasets, the majority of eSNVs detected from RNA-Seq
within exome probe bounadries, are also detected in exome-sequencing variant calling from the
same patients (Figure S2 and Figure S3). Previous studies have found that, from the same
patient, the concordance between sequencing platforms and variant calling software to be about
50% [27]. This suggests that the false positives from the eSNV RNA-Seq pipeline are much less
of an issue than other technical factors, such as the choice of sequencing platform.
While the models built and used in this study have strong performance (AUC) on balanced
datasets, the sparsity of SNPs and SNVs in a genome suggests that individual sites may not
be able to be definitively predicted with high certainty. Biologically, this is a result of the
stochastic nature of somatic point mutations. However, individual genes, lincRNAs, genomic
regions, or possibly individual exons or sections of lincRNAs may be predicted as more or less
likely to be mutated, relative to other exons or genes. This is an important step in finding the
biological and tumorigenic significance of genes and lincRNAs that are susceptible or resistant
to somatic mutations. In this study, we explored eSNV landscape in tumor samples, with a
focus on non-coding regions (specifically lincRNAs).
At the individual SNV level, we showed that mutations can be accurately classified, and the
probability of particular mutations can be estimated. At the lincRNA level, we showed that
lincRNAs had a spectrum of mutation profiles and correlates with gene expression. Interestingly,
lincRNAs that are known to be drivers in cancer tumorigenesis and function show markedly
higher gene expression, yet lower mutation probabilities. Finally, we showed that the combined
lincRNA mutation scores (average log odds of mutation) that integrates RNA-Seq, copy number
variation, nucleotide composition, histone marker data etc., has more robust clustering than
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just the expression data from RNA-Seq alone. In summary, we generate models capable of
predicting mutation probabilities of individual lincRNA nucleotide positions as well as overall
lincRNA mutations probabilities. This study advances the knowledge of the mutational forces
of lincRNAs in comparison to protein coding genes.
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Figure 1. A – Receiver operating characteristic (ROC) curve showing the performance of the random forest and logistic regression models
for differentiating somatic and germline mutations in the exome-sequencing data. B – Feature importance based on the random forest
model.
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Figure 2. Circle plot of the normalized lincRNA eSNV mutation density. For each cancer
type, the number of lincRNA eSNVs was binned using window sizes of 100,000 across the
genome. The bin count was then normalized by the lincRNA exon density in the corresponding
transcriptomic region. The outer layer shows the human genome cytogenetics. The inner layers
are the lincRNA eSNV densities from the datasets in order (from outermost to innermost):
BLCA, BRCA, HNSC, KIRC, LGG, LIHC, LUAD, LUSC, OV, PRAD, STAD and THCA. The
inner layer shows the exon density of the lincRNA transcriptome.
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Figure 3. Model performance differentiating somatic eSNVs from background in lincRNAs and protein coding genes for the 12 TCGA
datasets, using the Gradient boosted Trees machine learning algorithm.
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Figure 5. Heatmap of normalized mutual information between features in the eSNV lincRNA
model.
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Figure 6. Summarized mutation score and expression profiles for known lincRNA drivers (red) and non-driver/unknown lincRNAs (gray)
in each of the 12 TCGA datasets. Mutation scores were summarized as the mean log odds ratio over all base pairs of a lincRNA. Expression
was calculated as the log of the fragments per kilobase per million reads (FPKM) for each lincRNA.
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Figure 7. A-L – Clustering results for the 12 TCGA datasets, based on the lincRNA summarized eSNV score (mean log odds ratio of
somatic mutation). Clustering was performed using the link community clustering method. M-partition density measure for comparing
the clustering robustness between eSNV data and expression data.
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6.6 Appendix
6.6.1 Supplemental figures and tables
Table S1. Patient and eSNV and germline variant tabulations for the 10 TCGA datasets.
Table S2. eSNV and germline variant density based on mutation calls from RNA-Seq data.
Table S3. Description of features of the datasets and models used in this study.
Figure S1. Flow chart diagram describing the pipeline for the raw data processing, calling
eSNVs and calculating expression data.
Figure S2. Comparison barplots between RNA-Seq and exome-seq data from the same pa-
tients.
Figure S3. Heatmaps of the concordant variants detected in the RNA-Seq and exome-seq data.
Figure S4. Model performance differentiating germline variants or eSNVs from background in
the 12 TCGA datasets.
Figure S5. Feature importance for germline variant models for lincRNAs and protein-coding
genes.
Figure S6. Base pair distribution for detected eSNV models.
Figure S7. Feature distribution histograms for eSNV models.
Figure S8. Average distribution of mutation scores and expression for known lincRNA drivers
and non-driver/unknown lincRNAs. Both expression and mutation scores were significantly
different (p < 2.2e-16).
Figure S9. Link community clustering results for the 12 TCGA datasets, based on the lincRNA
expression data.
Figure S10. LincRNA expression distribution for detected eSNVs and negative background.
Supplemental methods. Supplemental information regarding the processing and filtering of
the eSNVs for variant calling.
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Table S1
cancer_type Patients Total variants Protein-coding eSNV LincRNA eSNV Protein-coding germline LincRNA germline
PRAD 491 33240.43 +/- 5951.55 693.98 +/- 235.50 106.92 +/- 37.44 24996.55 +/- 4292.20 2292.13 +/- 580.21
STAD 414 41056.52 +/- 7581.96 1178.52 +/- 483.83 151.19 +/- 82.21 29852.28 +/- 4825.27 3260.55 +/- 1218.17
OV 300 42750.73 +/- 6373.53 1207.35 +/- 310.14 225.18 +/- 106.01 30285.15 +/- 3770.79 3992.69 +/- 1113.04
THCA 497 34568.26 +/- 5288.24 760.66 +/- 171.73 116.07 +/- 38.49 25974.94 +/- 3788.85 2381.96 +/- 592.03
HNSC 514 29939.30 +/- 5093.94 641.67 +/- 188.29 59.34 +/- 25.45 22786.42 +/- 3672.31 1635.16 +/- 477.41
LIHC 364 25213.55 +/- 5372.64 548.04 +/- 151.57 62.30 +/- 23.87 19119.57 +/- 3981.40 1512.20 +/- 469.33
LGG 513 37286.35 +/- 4488.98 834.35 +/- 366.00 137.00 +/- 37.55 27651.25 +/- 3098.94 2897.41 +/- 526.35
LUSC 498 33415.90 +/- 4734.57 798.53 +/- 230.31 91.63 +/- 39.80 24948.94 +/- 3140.12 2243.06 +/- 608.68
LUAD 512 33001.78 +/- 5801.08 746.25 +/- 259.69 83.62 +/- 44.04 24595.81 +/- 3847.28 2084.84 +/- 709.07
KIRC 525 36731.71 +/- 6346.44 847.07 +/- 248.17 120.83 +/- 52.79 27061.65 +/- 4322.88 2710.20 +/- 780.21
BRCA 1084 34589.13 +/- 5619.00 875.70 +/- 286.37 108.86 +/- 46.07 25571.13 +/- 3813.70 2251.74 +/- 621.48
BLCA 406 29838.92 +/- 5182.94 742.48 +/- 242.29 78.19 +/- 33.93 22210.54 +/- 3614.80 1909.15 +/- 584.05
All 6118 34235.03 +/- 6927.45 817.49 +/- 320.50 108.77 +/- 61.39 25407.92 +/- 4663.37 2379.47 +/- 903.91
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Table S2
cancer_type Overall variants Protein-coding eSNV LincRNA eSNV Protein-coding germline LincRNA germline
PRAD 2.63e-04 +/- 4.71e-05 7.85e-06 +/- 2.66e-06 2.82e-06 +/- 9.88e-07 2.83e-04 +/- 4.86e-05 6.05e-05 +/- 1.53e-05
STAD 3.25e-04 +/- 6.00e-05 1.33e-05 +/- 5.48e-06 3.99e-06 +/- 2.17e-06 3.38e-04 +/- 5.46e-05 8.60e-05 +/- 3.21e-05
OV 3.39e-04 +/- 5.05e-05 1.37e-05 +/- 3.51e-06 5.94e-06 +/- 2.80e-06 3.43e-04 +/- 4.27e-05 1.05e-04 +/- 2.94e-05
THCA 2.74e-04 +/- 4.19e-05 8.61e-06 +/- 1.94e-06 3.06e-06 +/- 1.02e-06 2.94e-04 +/- 4.29e-05 6.29e-05 +/- 1.56e-05
HNSC 2.37e-04 +/- 4.03e-05 7.26e-06 +/- 2.13e-06 1.57e-06 +/- 6.72e-07 2.58e-04 +/- 4.16e-05 4.31e-05 +/- 1.26e-05
LIHC 2.00e-04 +/- 4.25e-05 6.20e-06 +/- 1.72e-06 1.64e-06 +/- 6.30e-07 2.16e-04 +/- 4.51e-05 3.99e-05 +/- 1.24e-05
LGG 2.95e-04 +/- 3.56e-05 9.44e-06 +/- 4.14e-06 3.62e-06 +/- 9.91e-07 3.13e-04 +/- 3.51e-05 7.65e-05 +/- 1.39e-05
LUSC 2.65e-04 +/- 3.75e-05 9.04e-06 +/- 2.61e-06 2.42e-06 +/- 1.05e-06 2.82e-04 +/- 3.55e-05 5.92e-05 +/- 1.61e-05
LUAD 2.61e-04 +/- 4.59e-05 8.44e-06 +/- 2.94e-06 2.21e-06 +/- 1.16e-06 2.78e-04 +/- 4.35e-05 5.50e-05 +/- 1.87e-05
KIRC 2.91e-04 +/- 5.03e-05 9.59e-06 +/- 2.81e-06 3.19e-06 +/- 1.39e-06 3.06e-04 +/- 4.89e-05 7.15e-05 +/- 2.06e-05
BRCA 2.74e-04 +/- 4.45e-05 9.91e-06 +/- 3.24e-06 2.87e-06 +/- 1.22e-06 2.89e-04 +/- 4.32e-05 5.94e-05 +/- 1.64e-05
BLCA 2.36e-04 +/- 4.10e-05 8.40e-06 +/- 2.74e-06 2.06e-06 +/- 8.95e-07 2.51e-04 +/- 4.09e-05 5.04e-05 +/- 1.54e-05
All 2.71e-04 +/- 5.49e-05 9.25e-06 +/- 3.63e-06 2.87e-06 +/- 1.62e-06 2.88e-04 +/- 5.28e-05 6.28e-05 +/- 2.39e-05
*Units are variants per bp
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Table S3 part 1
SNV posi�on features
Feature Descrip�on
conserva�on PhyloP conserva�on score downloaded from UCSC genome browser
transversion The variant is a transversion muta�on - 1, or a transi�on muta�on - 0
cnv_pos
Copy Number Varia�on from the matched DNA tumor sample in TCGA at the SNV 
posi�on
CG_0 C or G nucleo�de at the SNV posi�on - 1, otherwise - 0
AG_0 A or G nucleo�de at the SNV posi�on - 1, otherwise - 0
CG_down1 C or G nucleo�de 1 bp downstream - 1, otherwise - 0
AG_down1 A or G nucleo�de 1 bp downstream - 1, otherwise - 0
CG_down2 C or G nucleo�de 2 bp downstream - 1, otherwise - 0
AG_down2 A or G nucleo�de 2 bp downstream - 1, otherwise - 0
CG_down3 C or G nucleo�de 3 bp downstream - 1, otherwise - 0
AG_down3 A or G nucleo�de 3 bp downstream - 1, otherwise - 0
CG_up1 C or G nucleo�de 1 bp upstream  - 1, otherwise - 0
AG_up1 A or G nucleo�de 1 bp upstream - 1, otherwise - 0
CG_up2 C or G nucleo�de 2 bp upstream - 1, otherwise - 0
AG_up2 A or G nucleo�de 2 bp upstream - 1, otherwise - 0
CG_up3 C or G nucleo�de 3 bp upstream - 1, otherwise - 0
AG_up3 A or G nucleo�de 3 bp upstream - 1, otherwise - 0
A549H3k04me3_pos
H3K4 trimethyla�on at the SNV posi�on of the A549 cell line, used in lung cancer 
datasets
Ag04450H3k09me3_pos
H3K9 trimethyla�on at the SNV posi�on of the AG04450 cell line, used in lung cancer 
datasets
Ag04450H3k27ac_pos
H3K27 acetyla�on at the SNV posi�on of the AG04450 cell line, used in lung cancer 
datasets
Ag04450H3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the AG04450 cell line, used in lung cancer 
datasets
Be2cH3k04me3_pos H3K4 trimethyla�on at the SNV posi�on of the BE2C cell line, used in the LGG dataset
Hek293H3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the HEK293 cell line, used in the KIRC 
dataset
Hepg2H3k27me3_pos
H3K27 trimethyla�on at the SNV posi�on of the HEPG2 cell line, used in the LIHC 
dataset
Hepg2H3k36me3_pos
H3K36 trimethyla�on at the SNV posi�on of the HEPG2 cell line, used in the LIHC 
dataset
Hepg2H3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the HEPG2 cell line, used in the LIHC 
dataset
HmecH3k27me3_pos
H3K27 trimethyla�on at the SNV posi�on of the HMEC cell line, used in the BRCA 
dataset
HmecH3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the HMEC cell line, used in the BRCA 
dataset
HmfH3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the HMF cell line, used in the BRCA 
dataset
HpfH3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the HPF cell line, used in the lung cancer 
datasets
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Table S3 part 2
Mcf7H3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the MCF7 cell line, used in the BRCA 
dataset
NhlfH3k04me3_pos
H3K4 trimethyla�on at the SNV posi�on of the NHLF cell line, used in the lung cancer 
datasets
RptecH3k04me3_pos
H3K4 trimethyla�on at the SNV posi�on of the RPTEC cell line, used in the KIRC 
dataset
SknmcH3k04me3_pos
H3K4 trimethyla�on at the SNV posi�on of the SK-N-MC cell line, used in the LGG 
dataset
SknshraH3k27me3_pos
H3K27 trimethyla�on at the SNV posi�on of the SK-N-SH_RA cell line, used in the LGG 
dataset
SknshraH3k36me3_pos
H3K36 trimethyla�on at the SNV posi�on of the SK-N-SH_RA cell line, used in the LGG 
dataset
SknshraH3k4me3_pos
H3K4 trimethyla�on at the SNV posi�on of the SK-N-SH_RA cell line, used in the LGG 
dataset
Wi38H3k04me3_pos
H3K4 trimethyla�on at the SNV posi�on of the WI-38 cell line, used in the lung cancer 
datasets
Wi38H3k04me3Ohtam_pos
H3K4 trimethyla�on at the SNV posi�on of the WI-38_Ohtam cell line, used in the 
lung cancer datasets
Promoter and gene-level features
Feature Descrip�on
cnv_promoter
Copy Number Varia�on from the matched DNA tumor sample in TCGA at the 
promoter (TSS1500)
A549H3k04me3_promoter
H3K4 trimethyla�on at the promoter region of the A549 cell line, used in lung cancer 
datasets
Ag04450H3k09me3_promoter
H3K9 trimethyla�on at the promoter region of the AG04450 cell line, used in lung 
cancer datasets
Ag04450H3k27ac_promoter
H3K27 acetyla�on at the promoter region of the AG04450 cell line, used in lung 
cancer datasets
Ag04450H3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the AG04450 cell line, used in lung 
cancer datasets
Be2cH3k04me3_promoter
H3K4 trimethyla�on at the promoter region of the BE2C cell line, used in the LGG 
dataset
Hek293H3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the HEK293 cell line, used in the KIRC 
dataset
Hepg2H3k27me3_promoter
H3K27 trimethyla�on at the promoter region of the HEPG2 cell line, used in the LIHC 
dataset
Hepg2H3k36me3_promoter
H3K36 trimethyla�on at the promoter region of the HEPG2 cell line, used in the LIHC 
dataset
Hepg2H3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the HEPG2 cell line, used in the LIHC 
dataset
HmecH3k27me3_promoter
H3K27 trimethyla�on at the promoter region of the HMEC cell line, used in the BRCA 
dataset
HmecH3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the HMEC cell line, used in the BRCA 
dataset
HmfH3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the HMF cell line, used in the BRCA 
dataset
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Table S3 part 3
HpfH3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the HPF cell line, used in the lung 
cancer datasets
Mcf7H3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the MCF7 cell line, used in the BRCA 
dataset
NhlfH3k04me3_promoter
H3K4 trimethyla�on at the promoter region of the NHLF cell line, used in the lung 
cancer datasets
RptecH3k04me3_promoter
H3K4 trimethyla�on at the promoter region of the RPTEC cell line, used in the KIRC 
dataset
SknmcH3k04me3_promoter
H3K4 trimethyla�on at the promoter region of the SK-N-MC cell line, used in the LGG 
dataset
SknshraH3k27me3_promoter
H3K27 trimethyla�on at the promoter region of the SK-N-SH_RA cell line, used in the 
LGG dataset
SknshraH3k36me3_promoter
H3K36 trimethyla�on at the promoter region of the SK-N-SH_RA cell line, used in the 
LGG dataset
SknshraH3k4me3_promoter
H3K4 trimethyla�on at the promoter region of the SK-N-SH_RA cell line, used in the 
LGG dataset
Wi38H3k04me3_promoter
H3K4 trimethyla�on at the promoter region of the WI-38 cell line, used in the lung 
cancer datasets
Wi38H3k04me3Ohtam_promoter
H3K4 trimethyla�on at the promoter region of the WI-38_Ohtam cell line, used in the 
lung cancer datasets
Protein coding genes SNV addi�onal features
Feature Descrip�on
nonsyn Non-synonymous coding muta�on - 1, other - 0
nonsense Nonsense muta�on - 1, other - 0
nonstop Nonstop muta�on - 1, other - 0
utr5 The SNV occurs in the 5'UTR region of the protein coding gene - 1, otherwise - 0
utr3 The SNV occurs in the 3'UTR region of the protein coding gene - 1, otherwise - 0
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Figure S1
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Figure S2
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Figure S3
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Figure S4
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Figure S5
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Figure S6
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Figure S7 part 1
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Figure S7 part 2
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Figure S7 part 3
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Figure S7 part 4
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Figure S8
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Figure S9
BLCA expression clustering
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BRCA expression clustering
●
12
●
4
●
15
●
9●
22
●
19
●
16
●
1
●
23
●
13
●
25
●
26
●24
●
7
●
20
●
21 ●
8
●
18
●
14
●
10
●
17
●
11
●
5
●
6
●
3
● 2
(b)
HNSC expression clustering
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KIRC expression clustering
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PRAD expression clustering
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STAD expression clustering
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(k)
THCA expression clustering
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Figure S10
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6.6.2 Supplemental information
Supplementary Methods
Software versions used
• Java runtime environment: version 1.8.0 66
• STAR: version 2.5.1b
• GenomeAnalysisTK: version 3.5-0-g36282e4
• Picard Tools: version 2.1.1
Reference files used:
• Genome hg19 (Illumina iGenomes) downloaded from Illumina:
• dbSNP (version 138), Mills/1000 Genomes gold standard indels, 1000 Genomes down-
loaded from the Broad Institute: phase1 indels
eSNV processing steps:
1. Fastq files were aligned using the STAR aligner using 20 threads, using “basic” twopass-
Mode
2. Read groups were added to each sample using picard tools AddOrReplaceReadGroups
function
3. Duplicates were handled using picard tools MarkDupliactes function with parameters:
• -CREATE INDEX=true
• VALIDATION STRINGENCY=SILENT
4. Cigar strings were split using GenomeAnalysisTK SplitNCigarReads function with pa-
rameters:
• -rf ReassignOneMappingQuality
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• -RMQF 255
• -RMQT 60
• -U ALLOW N CIGAR READS
5. Indel realignment in GenomeAnalysisTK was performed using the Mills/1000 Genomes
gold standard and phase 1 indels as additional references. The RealignerTargetCreator
function was used followed by the IndelRealigner function.
6. Base recalibration in GenomeAnalysisTK was performed using the dbSNP, Mills/1000
Genomes gold standard and phase 1 indels as additional references. The BaseRecalibrator
function was used followed by the PrintReads function.
7. Raw variant calling in GenomeAnalysisTK was performed using dbSNP variants as addi-
tional references. The HaplotypeCaller function was used with the following parameters:
• -dontUseSoftClippedBases
• -stand call conf 20.0
8. -stand emit conf 20.0
9. -o $analysis id.raw.vcf
10. 8) Additional filtration was performed on the called variants using the VariantFiltration
function. Additional filtration parameters used were:
11. -window 35
12. -cluster 3
• -filterName FS
• -filter ”FS >30.0”
• -filterName QD
• -filter ”QD <2.0”
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6.7 Chapter summary
We use expressed single nucleotide variants (eSNV) in lincRNAs from RNA-Seq data to de-
termine important relations between somatic mutations and other molecular and clinical data.
Over 6000 RNA-Seq samples from 12 cancer types were processed for both eSNV data and
lincRNA and gene expression data. We use a variety of machine learning methods to determine
the molecular features that are highly correlated with somatic mutations. Subsequently, we
perform factor correlation using mutual information to find which molecular features cluster
together.
By asking what are the fundamental biological and molecular properties that are attributed
to somatic lincRNA mutations in cancer, this may eventually lead to a more fundamental
understanding of the tumorigenic process of genetic mutations leading to malignancy.
Chapter 7
Discussion
After the human genome project was completed in 2003, many scientists believed that we
would be able to soon fully understand our human biological nature and inner workings of our
cells. In fact, the original goal of the Human Genome Project was “the complete mapping
and understanding of all the genes of human beings.” [1] While the first goal, of mapping the
genome, has been thoroughly fulfilled, the second goal, of understanding all the genes of human
beings, will not be reasonably met in the near future.
While we know a relatively well the 2-3% of the genome that produces proteins and enzymes, we
know very little about majority of the 80% of the genome that is transcribed. This genomic “dark
matter” is profoundly unknown, and we are only just beginning to understand the functions
and processes of these transcribed non-coding regions. The study of non-coding RNAs is still
in its infancy.
Early genetic experiments on bacteria and single-celled systems, with limited ability to charac-
terize the full extent of DNA and RNA material, focused on abundant protein structures and
defined our understanding of the biological centra dogma – DNA is transcribed to RNA is tran-
scribed to proteins [2]. In simple organisms such as bacteria, lincRNAs and other non-coding
RNA elements generally do not exist.
As early as 2004, researchers found evidence that our basic understanding of how cells work
was fundamentally flawed. In an opinion article in Nature Genetics [3], John S. Mattick noted
that in bacteria, the number of regulatory proteins compared with the number of enzymatic
proteins had a quadratic relationship. But in eukaryotes this trend did not continue. Thus,
extrapolating from our prokaryotic counterparts, there clearly seemed to be a huge amount of
missing regulatory proteins that would be required for our cells to operate in a cohesive manner.
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Mattick suggested that the large deficiency in the number of expected regulatory proteins was
made up by non-coding RNAs – something that was missed completely in the original annotation
of the human genome. With the discovery of thousands of robustly transcribed non-coding RNA
through high-throughput sequencing, Mattick seems to have been proven correct. Indeed, even
among non-coding RNA species, the intergenic lincRNAs subclass is the largest group of RNA
transcripts found in the entire human genome [4].
7.1 Completion of specific aims
At the beginning on my doctoral project, I research the current state of the art in lincRNAs
and next generation sequencing. In the lincRNA review paper (Chapter 2), I comprehensively
explore the lincRNA literature, and focus on learning how lincRNAs are connected to cancer,
existing computational methods related to lincRNA research, and the challenges in this field.
To become proficient in analyzing RNA-Seq data, I perform a meta-analysis on differential
expression methods (Chapter 3). Using several public datasets, I evaluate the performance of
various differential expression tools, and study the relationship of sample size and sequencing
depth to the statistical detection power of different experimental designs.
In Aim 1 of this project, I process thousands of RNA-Seq cancer and tumor-adjacent normal
samples and quantify the expression of lincRNAs in these samples (Chapter 4). I explor the
expression landscape of lincRNAs across 12 cancer types, and find six common lincRNAs that
were differentially expressed in all cancer types. Using machine learning methods, the expression
of these lincRNAs can differentiate tumor and normal tissue samples with near-perfect accuracy.
Furthermore, these six lincRNAs are significantly correlated with patient survival in several
cancer datasets.
In Chapter 5, I explor how neural networks could be used to analyze high throughput datasets
linked to patient survival. I show that neural network survival analysis, termed Cox-nnet, also
has a unique advantage over other machine learning methods, such as revealing the biological
relevance of genes and pathways correlated with survival.
In aim 2 of my dissertation, I explore the mutational landscape of lincRNAs (Chapter 6).
Specifically, I analyze the expressed single nucleotide variations in cancer. Computationally,
this is my most ambitious project yet, and one that I would not have been able to accomplish
at the start of my research. This paper required large scale data processing on the UH manoa
high performance computing. From 6000+ RNA-Seq samples, I extract features on over 300
million single nucleotide variations and leverage state of the art machine learning methods. For
Chapter 8: Discussion 211
the result of this paper, I determine which features cause nucleotide positions to be more or less
likely to be mutated in cancer. I was also able to show that lincRNAs which are known to be
cancer drivers have different mutation and expression profiles.
7.2 Future work and directions
Previous GWAS studies have also linked disease-associated genetic variation and somatic muta-
tions to regions inside of, or in the vicinity of lincRNAs. LincRNAs are expressed differentially
in not only different tissues, but in different cancer types and subtypes. Thus, exploration of
the lincRNA landscape across cancers should focus on not only the common lincRNAs, but also
incorporate tissue and cancer specificity in analyzing the expression and mutation profiles.
To follow up on Aim 1, it will be necessary to fully sequence the six pan-cancer biomarkers.
Currently, the isoforms and exon structure of these lincRNAs are only computationally predicted
through high-throughput sequencing. Rapid amplification of cDNA ends (RACE) PCR will
helpful to explicitly determine the isoform structures and sequences. Further work should be
performed to validate the potential clinical applications of these biomarkers. Additional tissues
and also blood serum on retrospective and prospective cohorts will be great resources to further
explore the expression and presence of these lincRNAs as biomarkers. In addition, it might be
interesting to determine the molecular function and biological pathways that these lincRNAs
are involved in.
To follow up on Aim 2, somatic mutations from whole genome sequencing should be processed.
While whole genome sequencing processed results were not available at the start of this project,
WGS should provide complementary data to the eSNV data from RNA-Seq. Allele specific
expression from the RNA-Seq data could be an important factor in the analysis. Somatic
mutations in promoter and enhancer regions determined by WGS could complement the analysis.
Further computational work should also be performed in order to predict if a mutation on a
given nucleotide postion would have a deleterious effect or any disease association in cancer.
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